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Abstract 
PHOX2B (Paired-like homeobox2B) and PHOX2A (Paired-like homeobox2A), are two 
paired like homeodomain proteins required for the correct autonomic nervous system 
development and for the specification of the noradrenergic phenotype. The neuronal 
development and specification driven by PHOX2 proteins is the result of a fine temporal 
and spatial control of the two-paralogue proteins. In particular, PHOX2B is considered a 
“master regulatory gene” in the network leading to the cathecolaminergic phenotype 
specification, and regulate PHOX2A expression (Coppola et al., 2005).  
As PHOX2 proteins play crucial role in embryonic neuronal differentiation, their mutations 
or altered regulation are linked to congenital pathologies, such as Congenital Central 
Hypoventilation Syndrome (CCHS), a neurodevelopmental disorder characterized by a 
failure in the autonomic control of breathing, and neuroblastic tumours. 
The aim of this project was to disclose still unknown mechanisms involved in the 
pathogenetic mechanisms of PHOX2B-driven disease development, to improve the 
recognition of new sensitive therapeutic intracellular targets 
The results obtained during the three years of my PhD are organized in three parts. 
 
Part 1) In the first part of the project, we better characterized PHOX2B homeodomain-
mediated functions, as hetero-/homo-dimerization and nuclear import, also in the 
perspective of better analysing the possible effect of polyalanine expansion on these 
functions, as the expansion of the polyalanine tract in PHOX2B results in a protein with 
altered DNA-binding, reduced transcriptional activity and defect in nuclear localisation 
(Trochet et al., 2005; Bachetti et al., 2005; Di Lascio et al., 2013). Interestingly our data 
clearly underlined a strong interaction between PHOX2A and PHOX2B wild type/ mutants 
proteins, indicating a possible involvement of PHOX2A in the pathogenesis of CCHS. 
 
Part 2) Consistently with PHOX2B role as transcriptional regulator, it is reasonable to 
suppose that transcriptional dysregulation might be an important mechanism of CCHS 
pathogenesis and/or tumour development. Recently, studies conducted on NB cell lines 
have highlighted a correlation between drugs, used in NB treatment or clinical trials (e.g. 
GA, 17-AAG), and the modulation of PHOX2B gene expression. Moreover, NBs are very 
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sensitive to retinoids, and they were introduced in NB treatment as “additional drugs” in 
order to induce differentiation in residual cancer cells after NB surgical elimination. In the 
second part of the project, we showed that “all trans retinoic acid” (ATRA), a retinoid 
drug that is known to suppress growth in cancer, differently regulates both PHOX2A and 
PHOX2B expression in SK-N-BE(2)C neuroblastoma cell line, thus suggesting that the 
molecular mechanism for retinoic-induced cellular differentiation, in NB treatment, is due 
to a direct regulation of PHOX2 protein expression. 
 
Part 3) An interesting strategy into treatments of CCHS, that is currently under 
investigation, regards the use of progestinic drugs for ameliorating respiratory symptoms 
in patients. This strategy stems from the fortuitous observation of Straus and colleagues, 
that progestin drug Desogestrel can relief some symptoms in CCHS female patients. The 
molecular mechanism of the unexpected Desogestrel pharmacological effect is at the 
moment completely unknown, but this observation gave us a useful indication in the 
perspective of pharmacological interventions in CCHS. As previously data collected in my 
laboratory, on T47D cell line, suggested that 3-KDG can influence both the activity of 
PHOX2B and PHOX2A, and that this is mediated by the intracellular receptor PGR, we 
decided to deeply investigate the Desogestrel mechanism in a cellular background more 
properly associated with the physiological PHOX2B environment. To this purpose, we 
generated a neuroblastoma cell line (SK-N-BE(2)C) stably expressing nuclear progesterone 
receptor isoforms, and analysed the effect of 3-KDG treatment on endogenous protein 
amount and transcription levels by using western blot and quantitative PCR analyses. Our 
findings demonstrated that desogestrel treatment is able to alter PHOX2B and PHOX2A 
expression, as well as the expression of DBH and some other target genes of PHOX2 
proteins, particularly reducing their expression.  
 
Taking together these results point out the existence of a specific cross-talk between 
ATRA and 3-KDG treatments and PHOX2 pathway, suggesting that the regulation of 
PHOX2 proteins expression could be a common strategy into the treatment of NB and 
CCHS.  
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1.1 Phox2 proteins in nervous system development 
 
PHOX2B (Paired Like Homeobox 2B) and its paralogue gene PHOX2A (Paired Like 
Homeobox 2A) are members of the Q50 paired-like homeodomain transcription factor 
family, essential for the autonomic nervous system (ANS) development (Tiveron et al., 
1996). They also control adrenergic and noradrenergic neuronal differentiation in 
peripheral and central nervous system (Stanke et al., 1999), by coordinately regulating 
neuron cell cycle exit (Paris et al., 2006; Dubreuil et al., 2000). 
In vivo knockout experiments clearly revealed the Phox2a/b importance in early 
neurodevelopment and their significance as determinants of the noradrenergic 
phenotype.  
The Phox2a knockout mouse models die shortly after birth leading to a selective loss of 
the main noradrenergic centre of the brain, the locus coeruleus (LC)(Morin et al., 1997), 
whereas Phox2b null mutants mouse models die before birth because ANS circuits do not 
form or degenerate as well as brainstem (nor)-adrenergic centres (Pattyn et al., 1999). 
Different classes of neurons required the expression of Phox2 proteins for their 
differentiation and maintenance of neuronal phenotype. 
In particular, Phox2b is expressed: 
- in peripheric nervous system, in all autonomic ganglia (sympathetic, parasympathetic 
and enteric ganglia), in distal ganglia of the facial (VII), glossopharyngeal (IX), and vagus 
(X) cranial nerves;  
- in central nervous system, in all noradrenergic centres (A1-C1, A2-C2, A5 e A7), in motor 
cranial nuclei (except abducent and hypoglossal nuclei), in neurons of the nucleus of the 
solitary tract (NTS) and area postrema (AP) (Brunet and Pattyn, 2002) as in the hindbrain 
and spinal cord interneurons (Fig. 1). 
Phox2a expression during neurodevelopment is far more limited with respect to its 
paralogue protein, being it confined in principal noradrenergic centres as in the 
parasympathetic and sensory ganglia and in the aforementioned LC, and in neurons of 
oculomotor and trochlear nuclei. 
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Figure 1 Expression profiles of Phox2 proteins.  
Classes of neurons under Phox2a control are represented in blue; in red the ones regulated by Phox2b, in 
violet classes controlled by both Phox2a and Phox2b expression. The dashed boxes indicate neuronal types 
and nuclei that are not noradrenergic but transitorily expressing noradrenergic markers, as DBH (Brunet & 
Pattyn 2002). 
 
The Phox2a/b specification of neurotransmitter identity and neuronal fate starts soon 
during neurodevelopment, at the level of neuronal crest cells precursor.  
Nagashimada et al (2012) have identified a reciprocal regulation between Phox2b and 
Sox10 (SRY-related HMG-box), that is central to development of the autonomic ganglia, 
both enteric and sympathetic (Fig. 2). Neural crest cells initially express Sox10, but not 
Phox2b; after their migration to the site of ganglion formation they rapidly begin to 
express Phox2b. These Phox2b/Sox10 double-positive cells are bipotential progenitors 
whose future identity (either neurons or glia) is still undetermined. As differentiation 
proceeds, Phox2b- and Sox10-expressing cell populations are segregated and give raise to 
neurons and glia, respectively. Sox10 has the ability to suppress Phox2b expression (Kim 
et al., 2003). Phox2b has also the ability to suppress Sox10 expression, acting on a Sox10 
enhancer. Together, this reciprocal inhibition between Sox10 and Phox2b must be 
required to establish a balance between Sox10 and Phox2b expression, which is crucial 
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for the maintenance and differentiation of bipotential progenitors in the sympathetic and 
enteric ganglia (Nagashimada et al., 2012). 
 
 
Figure 2 Phox2b-Sox10 reciprocal regulation.  
Neural crest cells are Sox10+ Phox2b-. After their migration to the site of ganglion formation they begin to 
express Phox2b. Regulation of Phox2b and Sox10 expression by reciprocal suppression between these two 
transcription factors, at bipotential progenitors level, plays an important role in generating appropriate 
numbers of neurons and glia in the enteric and sympathetic ganglia. 
 
Phox2b expression is therefore the crucial step for the determination of the neuronal cell 
fate. In particular, neuroblast progenitors migrate from the neural crest and around 
neural tube to a region immediately lateral to the dorsal aorta, at embryonic day 10. The 
dorsal aorta secretes bone morphogenetic proteins (BMPs), members of the transforming 
growth factor-β superfamily, which induce the activation of a specific signalling pathway, 
essential for sympathetic-neuron development. Under normal conditions BMPs induce 
Phox2b and the helix-loop-helix transcription factor Mash1 (ASCL1 Achaete-scute 
homolog 1), which in turn induces Phox2a, the zinc finger protein GATA3 (GATA Binding 
Protein 3), and the basic helix-loop-helix transcription factor dHand (Howard et al., 2000). 
Finally, Phox2b, Mash1 and GATA3 regulate the expression of the tyrosine hydroxylase 
(TH) and dopamine β hydroxylase (DBH) enzymes, responsible for noradrenaline synthesis 
(Fig. 3). 
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Phox2b also regulates MSX1 (Msh homeobox 1) homeobox transcription factor (Revet et 
al., 2008), and ALK (Anaplastic lymphoma kinase) (Bachetti et al., 2010) both important 
for neural crest and peripheral nervous system development. 
Furthermore, in our laboratory it has been demonstrated that PHOX2A regulates the 
expression of the human α3 nAChR subunit gene (Nicotinic acetylcholine receptors, 
subunit α3), the ligand-binding subunit expressed in every terminally differentiated 
ganglionic cell, which represents a pan-autonomic gene that participates in the fast 
synaptic transmission between CNS and ganglia (Benfante et al., 2007). 
 
 
Figure 3 Transcriptional cascades for the control of the noradrenergic neuronal 
differentiation into different neuronal classes. Diagram of regulatory interactions between 
transcription factors deduced from the analysis of knock-out mice for individual genes. The wavy arrows 
indicate a role in maintaining gene expression (putative in the case of LC), while the dashed arrows indicate 
regulatory interactions derived exclusively from overexpression experiments. (Brunet & Pattyn 2002). 
 
Despite Phox2b and Phox2a are predominantly co-expressed in several noradrenergic 
regions, their expression is temporally regulated. 
Phox2a and Phox2b knock-out (KO) murine models clearly identified the temporal/spatial 
expression of the two transcription factors during noradrenergic differentiation. 
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Moreover, in vivo experiments based on the replacement of Phox2a gene into the Phox2b 
locus, and vice versa, demonstrated that Phox2 genes are not functionally equivalent 
(Coppola et al., 2005). 
Taking together, these data indicates that in the transcriptional cascades controlling 
noradrenergic differentiation, Phox2b regulates Phox2a expression. 
Indeed, deletion of Phox2b leads to failure in the development of most noradrenergic 
structures, in which Phox2b precedes Phox2a: the sympathetic ganglia and the 
parasympathetic ganglia of the brain stem, the enteric nervous system, and the hindbrain 
branchiomotor (bm)/visceralmotor (vm) neurons.  
On the other hand, Phox2a inactivation results in lack or atrophy of the oculomotor (nIII) 
and trochlear (nIV) neurons, the locus coeruleus (LC) and the three cranial ganglia as well 
as parasympathetic ganglia of the head, thus indicating that Phox2a precedes Phox2b in 
the development of such structures. However, the lack of Phox2b partially affects the 
correct development of cranial sensory ganglia, parasympathetic ganglia and LC (Pattyn et 
al, 1999, 2000) demonstrating that both factors are required for a proper neuronal 
development in these areas (Hirsch et al., 1998). 
Moreover, gene replacement of Phox2b in Phox2a locus generally rescues the defects 
exerted by Phox2a KO mouse, as in LC and cranial sensory ganglia, thus indicating that 
probably the main function of Phox2a in these structures is to switch on Phox2b 
expression. In fact, Coppola et al referred to Phox2a as a surrogate promoter of Phox2b in 
these structures. 
On the contrary, Phox2a substitution in Phox2b locus does not rescue the developmental 
defects of Phox2b KO mouse, indicating the predominant role of its paralogue gene. 
 
1.2 Phox2b and the brainstem respiratory circuit  
 
Numerous neurophysiology and molecular biology studies have identified that a limited 
number of neuronal types, which express and depend on the Phox2b transcription factor, 
play a crucial role in the control of breathing. In particular, Phox2b is known to be 
necessary for the correct development of anatomical structures responsible for hypoxia 
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and hypercapnia sensitivity: the Carotid Body (CB), Petrosal chemoreceptors (gP), and 
Nucleus of the Solitary Tract (NTS) (Fig. 4; Dubreuil et al., 2009). 
 
  
Figure 4 Functional anatomy of the visceral reflex circuits. Neurons represented in red are 
Phox2b-positive and their differentiation is Phox2b-dependent. Black arrows indicate the principal Phox2B 
dependent structures involved in chemosensitivity response. AM, adrenal medulla; AP, area postrema; BM, 
branchiomotor neuron; C1, adrenergic centre; CB, carotid body; ENS, enteric nervous system; GG, 
geniculate ganglion; NG, nodose ganglion; nTS, nucleus of the solitary tract; PG, petrosal ganglion; RTN, 
retrotrapezoid nucleus; pgSy, pre-ganglionic sympathetic neuron; PSy, parasympathetic ganglion; Sy, 
sympathetic ganglion; VM, visceromotor neuron (Dubreuil et al., 2009).  
 
The normal breathing is maintained and controlled by a network of neurons localized in 
the brainstem, responsible for respiratory rhythm generation by providing a regular 
respiratory input. 
Respiratory rhythm production is the result of the interaction of two distinct, but 
functionally linked, rhythmogenic networks: the retro-trapezoıd/parafacial respiratory 
group (RTN/pFRG) (Mulkey et al., 2004; Onimaru et al., 2003) and the pre-Bötzinger 
complex (pre-BötC), (Smith et al., 1991). Each of these oscillators controls different 
respiratory phases: the pre-BötC drives inspiration, while the RTN/pFRG controls active 
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expiration and plays an important role in central chemosensitivity (Guyenet et al., 2008; 
Janczewski et al., 2006) (Fig. 5, Panel A). 
In detail three main neuronal groups (Fig. 5, Panel B), bilaterally located at pons-medulla 
level, are responsible for the respiratory rhythm generation: 
- the dorsal respiratory group (DRG), 
- the ventral respiratory group (VRG);  
- the pontine respiratory group (PRG). 
 
 
 
Figure 5. Neuroanatomical representation of brainstem respiratory compartments of 
the rat. Overview of bilaterally distributed brainstem respiratory compartments of the rat arranged from 
the rostral pons to the caudal medulla. (a) horizontal (right) and coronal (left) brainstem sections, (b) a 
parasagittal section of one side of the brainstem. AP, area postrema; LRt, lateral reticular nucleus; NAd, 
nucleus ambiguus, dorsal division; Pn, ventral pontine nucleus; SO, IO, superior and inferior olivary 
complexes; SP5, spinal trigeminal nucleus; V, motor nucleus of the trigeminal nerve; V4, fourth ventricle; 
XII, hypoglossal motor nucleus. (Smith et al. 2013). 
 
The dorsal respiratory group (DRG) is localized in the dorsal portion of the bulb and 
mainly controls the inspiration. DRG consists of inspiratory neurons in the ventrolateral 
region of the NTS (Jordan, 2001). The NTS includes a series of nuclei forming a vertical 
column, in the dorsomedial position of the bulb, and is an important centre innervated by 
visceral afferences. The caudal third of NTS (CNTS) is the termination site of the vagus 
nerve (cranial nerve X) and glossopharyngeal (IX cranial nerve), that transmit sensory 
information from the peripheral chemoreceptors, baroreceptors as well as from different 
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types of receptors in the lungs. Neurons from caudal regions of the NTS and the DRG 
project to pontine and VRG compartments (Smith et al., 2013). 
The ventral respiratory group (VRG) is located in the ventrolateral position of the bulb 
and controls the exhalation. 
VRG extends from the facial nucleus (nVII) up to the spinal cord and consists of 
populations of excitatory and inhibitory interneurons, indicated as respiratory central 
pattern generator (CPG), which interact with each other and are interconnected with 
several pontine nuclei.  
The VRG output is transmitted through premotor networks to cranial and spinal motor 
neurons, which respectively control the muscles of the upper airways and diaphragm, and 
thoracic and abdominal respiratory muscles (Smith et al., 2013).  
VRG includes four different compartments: 
- the Bötzinger complex (BötC), containing glycinergic or GABAergic expiratory neurons 
(Ezure et al., 2003), which inhibit the inspiratory neurons during expiration, providing the 
inspiratory-expiratory phase alternation;  
- the pre-Bötzinger complex (pre- BötC), essential for normal inspiratory activity in vivo 
McKay et al., 2005). The pre-BötC cellular composition is very heterogeneous and 
includes glutamatergic neurons, representing the primary source of the rhythmic 
inspiratory pulse, as well as populations of inspiratory glycinergic (Winter et al., 2009; 
Morgado-Valle et al., 2010) or GABAergic (Kuwana et al., 2006) neurons, which inhibit 
expiratory neurons during inspiration; 
- the rostral ventral respiratory group (rVRG) contains the main group of inspiratory 
premotor bulb-spinal neurons (Alheid & McCrimmon 2008) transmitting the impulse to 
the spinal phrenic motor neurons that innervate the diaphragm;  
- the caudal ventral respiratory group (cVRG) is composed by excitatory bulbospinal 
expiratory neurons, receiving convergent inputs including those from the RTN/pFRG 
and BötC. 
Finally, the pontine respiratory group (pRG), also known as pneumotaxic center, is located 
dorsally in the upper portion of the pons, and mainly controls the frequency and depth of 
breathing (Lindsey et al., 2012). 
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In particular, pRG transmits signals to the inspiratory area regulating the transition from 
the inspiratory to the expiratory phase (Smith et al., 2013), in order to adjust the duration 
of inspiration in the respiratory cycle, of each breathing process.  
Multiple behavioural aspects stimulate the respiratory rate, regulated by the pontine 
circuits. 
In particular, the most potent drives for breathing are inputs generated by peripheral 
chemoreceptors that constantly monitor CO2 and O2 blood pressure.  
Inputs sensitive to the level of blood or brain O2 are originated from peripheral 
chemoreceptors (e.g. carotid body chemoreceptors), which provide input to the NTS. 
The central chemoreception, detection mechanism of CO2/ pH, is primarily mediated by 
chemoreceptors of the brainstem in the ventrolateral medulla. 
Currently there are two possible structures delegated to carry out these functions: 
- medullary serotoninergic neurons (5HT; Corcoran et al., 2009, Hodges et al., 2010) of 
the raphe nuclei; 
- retro-trapezoid nucleus (RTN; Guyenet et al., 2008 and 2009), a group of glutamatergic 
neurons placed ventral and immediately caudal to the facial nucleus (nVII), defined by the 
expression of Phox2b and by the absence of markers for catecholaminergic neurons 
(Goridis et al., 2010;Guyenet et al., 2013). They are vigorously activated by increases 
acidification in vitro, and by hypercapnia in vivo and selectively innervate brain regions 
containing the respiratory CPG (Mulkey et al., 2004; Dubreuil et al., 2008; Onimaru et al., 
2012b; Wang et al., 2013). 
It was found that injury or inhibition of RTN neurons widely attenuate the chemoreceptor 
reflex of breathing in adult rats, and their activation increases the respiratory rate, the 
inspiratory amplitude and active expiration (Guyenet et al. 2012). 
 
1.3 PHOX2 proteins in normal condition: structure and function 
 
PHOX2B and PHOX2A genes have similar genetic organization, as they are both composed 
by 3 exons and 2 introns. The PHOX2B gene is localized in the short (p) arm of 
chromosome 4 at position 12 (4p12), and encodes for a 314 amino acids long protein, 
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whereas the PHOX2A gene is localized in the long (q) arm of the chromosome 11 at 
position 13.4 (11q13.4) and encodes for a protein of 284 amino acids (Adachi et al., 2000). 
PHOX2A and PHOX2B share important sequence homologies, with 56.4% similarity in the 
region N terminal to the homeodomain, and 100% within the homeodomain (HD) (Fig. 6) 
(Vallarche et al., 1993; Zellmer et al., 1995; Pattyn et al., 1997; Yokoyama et al., 1996, 
1999). No homologies have been found in the C- terminal region, downstream the 
homeodomain. 
The HD is a highly conserved 60-amino acids long region that exerts critical protein 
functions. In particular, the HD is able to bind to specific ATTA sequences in target genes 
promoter, resulting in transactivation of their expression; to mediate nuclear import of 
the protein; and protein-protein interactions (Homo- and hetero- dimerization with other 
homeodomain-containing proteins among which PHOX2A itself). 
PHOX2B protein is characterized by the presence of two alanine stretches of 9 and 20 
residues in the third exon, encoding the C-terminal region of the protein. 
The exact function of the polyalanine stretch is not completely clear, but it has been 
supposed to be a flexible spacer element located between functional domains and 
therefore implicated in protein conformation, protein-protein interaction and DNA 
binding. 
 
Figure 6 PHOX2B and PHOX2A proteins. Panel A) Schematic representation of domain structure 
and amino acid sequence homology of PHOX2B and PHOX2A proteins. Numbers refer to the amino acid (aa) 
residues for each PHOX2 protein. N-ter, N-terminal domain; HD, Homeodomain; C-ter, C-terminal domain. 
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The percentage of homology is the results of the amino acids sequence comparison between 
PHOX2B/PHOX2A domains. Panel B) Protein sequence alignment of PHOX2B and PHOX2A aminoacid 
sequences. Red box indicates the homeodomain.  
 
From a molecular point of view, PHOX2A/PHOX2B transcription factors are able to 
regulate genes involved in autonomic nervous system development and neuronal 
specification by binding to specific “ATTA” sequence (Homeodomain Binding Site, HBS) in 
the promoter of target genes.  
Biochemical studies demonstrated that PHOX2A and PHOX2B bind with similar affinity to 
the multiple HD target sequences in the DBH promoter; and independently regulate the 
DBH transcription in a similar extent (Adachi et al., 2000; Seo et al., 2002). 
Interestingly, HBS are also present within PHOX2A and PHOX2B promoters, indicating that 
they can also be regulated by homeodomain transcription factors. Indeed, in our 
laboratory, it has been demonstrated that PHOX2B positively regulate the expression of 
its paralogue gene PHOX2A by binding to HBS present within its promoter (Flora et al., 
2001), and to modulate its own expression through a self-regulatory mechanism (Cargnin 
et al., 2005). 
Moreover, PHOX2B and PHOX2A positively regulate the TLX2 gene expression (T-Cell 
Leukemia Homeobox2) (Borghini et al., 2006, 2007), and both PHOX2B and TLX2 proteins 
are found to be downstream targets of BMP signalling (Tang et al., 1998; Howard et al., 
2000; Schneider et al., 1999). 
Functional analyses indicate that PHOX2A protein, deleted of the region C-terminal to the 
HD, results in a still functional protein, indicating that the N-terminal region represents 
the transactivation domain of PHOX2A (Adachi et al., 2000). Despite the high homology in 
this region between PHOX2A and PHOX2B proteins suggest that they may also share the 
same function, PHOX2B deletion analyses indicate that the N-terminal region alone is not 
sufficient to transactivate target genes (unpublished data, our laboratory). 
 
The main condition necessary for the vertebrate neural development is the coordination 
of cell cycle regulation and cell fate determination (Ohnuma et al., 2001). 
In the cathecolaminergic CAD cell line, a variant of Cath.a-cell line derived from locus 
coeruleus mice brain tumours, PHOX2A mediates cell-cycle exit and neuronal 
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differentiation by inducing the cell-cycle regulatory protein p27 Kip1 (Cyclin-dependent 
kinase inhibitor 1B), in response to the activation of the cyclic AMP (cAMP) pathway (Shin 
et al., 2009). In detail, PHOX2A is maintained in inactive-form by phosphorylation of 
Ser206/202 and 208, located in the C-terminal repression domain of PHOX2A (Swanson et 
al., 1999). The activation of the cAMP pathway mediates the dephosphorylation of Ser 
206, resulting in PHOX2A activation. Active PHOX2A binds to HBS of the p27 Kip1 promoter 
and induces its transcription (Shin et al., 2009). PHOX2A dephosphorylated in 
phosphoserine cluster is then recognised and phosphorylated by protein kinase A (PKA) 
on Ser153, which prevents PHOX2A DNA binding and turns off consequent p27Kip1 
transcription (Shin et al., 2009).  
Moreover, Adachi et al. (2000) demonstrated that both PHOX2A and PHOX2B are able to 
interact with PKA pathway and to synergistically increase the transcription of the DBH 
promoter (Adachi et al., 2000), suggesting that dephosphorylation/phosphorylation 
events may also control PHOX2B temporal activation. 
Direct proof of the role of PHOX2B in the coordination of cell cycle exit has been obtained 
by gain and loss of function experiments. In particular, forced PHOX2B expression in 
embryonic chick spinal cord drives cells to become post-mitotic; conversely, in the 
absence of PHOX2B, post-mitotic neuron precursors did not form properly (Dubreuil et 
al., 2000 2002). 
Despite their central role in embryonic neurodevelopment, so far very little is known 
about Phox2 proteins functions in adulthood. 
 
1.4 PHOX2 proteins and disease: 
 Neuroblastoma and Genetic disorders 
 
PHOX2 proteins are found to be correlated with congenital pathologies since homozygous 
mutations in PHOX2A gene result in congenital fibrosis of the extraocular muscles type 2 
(CFEOM2, OMIM 602078; Nakano et al., 2001), whereas heterozygous mutations in 
PHOX2B gene lead to Congenital Central Hypoventilation Syndrome (CCHS, OMIM 
209880; Amiel et al., 2003; Sasaki et al., 2003), Hirschsprung’s disease (HSCR; OMIM 
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142623)( Trochet et al., 2005 ; Berry-Kravis et al., 2006), and neuroblastoma (NB, 
Bourdeaut et al., 2005; Van Limpt et al, 2004).  
Moreover, both PHOX2A and PHOX2B are found to be over-expressed in NB samples 
(Longo et al 2008). 
 
1.4.1 Neuroblastoma 
 
Neuroblastoma (NB; OMIM 256700) is an embryonic neuroblastic tumour stemming from 
neural crest progenitors (Schleiermacher et al., 2014). 
NB represents the most common infant tumour (8-10% of pediatric tumours) often 
occurring in association with other genetic syndromes caused by the aberrant growth, 
migration and differentiation of neural crest cells.  
Neuroblastic tumours are characterized by a high heterogeneity in cellular differentiation 
stage, ranging from tumours with undifferentiated cells that are usually indicative of a 
poor prognosis to those with more differentiated cells that generally provide a favourable 
outcome (Park et al., 2008). 
 
Genetic basis of NB  
 
The increasingly frequent association of NB with genetic diseases and the observation of 
rare familiar cases (1% of NB) have suggested a possible involvement of genetic factors in 
the NB development. 
Evidences of NB genetic predisposition have been recently reported, involving mutations 
in different genes (Fig. 7): 
- constitutive activating ALK (Anaplastic Lymphoma Kinase) mutations, identified in more 
than 50% of familial cases (Janoueix-Lerosey et al., 2008; Mossé et al., 2008); 
- PHOX2B mutations, found in a small fraction of patients with sporadic or familial NB 
(Bourdeaut et al., 2005; Van Limpt et al, 2004); 
- amplification and overexpression of LIN28B gene (Lin-28 homolog B) resulting in high 
MYCN protein expression, an important prognostic factor in NB (Molenaar et al., 2012). 
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In addition, a functional relationship between two of the above-mentioned genes 
involved in NB has been described, as PHOX2B drives ALK transcription (Bachetti T. et al., 
2010). 
 
Figure n. 7 Sympathetic ganglionic cell differentiation and neuroblastoma. MYCN together 
with bone morphogenetic proteins (BMPs) induced neuroblast progenitors to migrate from neural crest up 
to the region laterally to dorsal aorta, here they become primary sympathetic ganglia (PGS). Later, nerve 
growth factor (NGF) determines the differentiation of cells into mature sympathetic ganglionic cell (blue) or 
apoptotic cells, in cases of  abnormal precursors. MYCN/PHOX2B/ALK are indicated as 'first hit' in NB 
manifestation, as mutations/overexpression of these genes are the primary events in tumour development. 
A 'second' hit is the acquisition of death resistance of neuroblast precancer cells (purple), following by a 
third change which induces transformation into neuroblastoma cells in early infancy (Marshall et al., 2014). 
 
PHOX2B pathogenetic mechanisms in NB 
 
The findings that PHOX2B is mutated and overexpressed in NB, as well as the PHOX2B-
mediated regulation of genes involved in NB (e.g PHOX2A, ALK) indicate this transcription 
factor as an important player in NB development.  
However, mechanisms whereby PHOX2B mutations or overexpression may be considered 
pathogenic are still unrevealed. 
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PHOX2B mutations, linked to NB, are both frameshift and missense mutations, which lead 
to truncated or malfunctioning proteins. An explanation for the role of these PHOX2B 
variants in NB predisposition is provided by the observation of increased proliferation and 
dedifferentiation of sympathetic neuron, as a result of overexpression of these protein 
variants (Reiff et al., 2010). Moreover, in NB patients with mutations in PHOX2B gene, it 
has been observed a 50% reduction of PHOX2B wild-type level, thus suggesting a 
dominant-negative mechanism of PHOX2B mutated proteins on its own transcription 
(Reiff et al., 2010). 
The pathogenetic function of PHOX2B overexpression opened a deep debate among 
scientists, as conflicting data have been obtained over the years. In particular, despite 
some works indicate that PHOX2B exerts an anti-proliferative and pro-differentiating 
function by regulating neuronal cell cycle-exit (Dubreuil et al., 2000; Reiff 2010), 
additional studies indicate the importance of this transcription factor in the proliferation 
of immature sympathetic neurons (Coppola et al., 2010; Ke et al., 2015).  
As mentioned before, patients with CCHS have a high predisposing risk to develop tumors 
of the sympathetic nervous system (Rohrer et al.2002); indeed, NB or ganglioneuroma 
tumours have been diagnosed in approximately 20% of CCHS patients, mainly in patient 
bearing non poly-alanine repeat mutations (NPARM, described later in Genetic basis of 
CCHS). 
In this regard, a quantitative expression analysis of PHOX2B and its paralogue PHOX2A 
was performed by Longo and co-workers in 2008 (Longo et al., 2008), using a panel of NB 
tumour samples and NB cell lines to detect a possible differential expression of the two 
paralogue genes. This study revealed that both PHOX2A and PHOX2B are over-expressed 
in NB cell lines and tumours samples. Particularly, the enhanced expression level of the 
two genes in NB samples suggests a possible involvement in tumour development 
through two possible mechanisms: a direct up-regulation or a failure in maintaining their 
correct transcript level after embryonic development. 
Unlike PHOX2B, in which both mutations and altered expression levels were found in 
correlation with NB development, no mutations were found in PHOX2A coding and 
promoter region of tumour samples (Wilzén et al., 2009). This observation does not 
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preclude that PHOX2 pathway deregulation is strictly linked to neuroblastoma onset and 
development. 
 
Pharmacological research in NB 
 
The Children’s Oncology Group (COG) classified NB children into 3 different risk groups 
(low, intermediate, and high) in order to predict the most effective treatment, in each 
specific case. The NB treatment varies significantly based on the risk for relapse 
classification of the disease.  
Generally, NB patients with a low risk disease have tumours that are localized to one 
area, which can be effectively surgically removed. However, sometimes, NB tumours 
spontaneously remit in part or completely and the potential risks of surgery to remove 
the tumour can be avoided. 
In intermediate risk disease, not always tumours can be easily and completely removed 
with surgery, they present a high heterogeneity in cellular composition (different 
differentiation stage), and may create symptoms related to the compression of other 
organs. In this stage, moderately intensive chemotherapy is given initially to reduce the 
tumour size and make it easier to surgically remove it . 
Finally, NB tumours are classified as high risk disease because of aggressive characteristics 
of the tumour cells or for the presence of tumours in multiple places. Patients, classified 
in this risk category, require a strong treatment combining chemotherapy, surgery, stem 
cell transplant, radiation therapy and immunotherapy. 
As high-risk patients often undergo a relapse of tumour, nowadays “additional drugs” 
aimed to eliminate residual tumours cells have been introduced, after consolidation 
therapy. 
These drugs act by stimulating body’s immune system (e.g. antibodies against GD-2, 
disialoganglioside; and IL-2, interleukin-2; IL-15 interleukin-15)(Yang and Sondel 2010; YU 
et al., 2010; Cappel et al., 2016) or stimulating the differentiation of residual immature 
cancer cells (e.g 13-cis-retinoic acid, isotretinoin).  
Neuroblastoma cells are very sensitive to retinoids, which are vitamin A derivatives that 
include, 13-cis- retinoic acid (RA), 9-cis-retinoic acid, and all trans-retinoic acid (ATRA).  
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Retinoids are known as differentiating agents because they are thought to inhibit the 
development and growth of several types of cancer, including gastrointestinal, oral cavity, 
skin, lung, and breast cancers (Niles et al., 2000; Niles et al., 2004; Altucci & Gronemeyer 
2001; Siddikuzzaman et al., 2011; Arrieta et al., 2010; Bryan et al., 2010).  
Since their efficacy in inducing cancer cells to differentiate has been demonstrated 
(Reynolds & Lemons 2001), retinoids have been introduced in some cancer treatment. 
In particular, ATRA is used alone in the treatment of acute promyelocytic leukaemia (APL) 
as non-chemotherapy drug or in combination with chemotherapy giving more solid long-
term results (Degos et al., 2001). 
Both ATRA and 13-cis-RA, are found to rapidly-drive immature cancer cells differentiation, 
reverting the malignant neuroblast phenotype (Altucci et al., 2001), and 13-cis RA is 
currently used as “additional drugs” in the treatment of high risk NB, given their 
advantageous pharmacokinetic properties (Chu et al., 2003).  
Despite retinoids are now being introduced in NB treatment, the molecular mechanisms 
by which they regulate different signalling pathways necessary for retinoic-induced 
cellular differentiation are still largely unknown. 
Starting from the knowledge that PHOX2B is mutated and overexpressed in NB, and since 
it is a direct regulator of ALK and PHOX2A, both linked to NB, a new pharmacological 
research strategy in treatment of such tumours regards the control of PHOX2B 
expression. 
In particular, in 2015, Di Zanni and co-workers analysed the effect on PHOX2B expression 
of different molecules and epigenetic modulators, known to be involved in PHOX2B 
expression regulation and already used in neuroblastoma clinical trials. 
In their analysis, different molecules were found to decrease PHOX2B mRNA expression 
and, in particular, in the case of Curcumin treatment it has been observed also a 
significant down-regulation of PHOX2B protein. 
In addition, the use of the natural spice has been already found to enhance the beneficial 
effect of epigenetic modifier Trichostatin (TSA) and Suberoylanilide hydroxamic acid 
(SAHA), both inhibitors of histone deacetylase, already established to have anticancer 
effects in combination to ATRA (De los Santos et al., 2007). 
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Very interestingly, the combination of Curcumin to TSA or SAHA results in a markedly 
effect on PHOX2B regulation with respect to the single treatment (Di Zanni et al., 2015).  
 
1.4.2 PHOX2 proteins in genetic disorders 
 
Congenital fibrosis of the extraocular muscles type 2 (CFEOM2) 
 
Homozygous loss-of-function mutations in PHOX2A gene are found to be causative for 
Congenital Fibrosis of the Extraocular Muscles type 2 (CFEOM2) (Nakano et al., 2001), a 
complex strabismus syndrome.  
CFEOM2 is inherited in autosomal recessive manner and mutations causing its 
manifestation, mainly upstream or within the PHOX2A homeodomain, result in a 
truncated not functional protein (Nakano et al., 2001). 
As discussed before, PHOX2A and PHOX2B have a primary role in noradrenergic neuronal 
development and determination. Oculomotor (nIII) and trochlear (nIV) neurons are the 
only Phox2a structures co-expressing Phox2b, that are missing in Phox2a -/- mouse but 
they are preserved in Phox2b -/- thus indicating that nIII/nIV are the only neurons Phox2a-
dependent that do not need Phox2b for proper development.  
This finding supports the idea that CFEOM2 is due to failure in the development of 
oculomotor and trochlear nerves, with consequent malfunctioning of muscles that they 
innervate. 
Human alterations in these structures result in bilateral severe congenital exotropia and 
ptosis and small unreactive pupils (Wang et al., 1998; Yazdani et al., 2003). 
Despite the primary role exerted by PHOX2A in neuron development and specification of 
oculomotor (nIII) and trochlear (nIV) neurons, locus coeruleus (LC), the three cranial 
ganglia and parasympathetic ganglia of the head, only III/IV cranial nuclei and nerves are 
found to be defective in CFEOM2 (Fig. 8). 
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Figure 8: Schematic lateral representation of the brainstem and left orbit in CFEOM2 
affected individual. nVI, abducens nucleus; CN VI abducens nucleus cranial nerve; CN V, trigeminal 
cranial nerve; are normal in CFEOM2 as well as muscles that they innervate. nIII, oculomotor and nIV, 
trochlear cranial nuclei (dotted pink nuclei) as CN III & CN IV, corresponding cranial nerves (dashed red 
lines), are abnormally developed as well as the muscles innervated by nIII (inferior oblique, medial and 
inferior recti, superior, levator palpebrae superioris,) and nIV (superior oblique) all represented in light blue. 
The ciliary ganglion status (question mark) is not clear yet. Modified from Nakano M. et al., 2001 Nature 
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Neurological examinations in individuals with CFEOM2 did not report any autonomic, 
cognitive or developmental neurological abnormalities, and neurological anatomical 
defects involve only the eyes and eyelids (Bosley et al., 2006).  
As afore described, Phox2b gene replacement in Phox2a locus is able to rescue almost the 
totality of anatomical defects manifested by Phox2a -/- mouse in neurological regions in 
which Phox2a/Phox2b are co-expressed. This suggest that PHOX2B may compensate for 
the lack of PHOX2A in CFEOM2 patients, in all the other brain regions regulated by both 
transcription factors. 
 
Congenital Central Hypoventilation Syndrome (CCHS) 
 
Congenital Central Hypoventilation Syndrome (CCHS), also known as Ondine's course, is a 
rare neonatal neurological disorder (1: 200.000 birth alive), caused by defective migration 
of the neuronal precursor from the neuronal crest tube.  
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CCHS is manifested as a respiratory disorder along with symptoms of autonomic nervous 
system dysregulation (ANSD), making part of a group of rare disorders defined as RADICA 
(Respiratory and Autonomic Disorders of Infancy, Childhood, and Adulthood; Weese-
Mayer., 2009). 
As PHOX2B is important for the development of structures responsible of the control of 
central respiration, this justifies the finding that mutations in this transcription factor are 
causative for CCHS.  
The principal feature of this autonomic syndrome is the breathing deficit mostly 
prominent during sleep hours, associated with diffuse autonomic dysregulation (Weese-
mayer et al., 1999 and Weese-Mayer et al., 2001), Hirschsprung’s disease (HSCR) 
(Vanderlaan et al., 2004) and neural crest tumours (Haddad et al., 1978).  
Hirschsprung’s disease (HSCR), or congenital aganglionic megacolon, is a developmental 
disorder characterized by the absence of ganglia in the lower digestive tract, resulting in a 
functional obstruction (Heanue et al., 2007). Aganglionosis is linked to incorrect 
development of the enteric nervous system (ENS), therefore, ganglion cells fail to 
innervate the lower gastrointestinal tract during embryonic development. Treatment for 
HSCR consists of surgery to remove the part of the gut that is not innervated and re-
connection of the remaining intestine to the anus. HSCR can occur alone or in syndromic 
disease (e.g. CCHS). Different studies have led to the identification of mutations in 
different genes (RET, GDNF, NRTN, PHOX2B, EDNRB, EDN3, ECE1, SOX10, ZFHX1B), which 
lead to isolated HSCR or syndromic HSCR phenotype (reviewed in Tam & Garcia-Barcelò 
2009). The association between CCHS and HSCR is configured as Haddad syndrome. Birth 
incidence of HSCR is approximately 1:5000 newborns, and occurs in 16% of CCHS patients. 
The ANSD symptoms of CCHS include altered blood pressure homeostasis (Trang et al., 
2005), decreased heart rate variability and attenuated heart rate response to exercise 
(Woo et al., 1992; Ogawa et al., 1993; Silvestri et al., 2000; Trang et al., 2005), ocular 
abnormalities (Weese-Meyer et al., 1992), severe constipation and oesophageal 
dysmotility (Weese-Mayer et al., 1992; Faure et al., 2002). 
Instead, the respiratory symptoms consist in ventilatory arrest during sleep and a reduced 
or, in severe cases, absent response to hypercapnia (Gozal et al., 1998; Chen et al., 2004). 
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The disease typically occurs soon at birth by hypoventilation or apnoea periods during 
sleep, even though severely affected infants are not able to breathe properly even during 
wakefulness (Gozal et al., 2008). Moreover, there are rare late-onset forms (LO-CCHS) of 
the disease (Weese-Mayer et al., 2005) in which the symptoms reveal during late 
childhood or even in adulthood (very few cases).  
Currently, there is no pharmacological treatment capable of restoring the normal 
ventilation in patients, therefore the only available support for CCHS affected patients is 
the mechanical ventilation by means of tracheotomy, nasal masks or phrenic nerve 
stimulation through diaphragmatic pacemaker implantation.  
The absence of adequate treatments can result in central hypoxia with consequent risks 
of neurological damages, and fatal consequences.  
 
Genetic basis of CCHS 
 
Almost the totality of CCHS patients (98%) presents mutations in the coding region of 
PHOX2B, and in some patients mutations have been reported in other genes involved in 
neuronal crest development: RET (REarranged during Transfection), GDNF (Glial cell 
Derived Neurotrophic Factor, RET ligand), EDN3 (Endothelin 3), BDNF (Brain Derived 
Neurotrophic Factor), MASH1 (Mammalian Achaete-Scute complex homolog 1), PHOX2A 
(Paired-like Homeobox 2A), GFRA1 (GDNF Family Receptor Alpha 1), BMP2 (Bone 
Morphogenetic Protein 2) and ECE1 (Endothelin Converting Enzyme 1) (reviewed in 
Gallego, 2012). 
PHOX2B mutations in CCHS patients are divided in two classes (Weese-Mayer et al., 2010) 
(Fig. 9): 
- Polyalanine repeat mutations (PARMs), due to the insertion of +5 to +13 Alanine in the 
20-Alanine stretch at the C-terminus of the homeodomain (95% of CCHS patients); 
- Non-Polyalanine repeat mutations (NPARMs), including frameshift mutations, in which 
the insertion/deletion of a single nucleotide induces a change in the reading frame of the 
protein (<5%), and very rare non-sense mutations in which the generation of a stop codon 
induces the consequent production of an incomplete non-functional protein.  
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Generally, patients with PARMs mutations exhibit a respiratory phenotype with a clear 
correlation between the length of the alanine tract and the severity of the symptoms; 
starting from the milder phenotype in the +5 alanine insertion mutation, up to the most 
severe phenotype in the +13 alanine insertion, whereas the +7 alanine insertion 
represent the most common mutation. 
On the other hand, in patients with the less frequent nPARM mutations, respiratory 
symptoms are more severe and often associated with Hirschsprung’s disease, 
neuroblastoma and serious autonomic dysregulation. 
 
 
Figure 9 PHOX2B mutations in CCHS. Schematic representation of PHOX2B mutations associated 
with CCHS. Red box indicates homeodomain. Yellow boxes represent polyalanine regions. The totality of 
polyalanine repeat mutations (PARMs) regards the 20-alanine long stretch at the C-terminus of exon 3. 
Non-polyalanine repeat mutations (NPARMs) are found to be located principally at 3' end of exon 2 or in 
exon 3. 
 
CCHS is inherited in an autosomal dominant manner. Most of the PHOX2B mutations in 
individuals with CCHS are de novo mutations. However, it is emerging that approximately 
10-25% of parents are asymptomatic carriers, responsible for transmission to their 
offspring (Weese-Mayer et al., 2003; Amiel et al., 2003, Parodi et al.,2008; Trochet et al., 
2008). Different possibilities are described for asymptomatic carriers, including the 
presence of minor polyalanine expansion (e.g. 20/23 genotype), and genotypes with 
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incomplete penetrance, somatic or germinal mosaicism (Loghmanee et al., 2009; Weese-
Mayer et al., 2003; Amiel et al., 2003, Parodi et al.,2008; Bachetti et al., 2014). 
 
Pathogenetic mechanisms in CCHS 
 
The clinical features of patients with CCHS are very variable. Indeed, patients bearing the 
same PHOX2B mutations may present different clinical manifestations and severity of the 
respiratory phenotype. In addition, NPARMs mutations are associated with increased 
number of clinical symptoms, compared to PARMs, thus suggesting that it could be 
associated with different pathogenetic mechanisms (Trochet et al., 2004 and 2005). 
The divergence in the pathological condition observed in CCHS patients, along with in vivo 
and in vitro studies, indicate the cooperation of different mechanisms at the basis of 
CCHS, including: 
1) haploinsufficiency; 
2) loss of function;  
3) dominant-negative function; 
4) gain of function. 
1) In vivo analysis, conducted on Phox2b heterozygous knockout mice (Phox2b +/-), is 
suggestive of a haploinsufficiency mechanism in CCHS pathogenesis. 
Phox2b +/-mice show a respiratory phenotype, limited to the first post-natal period, in 
association with life-long ANS dysfunctions (Durand et al., 2004). This finding indicates 
that a single copy of Phox2b gene leads to a reduction in protein amount that is not 
sufficient to perform the normal Phox2b function, resulting in aberrant phenotype. 
2) Phox2b 27 Ala+/- mutants phenocopy the Phox2b -/- null mutants and die in utero, 
suggesting that mutant proteins have lost their transactivation ability or the capacity to 
form homo- and heterodimers and to interact with transcriptional co-activators, 
impairing the correct developmental programme.  
In vitro experiments have demonstrated that mutated PHOX2B protein is less functional 
compared to the wild-type protein. PARM mutants have a significant reduction in their 
capability to regulate the DBH, PHOX2A and TLX2 gene expression, which represent three 
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of the known PHOX2B target genes (Trochet et al., 2005; Bachetti et al., 2005; Di Lascio et 
al., 2013).  
Moreover, in our laboratory it has been shown that PHOX2B is able to directly regulate its 
own expression by means of an auto-regulatory loop (Cargnin et al., 2005), and that 
expanded proteins interfere with this mechanism, inducing an additional critical 
reduction in the expression of the wild-type protein (Di Lascio et al., 2013).  
3) Mice bearing the most common polyalanine expansion observed in CCHS (Phox2b 
+/+7Ala), die soon after birth for respiratory failure, phenocopying the most severe CCHS 
cases (Dubreuil et al., 2008). Moreover, they show a selective loss of RTN neurons, but 
other Phox2b-expressing structures involved in respiratory control are preserved, thus 
indicating a gain of function of the Phox2b mutant protein in the development of 
susceptible neuronal structure. 
It has been observed, in vitro, that PHOX2B mutants, carrying frameshift mutations or the 
+12 alanine expansion, interfere with the synergistic transcriptional activation of the DBH 
gene mediated by the wild-type protein and the transcriptional co-activator CBP (CREB 
binding protein) (Wu et al., 2009). 
Moreover, in cells co-transfected with equal amount of mutant and wild-type protein, 
resembling the heterozygous pathological condition, PHOX2B +13 Ala protein affects the 
PHOX2B wild-type mediated expression of DBH, TLX2 and PHOX2B itself (Parodi et 
al.,2012; Di lascio et al., 2013). 
Furthermore, the negative effects of PHOX2B mutant proteins on the transcriptional 
activity of the wild-type protein are promoter-specific (Trochet et al.,2005; Di Lascio et al., 
2013), but it is not clear if the observed functional effects are the result of direct aberrant 
interactions between wild-type and mutant proteins and/or with other proteins. These 
data may explain the different susceptibility of neuronal structures to Phox2b mutations. 
4) Available data from literature (Trochet et al., 2005; Bachetti et al.,2005 and 2007) and 
from our laboratory (Di Lascio et al., 2013) have shown that, in vitro, the longest 
polyalanine expansions (+11, +13 residues) are responsible for the formation of nuclear 
and cytoplasmic toxic aggregate, and that there is a strong correlation between the 
length of the polyalanine tract and protein cytoplasmic mislocalization. It has been also 
described that, in vitro, PHOX2B protein carrying the longest polyalanine tract (+13 Ala), 
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can retain a fraction of wild-type protein in both nuclear and cytoplasmic inclusions 
(Bachetti et al., 2005; Parodi et al., 2012). 
The contribution of the cellular aggregates to the CCHS pathogenesis is still not 
completely clear and represents a key issue for the study of pharmacological agents 
capable of destroying PHOX2B aggregates or eventually of preventing their formation, 
e.g. activator of the protein degradation pathway, inhibitors of the protein incorrect 
folding, neuroprotective agents and apoptotic inhibitors. 
Furthermore, we cannot exclude that proteins with the shortest polyalanine expansion 
and NPARM mutated proteins, that correctly localize into the nucleus, are able to 
properly fold and to adequately interact with co-activators. In this regard Wu et al. (2009) 
have demonstrated that PHOX2B nPARM mutants interact with CBP co-activator (CREB-
binding protein) through different domains with respect to wild-type protein.  
 
Therapeutic approach in CCHS treatment: 
 
Aggregates targeting approach 
 
As of today no pharmacological respiratory stimulants have turned out to be effective; 
the ventilatory supports represent the only option available for CCHS affected children. 
Until now, the only pharmacological strategy investigated is targeted to dissolving intra-
cytoplasmic aggregates of longest expanded PHOX2B proteins by using pharmacological 
agents which activate the heat shock protein (HSP) response (Bachetti et al., 2007 Di 
Zanni et al., 2012). 
This observation starts from the remark that numerous chaperones, member of the HSP 
family, actively interact with intracellular aggregates of huntingtin protein, reducing their 
formation and cellular toxicity caused by the expanded polyQ tract (Abu-Baker et al., 
2003; Bachetti et al., 2007; Bao et al., 2004; Cummings et al., 1998; Hay et al., 2004; Jana 
et al., 2000; Wang et al., 2005). 
In particular, in 2007, Bachetti and co-workers demonstrated that geldanamycin (GA) is 
able to induce disaggregation of cytoplasmic protein aggregates in cell transfected with 
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PHOX2B carrying the +13 Ala expansion, thus also rescuing its nuclear localization and 
transcriptional activity (Bachetti et al., 2007). In addition, they observed that GA 
treatment in HeLa cell lines also induced a high increase in apoptosis (50%) after 5 days of 
treatment (Bachetti et al 2007). 
In 2012, the same group tested the effect of other compounds, known to be capable of 
dissolving protein aggregates or of preventing their formation (Di Zanni et al., 2012), on 
PHOX2B expanded protein. In particular, they analysed the effect on PHOX2B polyalanine 
protein disaggregation, on the rescue of its nuclear localization/transactivation activity, 
and the cellular toxicity of the treatment. In this work the authors found that in addition 
to the afore mentioned GA, also the treatment with its analogue 17-AAG (17-N-
allylamino-17-demethoxygeldanamycin), as well as the Curcumin (diferuloylmethane) 
(Cheng et al., 2001; Sharma et al., 2004), resulted to be effective. 
Indeed, these two drugs successfully eliminate PHOX2B +13 Ala protein aggregates 
formation inducing a 70-80% rescue of its transcriptional activity. 
Moreover, they confirmed that, as already observed for GA, 17-AAG induced HSP70, 
while Curcumin did not exert any effect on HSP70 expression, thus suggesting that it may 
use a different refolding mechanism. 
Interestingly, 17-AAG, GA or Curcumin induced a faster degradation of wild-type protein 
with respect to the expanded mutants probably as consequence of its more soluble 
conformation. 
This finding suggests the use of 17-AAG and curcumin as possible pharmacological 
strategy targeted to ameliorate the toxic cellular consequences linked to the presence of 
PHOX2B proteins containing expanded polyalanine tract. 
Another pharmacological target, studied for CCHS treatment, regards the induction of the 
Ubiquitine Proteasome Response (UPS) by overexpressing the E3 ubiquitin ligase TRIM11 
(Parodi et al.,2012). Usually, misfolded proteins are contacted by HSP, which refold them 
by reducing their toxic effects and restoring their normal phenotype. However, misfolded 
proteins are also targeted for the degradation by the UPS, and to this end the protein 
were ubiquitin marked by a process involving E1, E2, and E3 ubiquitin ligase enzymes, 
which act consequently. The TRIM11 protein is an E3 ubiquitin ligase that determines the 
substrate specificity, and it has been found to directly interact with PHOX2B wild-type 
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protein and to increase DBH expression (Hong et al., 2008). Parodi and co-workers (Parodi 
et al., 2012), in particular, demonstrated that TRIM11 overexpression is capable of 
inducing wild type and mutant protein degradation by UPS and of rescuing the 
impairment of transcription from DBH promoter associated with the dominant-negative 
effect exerted by mutant proteins. 
These data suggest that the mechanism, which induces TRIM11 up-regulation, may offer 
a potential target for CCHS treatment. 
Whilst these observations propose a possibility in the functional recovery of PHOX2B 
mutant protein, through dissolution of toxic cellular aggregates, on the other hand the big 
issue related to these strategies is that aggregation was demonstrated only in vitro. 
Therefore, we cannot exclude that aggregate formation could be the result of an artefact 
consequence of protein over expression in cells.  
In vivo, data obtained by the knock-in mouse carrying the most common heterozygous 
Phox2b +7 alanine expansion (Phox2b +/+7Ala) highlight the lack of RTN neurons 
development. However, it is not yet clear if the other neuronal regions, involved in the 
control of respiration, are correctly preserved and functioning. 
In humans, studies on the RTN are very difficult. RTN has been tentatively identified in 
man as a small neuronal region, PHOX2B positive, at the pontomedullary junction ventral 
to the facial nucleus and lateral to the superior olivary nucleus (Rudzinski & Kapur, 2010). 
Altered development of the putative hRTN (human RTN) has been identified in human 
sudden infant death syndrome (SIDS) victims (Lavezzi et al., 2012); thus suggesting a 
possible neuronal anatomical defect in this area, also in CCHS human patients.  
Very recently, analyses of post-mortem brain of two CCHS patients, one PARM and one 
NPARM, have shown the presence of anatomical abnormalities in different neuronal 
regions. 
In particular, locus coeruleus atrophy was found in both patients’ brain, whereas the 
NPARM patient presents markedly abnormalities in different brain regions including: 
decreases in the dorsal motor nucleus of the vagus nerve, absent mesencephalic 
trigeminal nucleus, and decreased serotonergic median raphe and DBH-positive adrenal 
medullary neurons (Nobuta et al., 2015). These findings indicate the presence of 
anatomical neurodevelopmental defects in CCHS patients, obviously irreparable with 
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pharmacological treatments. However, other neural structures involved in breathing 
control, whose function depends on PHOX2B, may get beneficial effects by the 
restoration of PHOX2B activity. 
An absolute limitation to the comprehension of the molecular mechanism underlying the 
disease is due to the substantial lack of information about the genes regulated by 
PHOX2B, and their specific involvement in the different clinical manifestations of the 
disease, as well as their implication in the regulation of the afore mentioned affected 
neuronal areas. The importance of better identifying PHOX2B target genes arise from the 
interesting prospective that some of them may become possible pharmacological targets 
in the CCHS treatment. 
 
The progestin desogestrel: from bedside to bench side 
 
In 2010 a hopeful indication for the treatment of CCHS patients came from a direct clinic 
observation. 
In particular, it has been observed that two female patients (20/25 and 20/26 genotype), 
using a progestin drug, Desogestrel, for contraceptive purposes, dramatically ameliorated 
the clinical symptoms of CCHS, showing chemosensitivity recovery (Straus et al 2010). 
This fortuitous observation suggests a possible link between this drug and the recovery of 
the CO2 chemosensitivity, however the molecular mechanism of this unexpected 
pharmacological effect is completely unknown.  
Starting from this observation Straus' group of clinicians from Groupe Hospitalier Pitie-
Salpetriere in Asistance Publique-Hopitaux de Paris has started a clinical trial to study the 
effect of desogestrel on ventilatory response to hypercapnia in a small cohort of female 
CCHS patients (clinicaltrials.gov. NCT01243697). 
The use of progestin drugs for CCHS treatment theoretically represent a strong option, as 
it is known that hormones can act as stimulants or inhibitors of respiratory activity even 
in healthy subjects (Bayliss and Millhorn, 1992; Pen᷉a and Garcia, 2006). 
Among the various classes of hormones involved in the endocrine modulation of 
breathing, steroid hormones, in particular sex hormones, have a major impact. 
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Sex hormones (androgens, oestrogens, and progesterone) are synthesized from 
cholesterol (Stoffel-Wagner, 2001) principally in the gonads, the adrenal gland and the 
placenta, but they are produced in the CNS (neurosteroids) as well (Nelson & Bulun et al., 
2001).  
Sex hormones have significant effect on the respiratory neuronal network during early 
development, as the activation of their receptors in embryonic brain induces differences 
in the number of neurons, organization of synaptic connections, and neurotransmitter 
expression in the adult brain nuclei (Negri-Cesi et al., 2008). 
Hormones are able to easily cross blood-brain barrier, and to contact neurons in 
peripheral and central nervous system. Possible mechanisms, whereby sex hormones can 
modulate breathing, include direct effects on gene expression in respiratory neurons (by 
steroid hormones receptors activation) or indirect regulation by neurotransmitter. 
Interestingly, sex hormone receptors  are expressed in several brain regions involved in 
respiratory control, including the NTS, hypoglossal and phrenic nuclei, and carotid body 
(reviewed in Behan & Wenninger 2008). 
As different studies have highlighted differences in respiratory parameters between men 
and women, and in different menstrual cycle phases in women, progesterone (Pg) has 
been pointed as a key hormone in the control of breathing. Indeed, despite Pg exerts its 
effect mainly on the uterus and the breast, it also induces numerous effects on other 
tissues different from its primary targets, as in brain areas (Brinton et al., 2008); indeed, 
its receptors were detected at the level of the trachea, lungs, brain and brainstem 
(Saaresranta, 2002). As a neurosteroid, Pg regulates neuronal function, primarily via 
allosteric regulation of some membrane-bound receptors, such as GABA-A (Gamma-
aminobutyric acid) receptors. In particular, Pg acts as a potent positive modulator of the 
GABA-A receptor, in the form of its neuroactive metabolite, allopregnanolone (Porcu et 
al., 2012; Andrade et al., 2012). Recently, etonogestrel, the active metabolite of 
desogestrel, has been shown to  positively modulate  GABA-A receptor resulting in 
increased respiratory frequency (Joubert et al., 2016). 
Progesterone is considered a powerful stimulant of the respiratory activity.  
Several studies have shown that the physiological Pg increases ventilation in women 
during pregnancy (Saaresranta et al., 2003), whereas Pg administration reduces apnoea 
37 
 
frequency in adult women (Shahar et al., 2003) and it has proposed as drug for the 
treatment of prematurity apnoea (Finer et al., 2006).  
In vivo experiments indicate that Pg administration enhanced the respiratory response to 
hypoxia in newborn rat (Hichri et al., 2012; Bairam et al., 2013); whereas R5020, a Pg 
receptor agonist, increased phrenic nerve activity and respiratory frequency, in male and 
female cats (Bayliss and Millhorn 1992).  
Taken together these data support the hypothesis that the use of progestin drugs 
theoretically represent a good option for CCHS treatment. 
Nevertheless, Sritippayawan and colleagues (2002) claimed that hypoventilation 
symptoms do not ameliorate in CCHS patients during gestation, in spite of the 
corresponding increase in progesterone level. The effect of Desogestrel on CCHS patients 
can be due to the greater biological potency of desogestrel with respect to natural 
progesterone (Wiegratz and Kuhl, 2004), as its affinity for the progesterone receptor is 
three times greater than that of progesterone (Straus et al., 2010; Wiegratz and Kuhl, 
2004).  
Starting from these observations, it is reasonable to suppose that the potent 
progesterone receptor agonist desogestrel may be able to induce changes in respiratory 
control by stimulating autonomic CO2 chemosensitive regions, affected by PHOX2B 
mutations. 
The Desogestrel is a progestin commonly used in hormonal contraception in association 
with the estradiol. 
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Figure 10 Bioactivation of the contraceptive steroid desogestrel mediated by CYP2C. Modified from 
Gentile et al., 1998. 
 
Desogestrel constitutes the pro-drug of the active metabolite 3-keto-desogestrel 
(etonogestrel, 3-oxodesogestrel, Org-3236), and this conversion is operated in vivo by 
cytochromes CYP450 2C9 (CYP2C9) and CYP450 2C19 (CYP2C19) (Fig. 10; Gentile et al, 
1998). 
 
- Progesterone receptors 
From the molecular point of view, the progesterone response is mediated by the binding 
to different Pg receptors (PGRs): 
- classical nuclear progesterone receptors (cPRs); 
- membrane progesterone receptors (mPRs).  
Usually, the binding of Pg to one of these two receptor types leads to different 
mechanisms of action, in particular, a rapid non-genomic mechanism mediated by 
progesterone membrane receptors, or a slower genomic mechanism mediated by nuclear 
progesterone receptor isoforms (described later). 
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- Classical nuclear progesterone receptors (cPRs)  
 
Classical nuclear progesterone receptors (cPRs) were described by Sherman et al in 1970 
(Sherman et al., 1970). Despite their principal reproductive functions, cPRs have been 
soon localized to different CNS regions including the hypothalamus, cortex, hippocampus 
and cerebellum (Auger et al., 2002; Guerra-Araiza et al., 2002; Quadros et al., 2007; Lopez 
& Wagner 2009). Over the years, accumulating data are emerging on the neuroprotective 
and neuroregenerative effects of progesterone in the brain (Callier et al., 2001; Guerra-
Araiza et al., 2002; Murphy et al., 2000). 
Progesterone exerts its action mainly by binding to classical nuclear progesterone 
receptor isoforms: the full length B isoform (PR-B, Progesterone Receptor-B) and the N-
terminal truncated isoform A (PR-A, Progesterone Receptor-A) (Conneely et al., 1987). 
The two isoforms are encoded by the same gene located on chromosome 11 (11q22) 
composed by 8 exons, with two alternative translational start sites (Fig. 11, Panel A). 
Further, some evidence described that the two PR isoforms may result from alternative 
transcripts driven by independent promoters (Kastner et al., 1990; Gronemeyer et al., 
1991). 
Both isoforms share an inactivation domain (IF, inhibition factor), two activation domains 
(AF), respectively AF1 in the N-terminal region, and a C-terminal AF2; a highly conserved 
DNA-binding domain (DBD), followed by a small hinge region (h) and a ligand-binding 
domain (LBD), which also contains a dimerization domain (DI) and 4 nuclear localization 
signals (NLS) (Fig. 11, Panel B) (Leonhardt et al., 2003). 
The short PR-A truncated isoform (94 kDa) lacks 164 amino acids, which encodes in PR-B 
(120 kDa) an additional activation domain (AF3) that acts in synergy with the two other 
activation domains (AF1-AF2) (Brinton et al., 2008). 
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Figure 11 Panel A) PGR gene structure. The classical progesterone receptor is composed of 8 exons 
with a coding region 3056-bp long and 5' - 3' -untranslated region. Both cPR-B and cPR-A isoforms are 
transcribed from this gene, but they use alternative initiation codons indicated by red horizontal arrows. 
Panel B) Functional domains of classical nuclear progesterone receptors (PR-B, PR-A). 
cPR proteins are both composed of an inactivation domain (IF) and an activation domain (AF1) encoded by 
exon 1, a highly conserved DNA-binding domain (DBD) encoded by exons 2 and 3, a variable hinge region 
(encoded by part of exon 4), a conserved ligand-binding domain (LBD, encoded by exons 4–8) and a second 
activation domain (AF2) encoded by part of exon 6 and exon 7. (Brinton et al., 2008). 
 
In the absence of ligand, nuclear PRs are maintained in an inactive form in the cytoplasm, 
complexed with different chaperone molecules, in particular with heat shock proteins 
(hsp90, hsp70, Hsp40). 
The binding of the hormone to the receptor causes a conformational change in the 
receptor, dissociation from the chaperone proteins, followed by dimerization of two free 
receptors, and dimer translocation into the nucleus, where it directly interacts with 
specific progesterone responsive elements (PREs) in the target genes promoter (Fig. 12) 
(Leonhardt et al. 2003). 
 
A) 
B) 
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Figure 12 Mechanism of action of nuclear progesterone receptors. Binding of progesterone 
to inactive nuclear progesterone receptor complex induces a conformational change that allows the 
dissociation of chaperone molecules, receptor dimerization, binding to PRE sequence on the promoter of 
target genes, and finally recruitment of co-activators, which act as bridge with the basal transcriptional 
apparatus (Leonhardt et al. 2003). 
Although the DNA-binding affinity of the two cPR isoforms is comparable, their 
transcriptional activity is variable depending on the cell type, as evidence suggests that 
they adopt distinct conformations within the cell, allowing them to interact with different 
co-regulators (Bain et al., 2000;Bain et al., 2001; Tetel et al., 1999).  
In mouse models, the selective ablation of one isoform has revealed that PR-A and PR-B 
have different exclusive roles, demonstrating that PR-B is essential for normal mammary 
gland development (Mulac-Jericevic et al., 2003), while PR-A is required for uterine 
development and reproductive function (Mulac-Jericevic et al., 2000).  
Moreover, given the differential roles of PR-A and PR-B, these two receptors occasionally 
play synergic roles in gene expression regulation. For instance, in certain breast cancer 
cell lines, it has been shown that an imbalance in the PR-A/PR-B ratio induces a 
remarkable increase in the transcription of genes involved in cell growth (Hopp et al., 
2004), resulting in a more aggressive phenotype of cancer. 
PR-A and PR-B isoforms are not equally expressed in all the cell types (Mote et al., 2000). 
In general, there are cell types where only a single PR isoform is expressed and in which 
the PR homodimer is the dominant molecular species, and cell types expressing both 
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isoforms, where the formation of three different molecular species (PR-B homodimers, 
PR-A homodimers and PR-A/PR-B heterodimers) can occur. 
PR-A and PR-B, affect the target genes in a different manner; PR-B generally represents 
the stronger transcriptional activator (Vegeto et al., 1993; Tung et al., 2006), while PR-A is 
a weaker activator of progesterone-dependent genes and is often inactive. When both 
the isoforms are activated, PR-A assumes a different conformation, which leads it to 
become a repressor of the same PR-B and estrogen receptor (hER) (Vegeto et al., 1993; 
Mohamed et al., 1994; Sartorius et al., 1994; Mulac-Jericevic et al., 2000). This 
conformation may expose sequences bound by transcriptional co-repressors and reactive 
amino acids that can be modified, resulting in some cellular contexts in repressor 
activities of PR-A (Giangrande et al., 2000). 
This difference in cPRs function lies in the fact that hPR-B contains three transcriptional 
activation domains, and the AF3, which is only present in the hPR-B, appears to be the 
critical point of the different action of the two isoforms. 
The study of the intracellular structure of PRs has shown that activator domains AF1 and 
AF2 act synergistically and their intermolecular interaction is necessary and essential for 
the recruitment of additional co-activators (steroid receptor co-activator, SRCs) and for 
the interaction with other transcription factors (Leo & Chen 2000). 
The AF1/AF2 interaction is prevented by the inhibitory domain (ID), which blocks the 
transcriptional activity as well; the presence of the AF3 domain in PR-B allows activating 
transcription, acting as suppressor of the inhibitory activity of the ID (Abdel-Hafiz et al., 
2002; Tung et al., 2006). 
 
- Membrane progesterone receptors (mPRs) 
 
In addition to the involvement of the classic nuclear receptors, progesterone can also 
interact with different membrane receptors (mPRs), including a seven trans-membrane 
Progesterone Receptor and single transmembrane receptors. 
The seven membrane receptor coupled to G proteins, 7TMPR (seven Trans-Membrane 
Progesterone Receptor), is a receptor with seven transmembrane domains associated 
with a G inhibitory protein, belonging to the progestins and adipo Q receptor family 
43 
 
(PAQR family) (Thomas & Pang, 2012; Zhu, et al., 2003). When bound to progestin, this 
receptor blocks the activity of the enzyme adenylyl cyclase, thus inhibiting the production 
of the intracellular second-messenger cAMP (Zhu et al., 2003). Three 7TMPR isoforms 
have been identified: – 7TMPRα, β, and γ. 7TMPR isoforms localize in different human 
compartments exerting different functions. In particular, 7TMPRα is expressed in 
reproductive tissues and in the kidney; the β form exclusively localizes in neural tissues 
including cerebellum, the cerebral cortex, pituitary gland, thalamus, caudate nucleus, and 
spinal cord; whereas the γ-subtype is present in the kidney, colon, and possibly in the 
adrenal and lung (Zhu et al., 2003).  
Pg binds also single transmembrane receptors, including PGRMC1 (Progesterone receptor 
Membrane Component 1) and PGRMC2 (Progesterone receptor Membrane Component 
2) (Gerdes et al., 1998). Only little information is available about this class of 
progesterone receptors. PGRMC1 is expressed predominantly in the liver and kidney, and 
it was shown to bind several cytochrome P450 enzymes, to play a role in chemotherapy 
resistance (Hughes et al., 2007), and to promote the antiapoptotic effect of Pg (Crudden 
et al., 2006; Peluso et al., 2008.) Moreover, it has been demonstrated that progesterone 
acts through PGRMC1 to increase brain derived neurotrophic factor (BDNF) release (Su et 
al., 2012), promoting survival of neurons (Gonzalez et al., 2005). 
PGRMC2 is particularly expressed in the placenta (Gerdes et al., 1998), and overexpressed 
in breast cancer (Causey et al., 2011). Both PGRM1 and PGRM2 are found to be expressed 
in different regions of the rat brain, particularly in all hypothalamic nuclei, indicating a 
possible role in neuroendocrine functions (Intlekofer et al., 2011).  
 
Progesterone: genomic and non-genomic mechanism 
 
Besides the known roles as sex hormones in menstrual cycle, pregnancy, and 
embryogenesis in human, Progesterone exerts important functions also in human brain. 
As mentioned before, almost all brain areas express PGRs, although difference of various 
receptor types in relative amounts and expression in brain regions are observed (Brinton 
et al., 2008; Intlekofer and Petersen, 2011). 
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Progesterone produces multiple effects in the CNS by means of three main mechanisms: 
gene regulation, neurotransmitters release modulation, and signalling cascades 
activation. Although the classical long-term genomic effect of progesterone has been 
considered for years the main mechanism of action, recent studies have highlighted the 
existence of short term non-genomic mechanisms. 
These short term progesterone-dependent effects appear linked to the activation of 
several cellular pathways that lead to membrane receptors regulation, ion channels 
activation, cytoplasmic second messengers increase, regardless of gene expression 
(Boonyaratanakornkit, et al., 2008; Leonhardt et al., 2003; Schumacher et al., 1999). 
Numerous studies have shown that the non-genomic effects of progesterone are the 
consequence of the activation of various extranuclear signals, such as second messengers 
(cAMP, cGMP) and kinases (PKA, PKC, CaMKII). The subsequent activation of signalling 
cascades, associated with these second messengers, finally induces post-translational 
modifications of transcription factors (TFs), co-activators and co-repressors of nuclear 
receptors, which in turn modify the activity of other transcription factors. 
One of the most characterized pathways activated by progesterone and progestogens, is 
the MAPK kinase cascade, through Src kinase activation (Fig. 13) (Leonhardt et al. 2003). 
However, the action of progesterone seems to be obtained from the integration of both 
mechanisms, the rapid non-genomic mechanism and the slowest genomic mechanism, 
which both provide a sensitive regulation of gene expression. 
 
Furthermore, besides the progesterone receptors-mediated effects, extensive data 
indicates that an important neuroactive metabolite of Progesterone, the 
Allopregnanolone (ALLO), could signal through pathways other than cPGR and mPRs. In 
particular, ALLO acts as a potent endogenous positive allosteric modulator of GABA-A 
(gamma-amininobutyric acid-a) receptor. Several data indicate that ALLO is the principal 
mediator of the neuroprotective effects of progesterone, including neurogenesis of 
cerebellar granule cells (Keller et al., 2004), neural progenitor proliferation (Wang et al., 
2005) and neuronal cell death decrement (Wang and Brinton, 2008), and all of these 
effects appear to be through GABA-A receptors. 
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Figure 13: Schematic representation of genomic and non-genomic progesterone 
mechanisms of action. The classic progesterone mechanism of action is mediated by nuclear receptors 
PRs, which promote interaction with co-activators and play the predominant role in the response to 
progesterone (genomic mechanism). Progesterone may mediate its effects also via second messengers 
(cAMP, cGMP), activation of kinase cascades (PKA, PKC, CaMKII), activation of the MAP kinase cascade 
(MAPK), the phosphorylation of transcription factors, co-activators and CREB responsive elements (non-
genomic mechanisms). All of these mechanisms appear to interact with each other mediating the biological 
effects of progesterone. (Contrò et al., 2015) 
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Aim of the thesis: 
The paired like homeodomain proteins PHOX2B (Paired-like homeobox2B) and PHOX2A 
(Paired-like homeobox2A) are deeply involved in autonomic nervous system 
development, as well as noradrenergic neuronal differentiation (Tiveron et al., 1996). 
In both Phox2a and Phox2b KO mice brain the principal noradrenergic centre locus 
coeruleus does not form (Morin et al., 1997; Pattyn et al., 1999), and confirming their 
central role in the specification of noradrenergic identity, both transcription factors 
directly regulate the expression of Dopamine Beta Hydroxylase (DBH), a key enzyme in 
noradrenaline synthesis (Adachi et al., 2000; Seo et al., 2002).  
The neuronal development and specification driven by PHOX2 proteins is the result of a 
fine temporal and spatial control of the two-paralogue proteins. In particular, PHOX2B is 
considered a “master regulatory gene” in the network leading to the cathecolaminergic 
phenotype specification, and regulate PHOX2A expression (Coppola et al., 2005). 
As PHOX2 proteins play crucial role in embryonic neuronal differentiation, their mutations 
or altered regulation are linked to congenital pathologies, such as CCHS, and neuroblastic 
tumours (Nakano et al., 2001; Amiel et al 2003, Weese-Mayer et al 2003 Longo et al., 
2008). Consistently with its role as transcriptional regulator, it is reasonable to suppose 
that transcriptional dysregulation might be an important mechanism of CCHS 
pathogenesis and/or tumour development. Current research into treatments of CCHS and 
neuroblastoma is on the strategy aimed at counteracting the toxic effects of the mutated 
PHOX2B protein and/or to down-regulate PHOX2B expression, respectively. In particular, 
drugs promoting the refolding and/or the clearance of mutant protein aggregates have 
been turned out to be effective in vitro in rescuing the nuclear localization and 
transactivation activity of mutants (Bachetti et al.,2007; Di Zanni et al., 2012). Moreover, 
screening of a FDA approved library led to the identification of molecules capable of 
down-regulating PHOX2B expression (Di Zanni et al., 2015), that may induce 
differentiation of neuroblastoma cells. Another strategy that is currently under 
investigation regards the use of progestinic drugs for ameliorating respiratory symptoms 
in CCHS patients. The molecular mechanism of this unexpected pharmacological effect is 
completely unknown, but this observation has a strong proof of concept value, in the 
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perspective of a pharmacological intervention in CCHS, at least for ameliorating 
respiratory symptoms. 
Absolute limitations to the comprehension of the pathogenesis of CCHS, and to develop 
new and effective treatments for this disease, regard i) the missing knowledge of target 
genes regulated by PHOX2B (whose expression may be eventually dys-regulated in the 
disease); and ii) substantial lack of information on the structure-function relationships in 
PHOX2B wild-type and mutant proteins. 
The aim of this thesis was to disclose still unknown mechanisms involved in the 
pathogenetic mechanisms of PHOX2B-driven disease development, to improve the 
recognition of new sensitive therapeutic intracellular targets. The results obtained during 
the three years of my PhD thesis are organized in three chapters, two of which (chapter 2 
and 3) report results that are summarized in published papers, here enclosed, whereas 
the third chapter concerns with the molecular mechanism of Desogestrel effect and are 
still unpublished results.  
 
In summary, the first paper “Alanine Expansions Associated with Congenital Central 
Hypoventilation Syndrome Impair PHOX2B Homeodomain-mediated Dimerization and 
Nuclear Import” by Di Lascio, Belperio et al. (Appendix 1), deals with a better 
characterization of PHOX2B functions, including homo-and hetero dimerization and 
nuclear import, also in the perspective of better analysing the possible effect of 
polyalanine expansion on these functions, as the expansion of the polyalanine tract in 
PHOX2B results in a protein with altered DNA-binding, reduced transcriptional activity 
and defect in nuclear localisation (Trochet et al., 2005; Bachetti et al., 2005; Di Lascio et 
al., 2013). Interestingly our data clearly underlined a strong interaction between PHOX2A 
and PHOX2B wild type/ mutants proteins, indicating a possible involvement of PHOX2A in 
the pathogenesis of CCHS. 
 
Recently, studies conducted on NB cell lines have highlighted a correlation between 
drugs, used in NB treatment or clinical trials (e.g. GA, 17-AAG), and the modulation of 
PHOX2B gene expression (Bachetti et al., 2007, Di Zanni et al., 2015).  
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NBs are very sensitive to retinoids, and they were introduced in NB treatment as 
“additional drugs” (Reynolds & Lemons 2001; Altucci et al., 2001; Chu et al., 2003) in 
order to induce differentiation in residual cancer cells after NB surgical elimination.  
In the second paper “PHOX2A and PHOX2B are differentially regulated during retinoic 
acid-driven differentiation of SK-N-BE(2)C neuroblastoma cell line” by Di Lascio et al., 
2016 (Appendix 2), we tested the hypothesis of a direct regulatory link between “all trans 
retinoic acid” (ATRA), a retinoid drug that is known to suppress growth in cancer, and the 
expression/activity of the candidate tumour suppressor gene PHOX2A and PHOX2B in the 
SK-N-BE(2)C neuroblastoma cell line. We showed that ATRA differently regulates both 
PHOX2A and PHOX2B expression, thus suggesting that they may be useful biomarkers for 
NB staging, prognosis and treatment decision making. 
 
Following the observation (Similowski and Straus, 2010) that desogestrel assumption 
ameliorates ventilatory symptoms in CCHS patients, we decided to investigate the 
mechanism underlying this effect (Chapter 3). 
Previous studies, conducted in our laboratory, on T47D cell line suggested us that 3-KDG 
can influence both the activity of PHOX2B and PHOX2A, and that this is mediated by the 
intracellular receptor PGR. We do not know at the moment the relative contribution of 
the two isoforms PR-A and PR-B. Although T47D cell line has been an invaluable tool to 
generate these very interesting and promising data, it presents limits due to a cellular 
background not properly associated with the physiological PHOX2B environment.  
To further exploit Desogestrel mechanism , we generated a neuroblastoma cell line (SK-N-
BE(2)C) stably expressing nuclear progesterone receptor isoforms. In order to analyse the 
possible effect of the progestin drug on the PHOX2B pathway we treated SK-N-BE(2)C 
stable clones with the active metabolite of desogestrel (3-keto-desogestrel) and 
evaluated alteration in endogenous protein amount and transcription levels by using 
western blot and quantitative PCR analyses. Our findings demonstrated that desogestrel 
treatment is able to alter PHOX2B and PHOX2A expression, as well as the expression of 
DBH and some other target genes of PHOX2 proteins, particularly reducing their 
expression.  
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Chapter 2 
 
 
 
Alanine Expansions Associated with Congenital Central 
Hypoventilation Syndrome Impair PHOX2B 
Homeodomain-mediated Dimerization and Nuclear Import 
 
Simona Di Lascio, Debora Belperio, Roberta Benfante, and Diego Fornasari 
 
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 291, NO. 25, pp. 13375–13393, June 17, 
2016 © 2016 by The American Society for Biochemistry and Molecular Biology, Inc. 
Published in the U.S.A. 
 
Inserted as Appendix 1 
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The most frequent PHOX2B mutations, leading to Congenital Central Hypoventilation 
Syndrome, include expansion repeat mutations in the second polyalanine stretch of the 
protein, and point mutations in different protein regions including the homeodomain 
(HD) (Weese-Mayer et al., 2010).  
Evidences collected so far indicate that the elongation in the PHOX2B polyalanine stretch 
leads to a protein with reduced functionality. In particular, nuclear import defects and 
cytoplasmic aggregate formation have been observed in the longer expanded mutants, 
whereas impairment of DNA-binding and transcriptional activity are also detectable in 
shorter expansions (Bachetti et al., 2005; Di Lascio et al., 2013).  
Furthermore, data collected hitherto support the idea that CCHS is not due to a pure loss 
of function mechanism, but also involves a dominant-negative effect and toxic gain of 
function of PHOX2B mutants. 
A recent study conducted in my laboratory (Di Lascio et al., 2013) provided novel in vitro 
experimental evidence of a transcriptional dominant-negative effect of PHOX2B 
polyalanine mutant proteins on wild-type protein functions, as they interfere with the 
PHOX2B mediated regulation of TLX2 gene. 
However, it was not clear if the observed functional effects of PHOX2B mutant variants 
were the result of direct aberrant interactions between wild-type and mutant proteins 
and/or with other proteins (e.g. transcription factors or co-activator). 
As we found that PHOX2B forms heterodimers with PHOX2A, in the first part of my 
project we tested the hypothesis that the dominant negative effects of the mutated 
proteins were due to non-functional/aberrant interactions with the wild-type protein or 
PHOX2A. 
Moreover, as PHOX2B function-structure relationships has not been fully elucidated so 
far, and knowing how PHOX2B protein is structured (i.e., domains involved in protein-
protein interaction; transactivation domain) may help in understanding how mutations 
can affect its function, we also focused on characterizing PHOX2B protein domains 
associated with the different functions, also in a view to better understand the molecular 
mechanism at the basis of CCHS. 
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From the molecular point of view, the HD has different important functions for the 
protein, including DNA binding, target genes transactivation, homo-/hetero-dimerization, 
and cellular localizations.  
On the other hand, the function of the polyalanine stretch is still unknown, although it 
has been supposed to be flexible spacer element located between protein domains and 
therefore it is likely to be involved in correct protein folding, DNA-binding and protein-
protein interaction. 
Starting from these findings, we better characterized PHOX2B homeodomain-mediated 
functions, as hetero-/homo-dimerization and nuclear import, and the effects of the 
alanine tract expansion on these activities. 
 
In particular, our findings showed that: 
- PHOX2B protein is able to homodimerize and to strongly heterodimerize with its 
paralogue gene, PHOX2A; 
-  PHOX2B polyalanine-expanded proteins weakly interact with wild-type protein 
but retain a partial ability to interact with PHOX2A; 
- PHOX2B polyalanine-expanded proteins do not interfere with PHOX2A-mediated 
transactivation of the DBH promoter, on the contrary they act synergistically; 
- the PHOX2B dimerization domain comprises the homeodomain and the C-terminal 
region and does not involve the alanine stretch; 
- the expansion of the polyalanine tract inhibits homeodomain-mediated PHOX2B 
nuclear import, interfering with PHOX2B nuclear localization signals (NLSs), that we have 
identified at the opposite ends of the HD. 
 
Our data exclude the possibility that the formation of non-functional heterodimers 
between PHOX2B wild-type protein and mutants may play a major role in CCHS 
pathogenesis. 
However, we cannot exclude that the formation of PHOX2A/PHOX2B mutants 
heterodimers could have some implication in the pathogenesis of the disease, as they 
could interact with different proteins (i.e. co-activators, co-repressors) to those usually 
recruited by PHOX2A/PHOX2B wild type heterodimers. Moreover, a deeper knowledge of 
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genes regulated by PHOX2B and PHOX2A is required, in order to better identify which 
genes are differentially regulated in the presence of PHOX2B mutant protein.  
 
 
 
Figure 14 PHOX2B:PHOX2A dimerization.  
A) Schematic representation of PHOX2B wild type and PHOX2B expanded mutant protein (i.e. +13 Ala). B) 
PHOX2B wt protein is transported into the nucleus by means of nuclear localization signals (NLSs)/nuclear 
pore interaction. In the nucleus compartment, PHOX2B wt protein is able to form homodimers and 
heterodimers with PHOX2A protein. C) The expansion of the 20 polyalanine tract induces a conformational 
change of the PHOX2B protein; the expansion interferes with PHOX2B NLSs function, by inhibiting its 
complete transport into the nucleus. In the nucleus, PHOX2B expanded mutant protein loses the ability to 
dimerize with its wild type counterpart, but it retains the ability to dimerize with PHOX2A protein. 
A) 
C) B) 
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PHOX2B, and its paralogue gene, PHOX2A, have been associated with the pathogenesis of 
neuroblastoma (NB), as they are found to be overexpressed in different NB cell lines and 
tumour samples (Longo et al., 2008). 
Unlike PHOX2B, in which both mutations and altered expression levels were found in 
correlation with NB development, no mutations were found in PHOX2A.  
As these findings clearly indicate that PHOX2 pathway deregulation is strictly linked to 
neuroblastoma onset and development, recently NB therapies aimed to reduce PHOX2B 
expression are emerging (Bachetti et al., 2007; Di Zanni et al., 2015). 
In view of the fact that retinoids have been introduced in NB treatment, as differentiating 
agents of cancer cells (Reynolds & Lemons 2001), in the second part of this project, we 
tested the hypothesis of a direct regulatory link between the retinoic drug “all-trans 
retinoic acid” (ATRA), and PHOX2 genes regulation. 
Retinoic acid (RA) has an important role in differentiation of neuronal crest-derived cells, 
supporting proliferation and survival of neuronal crest cells in early stage, and regulating 
the expression of receptors for neurotrophic factors in later stage of development (Thang 
et al., 2000; Wyatt et al., 1999). 
Retinoids play a fundamental role in embryonic development by interacting with two 
classes of nuclear receptors (NRs): the retinoic acid receptors (the multiple isoforms of 
the RAR α, β, and γ isotypes), and retinoid x receptors (the multiple isoforms of the RXR α, 
β, and γ isotypes). 
RXR and RAR receptors are capable to form heterodimers, which mediate Retinoids 
signals transduction during developmental processes. In particular, multiple RXR/RAR 
heterodimers regulate gene transcription by binding to retinoic acid responsive elements 
(RAREs) in the promoter regions of numerous sets of RA target genes (Mark M. et al., 
2006) 
Despite retinoids are now being introduced in NB treatment, the molecular mechanisms 
by which they induce cellular differentiation in cancer cells, are still largely unknown.  
In this part of the project it has been found that there is a regulatory link between ATRA, 
the candidate tumour suppressor gene PHOX2A and PHOX2B expression, in the SK-N-
BE(2)C NB cell line. 
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In detail, our findings demonstrated that: 
-  PHOX2A expression is finely controlled during retinoic acid differentiation at 
transcriptional level by up-regulating PHOX2A-mRNA; 
- extended ATRA treatment selectively degrades PHOX2A protein, while the 
corresponding mRNA remains up-regulated; 
- ATRA treatment down-regulates PHOX2B expression. 
 
Previously, in my laboratory, it has been demonstrated that PHOX2B regulates the 
transcription of the PHOX2A gene by directly binding and transactivating its promoter 
(Flora et al., 2001). It has been further defined that PHOX2B is able to regulate its own 
expression by directly binding to its promoter (Cargnin et al., 2005). Since we 
demonstrated that PHOX2A is capable of binding to the ATTA sequences on the PHOX2B 
promoter, negatively modulating its expression (Di Lascio et al., 2016), we investigated 
whether PHOX2B down-regulation, induced by ATRA treatment, was at least partially due 
to the increase in PHOX2A expression, by blocking the ATRA-induced PHOX2A up-
regulation using a shRNA against PHOX2A. 
However, our findings excluded that PHOX2A-mediated regulation of PHOX2B was 
involved in ATRA-induced PHOX2B down-regulation. 
On the other hand, PHOX2A mRNA up-regulation, followed by its protein degradation, 
together with PHOX2B down-regulation suggested that they might be useful biomarkers 
for NB staging, prognosis and treatment decision-making.  
In addition, as it is known that PHOX2B is down regulated in later stage of differentiation, 
we could speculate that the molecular mechanism for retinoic-induced cellular 
differentiation, in NB treatment, is due to a direct regulation of PHOX2 protein 
expression. 
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All trans-Retinoic Acid
(ATRA)
Figure n. 15 ATRA regulation of PHOX2A and PHOX2B 
SK-N-BE(2)C neuroblastoma cell line was treated with all-trans-retinoic acid (ATRA). ATRA binds RXR-RAR 
receptor heterodimer that binds DNA by recognizing the specific retinoic acid responsive elements (RAREs) 
in the promoter of target genes. The binding of this active complex to PHOX2A promoter is able to up-
regulate PHOX2A-mRNA enhancing gene transcription; extended ATRA treatment selectively degrades 
PHOX2A protein, by proteasomal degradation, while the corresponding mRNA remains up-regulated. ATRA 
treatment down-regulates PHOX2B-mRNA resulting in reduced PHOX2B protein level. 
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Chapter 4 
 
 
 
3-ketodesogestrel effects in SK-N-BE(2)C neuroblastoma 
cell lines stably expressing human progesterone receptors 
(hPGR) 
 
 
 
 
 
In preparation 
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4.1 Preliminary data 
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So far, a possible pharmacological treatment to ameliorate symptoms in CCHS aimed to 
counteract the toxic effects of the mutated PHOX2B protein; in particular, drugs 
promoting the refolding and/or the clearance of mutant protein aggregates have proved 
to be effective in rescuing the nuclear localization and transactivation activity of mutants 
in vivo (Trochet et al., 2005; Bachetti et al., 2007; Di Zanni et al., 2012). 
The fortuitous observation of Straus and colleagues, that progestin drug Desogestrel can 
relief some symptoms in CCHS female patients (Straus et al., 2010), represents a great 
proof of concept to provide new therapeutic strategies in the treatment of the disease. 
The molecular mechanism of the unexpected Desogestrel pharmacological effect is at the 
moment completely unknown, but this observation gave us a useful indication in the 
perspective of pharmacological interventions in CCHS, at least for ameliorating 
respiratory symptoms. 
Our first working hypothesis concerned the possibility that the progestin could act on the 
expression of PHOX2B or some PHOX2B target genes. 
Previous experiments conducted in our laboratory using breast cancer T47D cell line, 
clearly highlighted a correlation between the progestin treatment, PHOX2B expression, 
and the regulation of one of the known PHOX2B target gene, TLX2. As T47D cells have the 
advantage to express all the types of progesterone receptors (both membrane and 
intracellular receptors), but do not express PHOX2B protein, they represent a helpful and 
clean model in order to investigate the progestin mechanism (unpublished data). 
Data collected hitherto showed that, in this cellular contest, the 3-keto-desogestrel (3-
KDG) treatment enhanced PHOX2B transcriptional activity on TLX2 promoter, already at 
low concentration (50 ng of plasmid DNA; Fig 16, Panel A).  
Dose-response curve with increasing concentration of 3-keto-desogestrel (1 nM - 10 nM - 
100 nM - 1 mM) for 48 hours, on T47D cells co-transfected with 50 ng of PHOX2B cDNA 
and the TLX2-luc promoter construct, showed that cells were fully responsive already at 
lower dose (1 nM) of 3-KDG (Fig. 16,  Panel B). 
These treatments were performed by treating cells for 48 hours, as we assume that 
Desogestrel is administered, as contraceptive drug, in a chronic manner; however, recent 
studies have highlighted the existence of non-genomic mechanisms of action of 
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progesterone. We therefore investigated whether the effect of the 3-KDG on TLX2 
promoter activity, could already be measured at shorter time point (8-24 hours). 
8-24 hours treatment did not induce significant changes in the transcriptional activity of 
the reporter construct compared to untreated cells, leading us to exclude a rapid 
activation of PHOX2B target genes and to hypothesize that the action of the progestin 
involves a long term mechanism (Fig. 16, Panel C). 
Mutations in PHOX2B protein, particularly those due to the expansion of the 20 alanines 
stretch in the C-terminus region of the protein, are the principal cause for the onset of 
CCHS, causing a drastic reduction in PHOX2B protein transactivation activity correlating 
with the length of the expanded stretch (Di Lascio et al., 2013). 
1nM 3KDG treatment induced a partial rescue of the activity of +7 or +13 PHOX2B 
expanded mutant proteins, resulting in increased transactivation of TLX2 promoter 
(Fig16, Panel D, blue and green hatched bars), as they have lost their capability to 
transactivate the reporter gene (Fig. 16, Panel D, blue and green full bars). Moreover, we 
analysed the 3-KDG effects on another well known PHOX2B target gene, Dopamine β-
hydroxylase gene (DBH). Unexpectedly, this promoter was not responsive to the 3-KDG 
treatment (Fig. 16, Panel E, black hatched vs full bar), and no recovery was observed in 
the presence of mutant proteins (Fig. 16, Panel E, blue and green hatched bars), as well. 
These data suggested us that the progestin 3-KDG enhances the activity of some PHOX2B 
target genes in a promoter specific manner. 
This promoter specificity was previously observed also on the effects of the mutant 
proteins on gene regulation (Di Lascio et al., 2013) suggesting that a class of target genes 
more sensitive to PHOX2B amount and/or functional alteration exists. 
Given that T47D cell line express all kind of progesterone receptors, we used the selective 
antagonist for PgR nuclear receptors, Mifepristone (RU486) to verify which receptor 
mediate the effect of the progestin desogestrel. 
The co-treatment with 1 μM of RU486 together with 1 nM 3-KDG of T47D cells 
transfected with the TLX2 promoter reporter construct, abolished the progestin activity 
on reporter construct (Fig. 16, Panel F, orange hatched bar). 
These data suggested that the Desogestrel increases PHOX2B transcriptional ability 
through a mechanism mediated by the Progesterone intracellular receptors (PR-A/PR-B).
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A)  B)  
C)  D) 
 
 
 
  
E)  F) 
 
Figure 16 Panel A) Luciferase assay of the activity of the reporter construct TLX2-luc in T47D cells, in the 
presence of increasing amount of PHOX2B expression vector, treated or not (green bars vs blue bars), with 
100nM 3-keto-desogestrel for 48h. The values are expressed as luc/ ren ratio. In black fold-induction 
compared to untreated control (NT) is indicated.  Panel B)  Luciferase assay of the activity of the reporter 
construct TLX2-luc in T47D cells, in the presence of 50ng of PHOX2B expression vector and increasing 
concentrations of the progestin 3-keto-desogestrel (1 nM, 10 nM, 100 nM; 1 µM, green bars). NT = not 
treated. The values are expressed as luc/ ren ratio (arbitrary units). In black fold-induction compared to 
their untreated control (blue bars; NT) is indicated. Panel C) Luciferase assay of the activity of the reporter 
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construct TLX2-luc in T47D cells, treated for increasing time with 1nM 3-keto-desogestrel  (8h, 24h, 48h, 
green bars). T47D cells were co-transfected with 50 ng of PHOX2B (full bars) or the empty vector pcDNA3 
myc-his (hatched bars) and the TLX2-luc reporter construct. Values are expressed as luc/ ren ratio (arbitrary 
units). In black fold-induction (green bars) compared to their untreated control (blue bars; NT = not treated) 
is indicated. Panel D) Luciferase assay. The bars indicate the transcriptional activity of TLX2 constructs 
after co-transfection of the cDNA encoding the PHOX2B wild-type protein (orange bars) or mutant protein 
with the +7 alanine (green bars) or +13 alanine (blue bars) expansion, treated with 1 nM 3-keto-desogestrel, 
for 48h. The empty expression vector was used as negative control (black bars). Results are expressed as 
mean ± SD (error bars) of the transcriptional activity of the constructs tested in at least three independent 
experiments performed in triplicate *** p <0.001 (one-way ANOVA Tukey's test). Panel E) Luciferase 
assay. The bars indicate the transcriptional activity of the reporter constructs under the control of the DBH 
promoter after co-transfection of the cDNA encoding the PHOX2B wild-type protein (orange bars) or 
PHOX2B mutant protein bearing  +7 (green bars) or +13 (blue bars) alanine expansion, treated with 1 nM 3-
keto-desogestrel (hatched bars) for 48 hours. The empty expression vector was used as negative control 
(black bars). Results are expressed as mean ± SD (error bars) of the transcriptional activity of the constructs 
tested in at least three independent experiments performed in triplicate *** p <0.001 (one-way ANOVA, 
Tukey's test). Panel F) Effect of RU486 on the activity of the luciferase reporter construct TLX2-luc. Levels 
of the transcriptional activity of the reporter construct in untreated cells (black hatched line), in cells 
treated with 1 nM 3-KDG (hatched grey bar) and co-treated with 3-KDG (1 nM) and RU486 (1 mM) (hatched 
orange bar) are compared. The activity was measured 48 hours after treatment. The empty expression 
vector was used as negative control (cross-hatched bars). Results are expressed as mean ± SD (error bars) of 
the transcriptional activity of the construct tested in at least three independent experiments performed in 
triplicate. Significance was measured using ANOVA (§§§ and *** p <0.001). 
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      4.2 Material and methods 
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Cell cultures 
All mammalian cell lines (SK-N-BE(2)C, SK-N-BE, IMR32, CAD and T47D) are grown in RPMI 
1640 medium (LONZA) containing 10% fetal bovine serum (FBS, LONZA), with penicillin 
(100U/ml, Lonza), streptomycin (0.1 mg/ml, Lonza),and L-glutamine (2 mM, Lonza). 
The T47D breast cancer cell line is maintained in medium added with Insulin (human 
insulin, 100 mg/ml in 25mM Hepes, pH 8.2, Sigma) to a final concentration of 5μg/ml. 
SK-N-BE(2)C 5.8 and 6.30 stable clones are maintained under selection by adding  
Geneticin (G-418 Sulfate, Gibco) at 0.4 mg/mL final concentration, with selective medium 
changing every second day. 
All cell lines grow in adhesion in 75 cm2 and 175 cm2 culture flasks (Primo, Euroclone) 
incubated at 37°C with 5% CO2. 
 
Transient Transfections and Luciferase Assays 
Cells are transiently transfected by lipofection method using FuGENE HD Transfection 
Reagent (Promega), as described in Flora et al (2001). 
Briefly, the day before transfection, cells are plated on 6-well plate at different density 
depending on the cell line used (1.7 x 105 SK-N-BE(2)C; 1.6 x 105 SK-N-BE; 2.0 x 105 IMR32; 
3.0 x 105CAD; 2.0 x 105 T47D) in 2 ml RPMI 1640 supplemented with fetal bovine serum 
and L-Glutamine, without antibiotics. 
For the co-transfection experiments in T47D cells, different DNA mixtures are prepared.  
Each mixture contains 72 femtomoles of the RL-TK reporter construct, used to normalize 
the data obtained according to differences in transfection efficiency, mixed with 
equimolar amounts of TLX2 promoter reporter constructs and 11.6 femtomoles of 
PHOX2B wild type expression vector (PHOX2B/pcDNA3.1 myc-his) or equimolar amount 
of pcDNA3.1 myc-his empty vector, used as empty control vector. 
The mixture of plasmid DNA is incubated with Fugene HD in a 3: 1 ratio (3 μl FuGene HD, 
1 μg DNA), in plain DMEM medium. After incubation for 15 minutes at room temperature 
the mixtures are added dropwise to the cells (100 µL / well).  
For the co-transfection experiments in neuroblastoma cell line, 74 femtomoles phRGB 
reporter construct (or RL-TK in IMR32), used to normalize data, are mixed with equimolar 
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amounts of TLX2 promoter reporter constructs or pGL3b empty control vector along with 
54 femtomoles of the hPGR-pcDNA 3.1 myc-His. Cells are transfected with Fugene HD in 
6: 1 (SK-N-BE(2)C, SK-N-BE, CAD) or 4:1 ratio (IMR32 cells). 
In all co-transfection experiments, cells are treated, 24 hours after transfection, with 1nM 
of the active metabolite of progestin Desogestrel, 3-keto-desogestrel (3-KDG also 
indicated as Etonogestrel, 3-oxodesogestrel, Org-3236; Implanon), alone or in 
combination with 1 μM of the nuclear progesterone receptors antagonist, RU486 
(Mifepristone, Sigma), as indicated in the figure legends. Luciferase activity or western 
blot analysis was determined after 48 hours of treatment  
The luciferase assay is carried out using the Dual-Luciferase reporter assay system 
(Promega) as described previously (Flora et al 2001, Battaglioli et al 1998). All of the 
transfections are performed in triplicate, and each construct is tested in at least three 
independent experiments using different batches of plasmid preparation. The number of 
independent transfection experiments is indicated in the figure legends.  
 
Plasmids used: 
 
Expression plasmids: 
- hPGR-pcDNA 3.1 myc-His: expression vector containing the human intracellular 
progesterone receptor coding sequence in pcDNA 3.1 myc-His plasmid (Invitrogen) 
bearing neomycin resistance used for the generation of stable clones (described in Erika 
Di Biase master degree thesis). 
- PHOX2B-pcDNA 3.1 Myc-His: expression vector containing the coding sequence of the 
human transcription factor PHOX2B in pcDNA 3.1 Myc-His (Di Lascio et al., 2013). 
- pcDNA 3.1 Myc-His: (Invitrogen) expression vector in eukaryotic cells containing the 
promoter of the cytomegalovirus (CMV),  Myc epitope and has a poly-histidine tag. 
 
Reporter constructs: 
- TLX2-luc: reporter vector containing the promoter sequence (-1885 bp) of TLX2 gene, 
cloned upstream of the Firefly Luciferase gene in pGL3b (Borghini et al., 2006). 
66 
 
- TLX2 mut HBS -luc: reporter vector containing the promoter sequence of the TLX2 gene 
(-1885 bp / -36 bp) with two mutated ATTA sites, cloned upstream of Firefly Luciferase 
gene in pGL3b (Borghini et al., 2006). 
- TLX2 3X mut-luc: reporter vector containing the promoter sequence of the  TLX2 gene (-
1885 / -36) with the three ATTA consensus sequences mutagenized, cloned upstream of 
the Firefly Luciferase gene in pGL3b. 
- TLX2 -1455 bp: reporter vector containing the promoter sequence of the TLX2 gene( - 
1455 pb / -36 bp) cloned upstream of the Firefly Luciferase gene in pGL3b. 
- pRL-TK: (Promega) vector containing the minimum promoter of thymidine kinase of the 
herpes simplex virus (HSV-TK) upstream of the reporter gene encoding the Renilla 
luciferase. Used to normalize transfection efficiency. 
- phRG-B:(Promega) promoter-less mammalian vector encoding Renilla luciferase. Used 
to normalize transfection efficiency. 
 
Total protein extraction 
 
Proteins were extracted from subconfluent cells grown in 10 cm Petri dishes. The cells are 
washed with 1 ml of 1X PBS, mechanically harvested and collected by centrifugation for 5 
minutes at 5000 rpm at 4°C in an Eppendorf centrifuge. The pellet is then resuspended in 
an appropriate volume of 1X PBS containing 0.2 mM PMSF, 0.5 mM DTT phosphatase 
inhibitors (Cocktail I, Sigma) and protease inhibitors (Cocktail II, Sigma). The homogenate 
is subjected to three freeze / thaw cycles in liquid nitrogen and 37°C, to obtain complete 
cell lysis. Then an appropriate volume of NaCl to a final concentration of 420 mM, is 
added to extract the nuclear proteins. After 30 minutes incubation at 4°C on a slowly 
turning rotating wheel, the extract is clarified by centrifugation at 13000 rpm for 30 
minutes at 4°C. The supernatant is aliquoted, quickly frozen in liquid nitrogen and stored 
at -80°C; the concentration is evaluated using the Bradford method (Bradford, 1976). 
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SDS-PAGE and Western blot 
 
20 μg protein extract from T47D transfected cells, native SK-N-BE(2)C and over-expressing 
PGR stable clones 5.8 and 6.30 treated with 3-KDG at different time point have been 
analyzed using western blot. 10 μg proteins from T47D and 7.5 μg nuclear extract from 
IMR32 are used as positive control. Protein extract are separated on a 10% denaturing 
polyacrylamide gel in the presence of 0.1% SDS extract (sodium dodecyl sulphate). Before 
loading, each sample is added with 3X Laemmli loading solution (final concentration 1X) 
and denatured at 100°C for 5 minutes. 
After gel separation at 25 mA in Tris-glycine (25 mM Trizma base, 192 mM Glycine, 0.1% 
SDS) for about 2 hours, the proteins are transferred to nitrocellulose membrane 
(Schleicher and Schuell) by electroblotting at 30 V over-night in transfer buffer (25 mM 
Trizma base, 192 mM Glycine, 20% MetOH). The membrane is then stained with Ponceau 
S to control the transfer, washed with distilled H2O and saturated with blocking buffer 
(5% non-fat milk, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20). After one hour 
blocking, primary antibodies diluted in blocking solution are added and incubated for 2 
hours, or over-night, depending on the manufacture’s instructions. At the end of 
incubation excess of primary antibodies is removed with three 5 minutes washes with 
blocking buffer, and the membrane incubated in the presence of the appropriate 
secondary antibody conjugated to horseradish peroxidase (HRP), diluted in blocking 
buffer, for 1 hour. The excess antibody is then removed by two washes with blocking 
buffer for 5 minutes, followed by three washes in 1X TS (20 mM Tris-HCl pH 7.5, 150 mM 
NaCl) + 0,1% Tween-20, three washes in 1X TS + 0.3 % Tween-20 and three final washes in 
1X TS. 
The membrane is then incubated for 5 minutes with the peroxidase substrate, Super 
Signal West Dura (Pierce) and the signal detected by Hyperfilm ECL films (Amersham) at 
different time exposures. 
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The antibodies used in Western blot experiments are the following: 
 
Primary Antibody Diluition 
Progesterone receptor A/B (D8Q2J) XP Rabbit mAb (Cell Signalling 
Technology)  
1:1000 O.N 
Phox2b (B-11):sc-376997 mouse mAb (Santa Cruz Biotechnology)  1:10000 
Phox2a chicken Ab (Davids Biotechnologie)  1:1000 
Dopamine-β-Hydroxylase (N-terminal) sheep mAb (Sigma)  1:500 
CREB (48H2) Rabbit mAb (Cell Signalling Technology)  1:1000 O.N. 
Sp1 (PEP2):sc-59 rabbit Ab (Santa Cruz Biotechnology)  1:10000 
c-Jun (N):sc-45 rabbit Ab (Santa Cruz Biotechnology, INC.)  1:500 
Ap-2α (C-18):sc-184 rabbit mAb (Santa Cruz Biotechnology, INC.)  1:500 
GATA3  (D13C9) XP rabbit mAb (Cell Signalling Technology)  1:1000 O.N.  
β-Tubulin (D3U1W) mouse mAb (Cell Signalling Technology) 1:1000 O.N.  
 
Secondary Antibody Diluition 
Stabilized Goat anti-rabbit HRP-coniugated (PIERCE) 1:10000 
Stabilized Goat anti-mouse HRP-coniugated (PIERCE) 1:10000 
Rabbit Ab against chicken IgG-HRP (Davids Biotechnologie) 1:10000 
Donkey Ab against sheep IgG-HRP (Abcam) 1:5000 
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RNA extraction 
Total RNA, from cultured cells, was extracted by means of the kit "RNeasy Mini" 
(Qiagen,), according to the instructions provided by the company. 
Briefly, about 107 cells, grown in 10 cm Petri dishes, are washed twice with 10 ml of 1X 
PBS (0.14 M NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4), detached 
mechanically and collected by centrifugation for 5 minutes 5000 rpm at 4 °C in an 
Eppendorf microcentrifuge. 
The pellet is homogenized in 350 µL of RTL buffer previously added with β-
mercaptoethanol (10 µl / ml RTL) and the viscosity reduced by passage through the 
column "Qiashredder" (Qiagen). After the addition of a volume of 70% ethanol, the eluate 
containing precipitated RNA is loaded onto a column and centrifuged for 30 seconds at 
8000 rpm. The matrix of the column, to which RNA is bound, is treated with DNase I (2.73 
U / uL) for 15 minutes at room temperature. After subsequent washing, the RNA is eluted 
with 60 µL of double-distilled RNAse-free water. 
RNA concentration is determined by a spectrophotometer reading at 260 nm (1 OD260 = 
40 µg / ml) and its purity assessed by the ratio of the readings at 260 nm and 280 nm (≥ 
2). To analyze transcript stability, cells were treated with 75µM DRB (Sigma), and RNA 
was extracted using  “RNA plus micro kit” (Qiagen, Hilden, Germany) at time points 
indicated in figure legend. 
 
Retrotranscription 
 
1 µg of total RNA was subjected to reverse transcription using the kit GoScriptTM Reverse 
Transcriptase (Promega), according to information provided by the company. 
Briefly, total RNA is incubated at 70 ° C for 5 minutes in the following reaction mixture: 
RNA    1 μg 
Random primers (Hexamers)  50 µM 
Nuclease-free water       to a volume of 5 μl  
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After 5 minute on ice, each sample are added with 15 µl of a mixture composed by:  
GoScriptTM 5X Reaction Buffer     4 μl 
MgCl2 (final concentration4mM)     3.2 μl 
PCR Nucleotide Mix (final concentration 0.5mM each dNTP) 1 μl 
Recombinant RNasin®Ribonuclease Inhibitor   20units 
RNase OUT Recombinant RNase Inhibitor (40 U/μl)                        1 μl 
GoScriptTM Reverse Transcriptase     1 μl 
Nuclease-Free Water                                to a final volume of 15 μl 
The reaction is continued at 25 ° C for 5 minutes, 42 ° C for 1 hour, 70 ° C for 15 minutes. 
The cDNA of interest are then amplified and analyzed quantitatively by Real-Time PCR. 
 
Quantitative Real-Time PCR 
 
Gene expression analysis was performed by quantitative Real-Time PCR assay using the 
ABI Prism Thermocycler (QuantStudio 5, Applied Biosystems, CA). The target sequences 
were amplified from 50 ng of cDNA in the presence of TaqMan® Gene expression master 
mix (Life Technologies, Inc.). 
The TaqMan® primer and probe assays (Life Techologies, Inc.) used were human PHOX2B 
(ID #Hs00243679_m1), human PHOX2A (ID #Hs00605931_m1) human PGR (ID 
#Hs01556702_m1), human DBH (ID #Hs00168025_m1), human TLX2 (ID 
#Hs00740145_g1) and the endogenous control glyceraldehyde-3 phosphate 
dehydrogenase GADPH (ID #Hs99999905_m1). Each sample was run in triplicate, and the 
results were calculated using the 2−ΔCT and the 2−ΔΔCT method, thus allowing the 
normalization of each sample to the endogenous control, and comparison with the 
calibrator for each experiment (set to a value of 1).  
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4.3 Results 
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4.3.1 PHOX2B binding to "ATTA" consensus sequences on TLX2 
promoter is necessary for the 3-KDG effects 
 
Preliminary data, obtained in our laboratory, have shown that the progestin Desogestrel 
induces an increase in PHOX2B transcriptional activity on the T-Cell Leukemia homeobox 
gene 2 (TLX2), a key regulator of neural crest cells differentiation in autonomic neurons. 
The regulation of the TLX2 promoter by PHOX2B transcription factor has been previously 
well studied and characterized in the SK-N-BE(2)C neuroblastoma cell line (Borghini et al., 
2006).  
The regulatory region of TLX2 gene contains two highly conserved regions, between 
humans and mice, localized in human in position -1517 / -1187 and -801 / -638 (Fig. 17, 
gray boxes).  
The -1711/ -1396 region is important for the transcriptional tissue specific regulation of 
the TLX2 gene. The deletion of this region results in a strong decrease in the activity of 
the promoter in some neuronal cell lines, particularly in human neuroblastoma cell lines 
(Borghini et al., 2006). 
In this region, different binding sites for transcription factors including three "TAAT / 
ATTA" sites repeated in tandem, also known as HBSs (Homeodomain Binding Sequences), 
have been identified (Fig.17, black mark). 
PHOX2B transactivates TLX2 promoter, by binding to two "TAAT/ ATTA" sequences 
located in the -1489 / -1480 region. Indeed, the site-specific mutation of these two 
sequences results in a dramatic reduction in TLX2 promoter transactivation by PHOX2B 
(Borghini et al., 2006). 
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Figure 17 Regulatory region of the human TLX2 gene. Grey boxes indicate the highly conserved 
region between humans and mice. In black the "TAAT/ATTA" homeodomain binding sites are marked. With 
del the deletion start points for the generation of the TLX2 promoter deletion constructs, tested in IMR32 
and SK-N-BE neuroblastoma cell lines, are indicated (Borghini et al., 2006). 
 
Given the importance of the two sequences in TLX2 promoter, we wondered if the 
PHOX2B binding to "TAAT/ ATTA" sites was necessary to mediate the effect of 
Desogestrel. 
To this aim we tested the effect of the 3-KDG on the TLX2 promoter construct in which 
the two “TAAT/ATTA” in position -1489/-1480 were mutagenized (indicated as TLX2 mut 
HBS), on a construct in which all the three HBSs were mutagenized (TLX2 3Xmut) and on a 
deletion construct of the promoter characterized by the absence of all the HBS sequences 
(TLX2 -1455) (Fig. 18, Panel A). 
The TLX2 mut HBS construct appears to be still responsive to PHOX2B, even if at a lesser 
extent compared to wild-type promoter. The mutation and the deletion of all the 
homeodomain binding sites result in constructs not responsive to PHOX2B transactivation 
(Fig. 18 Panel B, compare black bars). 
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Treatment with 3-KDG induces a 1.7-fold statistically significant increase, compared to the 
respective untreated construct, in the activity of both luciferase reporter constructs 
containing the TLX2 wild-type promoter or the promoter with the two mutagenized 
sequences "TAAT / ATTA", in the presence of PHOX2B (Fig.18, Panel B, black vs striped 
bars). 
The -1455 deletion, which removes all three "TAAT / ATTA" sites, as well as the mutation 
of the three HBS sites, destroy the responsiveness of the constructs to the 3-KDG both in 
the absence and in the presence of PHOX2B (Fig.18, Panel B, TLX2 3X mut and TLX2 -
1455). 
 
Figure 18 Luciferase assay activity of TLX2 reporter constructs after 48h treatment with 
3-KDG. The bars indicate the transcriptional activity of the reporter constructs under TLX2 promoter 
control after co-transfection of the cDNA encoding the PHOX2B wild-type protein (black and hatched bars) 
or empty expression vector (grey and black and white stripes bars) treated with 1 nM 3-KDG (black and grey 
bars) for 48 hours. The data of each construct are expressed as fold-induction compared to untreated 
sample transfected with PHOX2B (black bars). The results are expressed as mean ± SD (error bars) of the 
transcriptional activity of the constructs tested in at least three independent experiments performed in 
triplicate *** p <0.001 (one-way ANOVA, Tukey's test)  
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These data suggest that the PHOX2B binding to at least one of the "ATTA" sequence in 
the region -1490 / -1458 is sufficient and necessary to mediate PHOX2B dependent effect 
of 3-KDG. 
 
 
4.3.2 3-KDG treatment increases the PHOX2B protein amount in 
T47D cell line  
 
Figure 16 shows that, in T47D cells, 3-KDG treatment is able to increase PHOX2B 
transcriptional activity on TLX2 target gene, and that this effect is mediated by nuclear 
progesterone receptors, since the co-treatment with specific inhibitors of nuclear 
receptors (RU486) completely abolished the drug effect on TLX2 promoter. 
As T47D cells do not express PHOX2B, and we cannot study a possible direct effect on 
PHOX2B gene expression, we asked whether 3-KDG had a direct effect on protein level. 
We then transfected T47D cell line with PHOX2B-Myc tagged expression vector and 
treated cells with 1 nM 3-KDG alone (Fig. 19, lane 4) or in combination with 1 μM RU486 
(Fig. 19, lane 6), for 48 hours. 
The 3-KDG treatment alone results in a visible increment of PHOX2B protein amount with 
respect to untreated sample (Fig. 19, compare lane 4 vs lane 3), whereas in sample co-
treated with both 3-KDG and RU486 no changes in PHOX2B protein level were observed 
(Fig 19 compare lane 6 vs lane 5). 
These data suggest that the enhancement in TLX2 promoter activity, obtained by the 
progestin treatment, could be mediated by increasing level of PHOX2B protein, maybe 
due to post-translational modifications that stabilize the protein, or inhibition of protein 
degradation mechanisms.  
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Figure 19. Western blot analysis of PHOX2B protein after 48 hours treatment with 3-
KDG alone, or in combination with RU486, in T47D cell line. Representative immunoblotting 
image showed the expression of PHOX2B Myc-tagged protein (lanes 3-4-5-6) in T47D samples after 48 
hours treatment with 1 nM 3-KDG alone (lanes 2-4) or in combination with 1 μM RU486 (lane 6). T47D not 
transfected samples are used as control (lanes 1-2). The whole cell lysate was immunoblotted with Myc-
antibody. The same blot was reprobed with β-tubulin to compare the loading of each lane.  
 
4.3.3 Analyses of the endogenous nuclear progesterone receptor 
level in neuroblastoma cell lines 
 
Data collected so far, related to the 3-KDG effects on PHOX2B expression and activity, 
were obtained using T47D as cellular model. 
The presence of all kind of progesterone receptors make T47D cell line a useful model of 
study in our project. However, the identification of the nuclear receptors, as mediators of 
the 3-KDG effects, gave us the opportunity of moving to a more physiologic cellular 
context (i.e. neuronal cell lines). 
Being the CCHS a neurodevelopmental disorder, we started to investigate the 3-KDG 
effects in a neuroblastoma cellular model. 
Using quantitative Real-time PCR analysis, we measured the PGR amount in different 
neuronal cellular models, comparing PGR levels detected with those of T47D, and MCF-7 
(Fig. 20, yellow and green bars, respectively), a breast cancer cell line also expressing high 
levels of PGR. 
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The graph in figure 20 shows the PGR expression level measured in the different cell lines 
relative to SK-N-BE(2)C, in particular: 
- SH-SY5Y, a human derived cell line subcloned from SK-N-SH cell line, isolated from a 
bone marrow biopsy taken from a four-year-old female with neuroblastoma, turned out 
to be devoid of PGR; 
- SK-N-BE(2)C (used to compare the PGR level of the other neuroblastoma cell lines 
analyzed, set =1, grey bar), a clonal subline of the SK-N-BE(2) human neuroblastoma cell 
line, shows a very low PGR expression level than T47D cell line (Fig. 20,compare grey bar 
vs green bar, 200.000 fold less); 
- IMR32, a human derived cell line established by an abdominal mass of a 13-month-old 
male patient with neuroblastoma, shows higher PGR amount compared to SK-N-BE(2)C 
about 60 fold higher compared to SK-N-BE(2)C (Fig. 20, compare blue vs yellow bar). 
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Figure 20 Real-time quantitative PCR of intracellular Progesterone Receptor (PGR) 
mRNA expression in SH-SY5Y, SK-N-BE(2)C, IMR32, MCF-7 and T47D cell lines.  
1 µg of total RNA was reverse transcribed and analysed by Real Time PCR, using a specific TaqMan assay for 
the human transcript PGR. The level of messenger RNA is expressed as relative to the cell line SK-N-BE (2) C, 
(set to a value of 1). The 2
−ΔΔCT
 method was used to calculate the results. 
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4.3.4 3-KDG treatment alters the TLX2 promoter activity in 
neuroblastoma cell lines 
 
Given that PHOX2B is a neuro-specific transcription factor and its ability to activate TLX2 
gene transcription has already been studied in the human SK-N-BE neuroblastoma cell 
line (Borghini et al 2006), we assessed whether the 3-KDG effect is also expressed in 
neuroblastoma cell lines, by measuring the TLX2 promoter activity using luciferase assay.  
As qPCR analysis conducted in neuroblastoma cell lines revealed low level of nuclear 
progesterone receptors in these cell lines with respect to the breast cancer cells (T47D 
and MCF7) used as positive control, we decided to transfect different neuroblastoma cell 
lines with an expression vector containing the coding sequence of human PGR gene, 
allowing cells to be responsive to 3-KDG treatment. 
Transfection of IMR32 and SK-N-BE(2)C with TLX2 promoter along with human PGR gene 
expression vector, results in a strong basal activity of the promoter, higher in IMR32 (950-
fold respect to pGL3b; Fig. 21, Panel B compare black vs white bar) compared to SK-N-
BE(2)C (73-fold respect to pGL3b; Fig. 21, Panel A compare black vs white bar) probably 
due to the presence of endogenous PHOX2B / PHOX2A transcription factors. In these cell 
lines, 1nM 3-KDG treatment for 48 hours induced a strong reduction in TLX2-promoter 
transactivation, with a more drastic effect in IMR32 with respect to SK-N-BE(2)C cells (Fig 
21, compare black striped bars, panel B vs panel A). 
The same result was obtained with the CAD cell line (Cath.a-differentiated), a CNS 
cathecolaminergic cell line derived from Cath.a cell line originated from locus coeruleus 
brain tumours of transgenic mice expressing the simian virus 40 T antigen under the 
control of the TH promoter (Suri et al., 1993). TH and DBH expression, along with 
catecholamines synthesis, characterize this cell line, and it is known that CAD cell 
differentiation depends on PHOX2A expression and activation mediated by cAMP 
pathway (Chen et al., 2005). In this cellular model the TLX2-luc promoter activity was 
drastically reduced by 3-KDG treatment (331-fold respect to pGL3b; Fig. 21, Panel C 
compare black vs white bar). 
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Figure 21 Luciferase assay activity of TLX2 reporter constructs in neuroblastoma cell 
lines after 48 hours treatment with 1nM 3-KDG. The bars indicate the transcriptional activity of 
the reporter constructs under TLX2 promoter control after co-transfection of the TLX2-luc promoter 
reporter construct (black bars) or pGL3b empty vector (white bars) treated with 1 nM 3-KDG (white and 
black hatched bars) for 48 hours. The data are expressed as fold-induction compared to untreated sample 
transfected with TLX2-luc construct (black bars). The results obtained in SK-N-BE(2)C, IMR32 and SK-N-BE 
cells are expressed as mean ± SD (error bars) of the transcriptional activity of the constructs tested in at 
least three independent experiments performed in triplicate (n=3), *** p <0.001 (one-way ANOVA, Tukey's 
test). The graph obtained in CAD cells is to consider as representative (n=1). 
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On the contrary, in the SK-N-BE neuroblastoma cell line, that lacks PHOX2B expression 
(Borghini et al 2006) whereas it expresses PHOX2A, TLX2 -luc basal activity appears to be 
lower than other neuroblastoma cell lines (7 -fold respect to pGL3b; Fig 21, Panel D 
compare black vs white bar). This may be due to the lack of PHOX2B expression in this cell 
line. Unexpectedly the 3-KDG treatment induces an increase in TLX2 promoter activity 
(13-fold, Fig. 21, Panel D compare black striped vs black bar), similarly to the situation 
observed in T47D cell line (see preliminary data). The opposite results observed in the 
TLX2-luc promoter activity, between SK-N-BE(2)C, T47D and the other neuronal cell lines 
tested, could be due to the recruitment of different co-factors (i.e. co--activators and/or 
co-repressors), mediated by 3-KDG, in the different cellular contexts. 
 
 
4.3.5 3-KDG treatment does not alter PHOX2B / PHOX2A mRNA 
levels in SK-N-BE(2)C cell line transiently overexpressing human 
PGR. 
 
Results obtained measuring the luciferase activity of TLX2 reporter constructs in 
neuroblastoma cell lines after 48 hours treatment with 1nM 3-KDG indicated that, 
interestingly, the progestin treatment in these cell lines induces the opposite effect on 
TLX2 activity with respect to T47D breast cancer cell line, with the exception of SK-N-BE 
cell line. 
Given the predominant decrement in TLX2 activity after 3-KDG treatment in neuronal 
context, we wondered if a possible mechanism of action of desogestrel, in reducing TLX2 
expression, could be explained by a direct effect of the progestin on PHOX2B. 
To answer this question, we decided to treat SK-N-BE(2)C cells with 3-KDG at increasing 
time point in order to analyse its possible effect on PHOX2B transcript level by means of 
qPCR. 
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Figure 22 shows the quantification of PGR mRNA expression level in four independent 
experiments of PGR construct transfection in SK-N-BE(2)C cell line, which results in a 
highly variable transfection efficiency of progesterone receptor in different experiments.  
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Figure 22 mRNA expression level of transfected PGR in SK-N-BE(2)C cell line under 3-
KDG treatment at different time point.  
Symbols indicate the mRNA levels of transfected PGR in SK-N-BE(2)C in four different transfected samples 
(A, B, C and D)  treated with 1nM 3-KDG for different time (24h, 48h, 72h, 96h, 120h).  The level of 
messenger RNA is expressed as relative expression normalized to that o GAPDH endogenous gene and 
expressed according to the 2−ΔCT method. 
 
The analysis of PHOX2B mRNA (Fig. 23) extract from cells treated at different time (24h, 
48h, 72h, 96h and 120h), in the four independent experiments, did not reveal significant 
alteration with respect to untreated sample (Fig. 23, compare hatched bars vs black bar), 
even in the experiment with the higher level of PGR expression (red dots in Fig, 22). 
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Figure 23 qPCR analysis of PHOX2B expression level in SK-N-BE(2)C cell line transfected 
with PGR expression vector treated with 3-KDG at different time point.  
Total RNA was extracted from cells treated for different times with 1 nM 3-KDG (24h, 48h, 72h, 96h, 120h; 
hatched bars) and the level of PHOX2B determined by qPCR.. The bars are the mean values ± SD (error bars) 
of the PHOX2B mRNA expression level detected in four independent experiments performed in triplicate, 
and are expressed as fold relative to the untreated cells (NT=1, black bar). 
 
Given that TLX2 gene is also a transcriptional target of PHOX2A (Borghini et al 2007), 
along with the fact that we observed a 3-KDG effect also in neuroblastoma cell lines, 
which express PHOX2A but not PHOX2B (SK-N-BE cell line), we considered the hypothesis 
that 3-KDG effect could be mediated by PHOX2A. 
To test this hypothesis, we analysed also PHOX2A mRNA in the same cell samples used for 
PHOX2B mRNA analysis. 
However, the analysis of the PHOX2A mRNA revealed a not statistically significant 
increase in samples treated at different time point (Fig. 24; compare hatched bars vs 
black bar), suggesting that the action of the progestin is not directed on regulating 
PHOX2B/2A gene expression. 
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Figure 24 qPCR analysis of PHOX2A expression level in SK-N-BE(2)C cell line transfected 
with PGR expression vector treated with 3-KDG at different time point.  
Total RNA was extracted from cells treated for different times with 1 nM 3-KDG (24h, 48h, 72h, 96h, 120h; 
hatched bars) and the level of PHOX2A determined by qPCR. The bars are the mean values ± SD (error bars) 
of the PHOX2A mRNA expression level detected in four independent experiments performed in triplicate, 
and are expressed as fold relative to the untreated cells (NT=1, black bar). 
 
However, we cannot rule out whether the considerable difference in the levels of PGR in 
the different samples could result in an underestimation of the 3-KDG effect in this cell 
line. 
 
4.3.6 3-KDG treatment induces a decrement in PHOX2B protein 
amount in SK-N-BE(2)C cell line transiently overexpressing human 
PGR. 
 
Data obtained in T47D cell line have shown that 3-KDG treatment induces an augment in 
PHOX2B ability to transactivate one of its target gene, TLX2, probably due to an increase 
in transfected PHOX2B protein level. 
Given the known PHOX2B-mediated regulation of TLX2 promoter in neuroblastoma cell 
lines, we asked whether the consistent alteration in TLX2 promoter luciferase activity, 
observed upon 3-KDG treatment in SK-N-BE(2)C cell lines, is related to a change in 
endogenous PHOX2B protein amount. To test this hypothesis we evaluated endogenous 
84 
 
3 KDG                -                         + 
PHOX2B protein level in SK-N-BE(2)C cells transfected with human PGR cDNA expression 
vector (hPGR in pCDNA3.1 Myc-Hys), treated with 1nM 3-KDG for 48 hours. 
Western blot analysis (Fig. 25, Panel A) of total extract from SK-N-BE(2)C cell line 
transfected with PGR expression vector (Fig. 25, Panel A, lanes 1 and 2), and treated with 
3-KDG (Fig. 25, panel A, lanes 2 and 4), has shown a 3-fold reduction in PHOX2B protein 
(Fig. 25, Panel B), thus suggesting that 3-KDG has a direct effect on PHOX2B protein also 
in this cell line, although contrary to what we have observed in T47D cells, and that the 
reduced activity of TLX2 promoter could be due to decrease PHOX2B protein availability. 
The 3-KDG treatment induces an increase also in the progesterone receptors amount (Fig. 
25 PR-A/PR-B, compare 5 vs 4 lanes) while no changes were observed in PGRs mRNA (Fig. 
22), indicating that an increment in the stability of the protein or of the ligand/receptor 
complex after progestin treatment can occur. 
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Figure 25 Western blot analysis of PHOX2B protein amount after 48 hours 3-KDG 
treatment in SK-N-BE(2)C cell line transiently expressing hPGR. Panel A) Representative 
immunoblotting image showed the expression of PHOX2B endogenous protein in SK-N-BE(2) C cells 
transfected with hPGR expression vector (lanes 3-4) or equimolar amount of empty vector, used as negative 
control (lanes 1-2) after 48 hrs treatment with 1 nM 3-KDG (lanes 2-4). IMR32 nuclear extract are used as 
PHOX2B positive control (IMR32 NE, lane 5); T47D are used as hPGR positive control (lane 6). The 
nitrocellulose membrane was immunoblotted with PGR antibody (upper panel) to detect PGR isoforms and 
PHOX2B antibody (lower panel). The same blot was reprobed with α-tubulin to compare the loading of each 
lane (middle panel). Panel B) Quantification of PHOX2B endogenous protein in SK-N-BE(2)C cells transfected 
with hPGR vector after 48h 3-KDG treatment. Value are expressed as mean ± SEM (n=2) of PHOX2B values 
normalized to that of tubulin. 
A) B) 
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To study the mechanism underlying this reduction, and in order to avoid the limited step 
of PGR transfection, SK-N-BE(2)C stably expressing hPGR were generated. The details 
about the generation of SK-N-BE(2)C stably expressing hPGR are described in the master 
degree thesis by Erika Di Biase (our lab).  
The hPRG expression vector used for transient transfection and for the generation of 
stable clones encodes for both PR-A and PR-B isoforms. Of the screened clones, we 
obtained 16 out of 95 positive clones. All clones express PR-B isoform, whereas PR-A 
expression was present only in a small percentage of clones. Taking into account that 3-
KDG effect on neuroblastoma cells may vary depending on different amount of PR-B and 
PR-A expressed, we started our analysis on the effect of 3-KDG by focusing on two SK-N-
BE(2)C positive clones (5.8 and 6.30), that differ for the relative expression level of the 
two isoforms, PR-B and PR-A (Fig. 26, blue and red bars, respectively). The graph in figure 
26 shows the protein level of the two receptor isoforms in the two selected clones, 
expressed as percentage compared to that measured in T47D cells (set=1). Clone 5.8 
expresses comparable amount of PGR-B as in T47D and 10% of PGR-A, whereas in clone 
6.30, PR-B expression is 50% compared to that of T47D (Fig. 26); in this clone no PGR-A 
expression was detected.  
 
Figure 26 Western blot quantification of PR-A and PR-B protein amount in SK-N-BE(2)C-
PGR stable clones. Relative quantification of intracellular progesterone receptor isoforms PR-A (red 
bars) and PR-B (blue bars) in SK-N-BE(2)C clones 5.8 and 6.30 and T47D cell line,  expressed as ratio of PR-A 
or PR-B to β-Tubulin.   
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4.3.7 Effect of 3-KDG in SK-N-BE(2)C cell lines stably over-
expressing human progesterone receptors. 
 
The SK-N-BE(2)C cell lines, stably over-expressing human PGR receptors, provide suitable 
cell models for studying the effects of 3-KDG in a neuronal background. 
In order to analyse the 3-KDG effect on the endogenous level of PHOX2 transcription 
factors and of some known PHOX2 target genes, clones 5.8 and 6.30 and native SK-N-
BE(2)C used as control cell line (mock), have been treated with 1nM 3-KDG for 8, 24 and 
48 hours (Fig. 27). 
Western blot analysis and quantification (Fig 27 and Fig 28, respectively) revealed that in 
both clones the level of all the proteins known to be regulated by PHOX2A/B transcription 
factors (PHOX2A, PHOX2B, DBH and AP2α (Activator protein 2 alpha), with the exception 
of GATA3) are significantly reduced upon treatment at each time point, compared to 
untreated clones (Fig. 27, Panel A), with different kinetics between clones. Indeed, in 
clone 5.8, PHOX2B, PHOX2A and DBH proteins decrease with a faster kinetic than in clone 
6.30 (Fig 27, Panel A, compare lanes 5-8 vs lanes 9-12). 
In detail, at 8 hours treatment, PHOX2B was reduced by 60% in clone 5.8 vs 30% in clone 
6.30 (Fig. 28, Panel A, compare black vs white bar), PHOX2A reduced by 90% in clone 5.8 
vs 20% in clone 6.30 (Fig. 28, Panel B, compare black vs white bar); at 48 hours, DBH was 
undetectable in clone 5.8 vs 90% reduction in clone 6.30 (Fig. 28, Panel C, compare black 
vs white bar), Ap2α was undetectable in clone 5.8 vs 50% reduction in clone 6.30 (Fig. 28, 
Panel D, compare black vs white bar). 
As a control, we analysed the expression level of proteins that are not direct PHOX2B 
target genes (Fig. 27; Panel B), such as Sp1 (Specificity Protein 1), CREB (CAMP Responsive 
Element Binding Protein) and c-Jun ( c-Jun proto-oncogene). No significant changes in the 
expression of these proteins were detected in the clones, as well as in the control cells 
(Fig 28, Panels F, G H), thus correlating the clinical observation with a direct effect on 
PHOX2B activity. Whether PHOX2B has to be down- or up-regulated to allow the recovery 
of chemosensitivity observed in the two French CCHS patients, is an important topic that 
needs to be further investigated. 
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Figure 27 Representative western blot image of endogenous proteins in SK-N-BE(2)C cell 
lines stably over-expressing hPGR and SK-N-BE(2)C not transfected cells, after 3-KDG 
treatment.  
SK-N-BE(2)C not expressing hPGR (lanes 1-4), SK-N-BE(2)C clone 5.8 expressing both PR-B and PR-A isoforms 
(lanes 5-8), and  SK-N-BE(2)C clone 6.30 expressing only PR-B isoform (lanes 9-12) were treated with 1 nM 
3-KDG at different time point: 8 hours (8h; lanes 2,6, 10); 24 hours (24h; lanes 3, 7, 11); 48 hours (48h; lanes 
4, 8, 12); or not treated (-; lanes 1, 5, 9). IMR32 nuclear extract (IMR32 NE) is used as PHOX2A/B positive 
control (lane 13). T47D total extract is used as progesterone receptor isoforms positive control (lane 14). 20 
µg of total lysate for each sample were separated by 10 % SDS-PAGE. PR-A, PR-B, PHOX2B, PHOX2A, DBH, 
Ap2α, Sp1, GATA3, CREB, c-Jun were detected with specific antibodies.  All blots were reprobed with β-
tubulin (TUB) to compare the loading of each lane.  
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Figure 28 Quantification of endogenous proteins amount in SK-N-BE(2)C cell lines stably 
over-expressing hPGR and SK-N-BE(2)C not transfected cells, after 3-KDG treatment.  
Quantification of PHOX2B, PHOX2A, DBH, Ap2α, GATA3, Sp1, C-Jun, CREB endogenous protein amount in 
SK-N-BE(2)C not expressing hPGR (grey bars), SK-N-BE(2)C clone 5.8 expressing both PR-B and PR-A isoforms 
(black bars), and SK-N-BE(2)C clone 6.30 expressing only PR-B isoform (white bars). Intensities of 
immunoreactive bands on western blots were quantified by densitometry analysis (ImageJ). Data are 
represented as relative fold induction of treated samples (8h, 24, 48h) with respect to untreated samples(-). 
The results obtained in SK-N-BE(2)C, SK-N-BE(2)C clone 5.8 and SK-N-BE(2)C clone 6.30 are expressed as 
mean ± SD (error bars) of the densitometry intensity of each lane normalized vs respective tubulin in at 
least three independent experiments (n=3). *** p <0.001, **p <0.01, * p <0.05 (one-way ANOVA, Tukey's 
test).  
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4.3.8 Effect of 3-KDG on endogenous PHOX2A, PHOX2B TLX2 and 
DBH transcript levels in SK-N-BE(2)C cell line stably over-
expressing PR-B and PR-A progesterone receptors. 
 
The 3-KDG treatment, in SK-N-BE(2)C cell line stably expressing hPGR, resulted in a strong 
reduction in the level of all the proteins known to be regulated by PHOX2A/B 
transcription factors, with the exception of GATA3. On the contrary, the level of all 
PHOX2B non-target proteins, here analysed, seemed not to change between treated and 
untreated clones, thus indicating a specific effect of 3-KDG treatment on PHOX2B 
pathway.  
Moreover, we previously observed a strong decrement in TLX2 promoter activity in 
neuronal cell lines transiently expressing hPGR, with the exception of SK-N-BE, after 3-
KDG treatment. 
To study the mechanism underlying these effects, we performed a quantitative PCR 
analysis, in order to test whether the decrease in protein level is due to a reduced 
transcription or mechanism acting at post-transcriptional level.  
Quantitative PCR analysis of PHOX2B, PHOX2A, DBH and TLX2 mRNA (Fig. 29), extract 
from SK-N-BE(2)C clones 5.8 and 6.30 and native SK-N-BE(2)C cell samples, treated with 
1nM 3-KDG for 8, 24 and 48 hours, shows a significant reduction in their expression level, 
in 5.8 clone (Fig. 29, black bars), and to a much less extent in clone 6.30 (Fig. 29, white 
bars), similarly to the decrement observed in protein levels (Fig. 27 and 28). However, the 
reduction is more pronounced for PHOX2A and DBH gene than PHOX2B and TLX2 that, 
after 48 hours treatment, decreased by 50% and 60%, respectively, in 5.8 clone (Fig. 29, 
Panel A and C, compare black hatched bars vs black bar) and by 40% and 20%, 
respectively, in clone 6.30 (Fig. 29, Panel A and C, compare white hatched bars vs white 
bar). On the contrary, PHOX2A and DBH transcripts decreased up to 80% and 90%, 
respectively, in clone 5.8 (Fig. 29, Panel B and D, compare black hatched bars vs black bar) 
and by 20% and 30%, respectively, in clone 6.30 (Fig. 29, Panel B and D, compare white 
hatched bars vs white bar). In native SK-N-BE(2)C cells, no changes in the level of mRNA 
have been observed for all the genes, but PHOX2A expression is again down-regulated, 
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although we have never observed such a reduction in SK-N-BE(2)C cells transient 
transfected with PGR (Fig. 24).  
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Figure 29 qPCR analysis of  endogenous PHOX2A, PHOX2B, DBH and TLX2 mRNA 
expression in SK-N-BE(2)C cell lines stably over-expressing hPGR and SK-N-BE(2)C not 
transfected cells, after 3-KDG treatment at different time point.  
The bars indicate the mRNA levels in SK-N-BE(2)C samples (grey bars), SK-N-BE(2)C clone 5.8 (black bars) 
and SK-N-BE(2)C (white bars) treated with 1nM 3-KDG at different time points (0h, 8h, 24h, 48h). The bars 
are the mean values ± SD (error bars) of the PHOX2B, PHOX2A, DBH and TLX2 mRNA expression level 
detected in a single representative experiment, performed in triplicate, and are expressed as fold relative to 
the untreated cells (=1). The 2
−ΔΔCT
 method was used to calculate the results. 
 
These data support the hypothesis that the reduction in protein levels observed for 
PHOX2B and its target genes, is in part due to a reduction of mRNA level, that can occur 
because of reduced transcription or reduced transcript stability.  
To deeply investigate the transcriptional mechanism involved in 3-KDG treatment, we 
choose to analyse the stability of PHOX2B mRNA in clone 5.8, which showed the most 
rapid kinetic reduction in PHOX2B target proteins. 
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SK-N-BE(2)C clone 5.8 cells were then pre-treated with 1nM 3-KDG, and, after 24 hours, 
the transcriptional inhibitor 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole (DRB) was 
added and the cells lysed and analysed at the times indicated in figure 30. 
As shown in Figure 30, in not treated cells (black dots) PHOX2B mRNA is stable, as its level 
remains constantly over 50%; 3-KDG drastically affects PHOX2B mRNA stability, by 
decreasing its half-life to 60 minutes (Fig. 30, red dots) thus indicating an increased 
degradation of the PHOX2B transcript upon treatment.  
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Figure 30 Effect of 3-KDG treatment on PHOX2B transcript stability. 
SK-N-BE(2)C clone 5.8 was treated with 1nM 3-KDG . After 24h of treatment, cells were incubated with 0.75 μM DRB for 
30, 60, 120, 240 or 480 minutes (red dots). SK-N-BE(2)C clone 5.8 not treated cells, incubated with DRB at the same 
time points, were used as control (black dots). The values are mean ± SD of three independent experiments, performed 
in triplicate, and are normalized to the endogenous gene GAPDH, and are expressed as percentage relative to the time 
0 (=100%), calculated by means of the 2
−ΔΔCT
 method. 
However, the reduction of PHOX2B mRNA level, measured in the experiment in Fig. 29, 
does not totally justify the reduction in protein levels, observed in clone 5.8 upon 3-KDG 
treatment (Fig. 28). Other mechanisms, which impair stability and/or protein translation, 
due for example to post-translational modifications (i.e. phosphorylation/de-
phosphorylation), can be involved in mediating the effect of 3-KDG. We do not know at 
the moment if the reduced stability of PHOX2B mRNA can be a general mechanism by 
which 3-KDG down-regulates the expression of PHOX2B target genes. This topic is still 
under investigation. 
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General discussion 
 
PHOX2 proteins are homeodomain transcription factors deeply involved in ANS 
development and specification of the noradrenergic phenotype in embryonic 
neurodevelopment. Phox2b and Phox2a not only have a crucial role in developing brain, 
but are also found to be widely expressed in mouse post-natal brain, even though in 
different neuronal populations (Kang et al., 2007 and Card et al., 2010). However, 
contrary to the important role in neurodevelopment and neuronal specification in early 
embryogenesis, the role of PHOX2B expression in adult is still unclear. Interestingly, 
Phox2b expression in adult mouse brain is far more limited than that of Phox2a, and they 
show divergence in the function of their gene products in adult brain. In particular, 
immunostaining experiments revealed consistent divergence within the A1, A5, A6, Locus 
Coeruleus (LC), and A7 noradrenergic cell groups, which densely stain for Phox2a (Card et 
al. 2010) but do not express Phox2b in the adult rat brain (Kang et al., 2007).  
The evident decrement of Phox2b concentration between embryonic and adult 
noradrenergic neurons, indicates that, despite the pioneer role of Phox2b in 
noradrenergic development, this transcription factor is not necessary for the 
(nor)adrenergic phenotype maintenance in the adult brainstem, such function is probably 
more controlled by Phox2a protein given its highest expression in noradrenergic adult 
circuits. 
Despite the considerably differences in Phox2 proteins expression patterns in adult brain, 
there is a substantial overlap in their distribution in several brain regions (summarized in 
the table n. 1). 
 
Taking together that Phox2 proteins expression is dynamically regulated between 
neurodevelopmental and adult mouse brain, and that their overexpression is linked with 
neuroblastoma (NB) manifestation, we can assert that a tight control of their expression 
is necessary in order to avoid pathologies and neurological abnormalities. 
As proof of this observation, we found that treatment with the differentiating agent all-
trans retinoic acid (ATRA) finely control PHOX2 proteins, we therefore hypotesize that 
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PHOX2 proteins decrement could be linked with the consequent beneficial effect in 
tumours treatment (see appendix 2). 
In particular, our data indicates that PHOX2A protein product increases during the first 24 
hours of ATRA treatment and disappears after 48 hours, by proteasome degradation, 
while the expression of PHOX2A mRNA remains constantly up-regulated. PHOX2B protein 
instead appears to be immediately down-regulated following ATRA treatment. 
Recently, other molecules, which have already reported to have anticancer activity in NB 
or other tumours, (Curcumin, Tricostatin-TSA and Suberoylanilide hydroxamic acid-SAHA) 
are found to have a marked effect on PHOX2B down-regulation (Di Zanni et al., 2015).  
This data, together with the observation that PHOX2B is down-regulated during final 
neuronal differentiation (Alam et al., 2009,) suggest that the dysregulation of PHOX2 
pathway induces a strong alteration in the differentiation process and that ATRA-
dependent PHOX2B down-regulation, may possibly drive the differentiation of NB cells.  
 
Besides being involved in neuroblastoma manifestation and progression, and given their 
relevant role in neurodevelopment, mutations in PHOX2 transcription factors are found 
to be correlated with congenital pathologies. 
In particular, homozygous mutations in PHOX2A gene result in congenital fibrosis of the 
extraocular muscles type 2 (CFEOM2) whereas heterozygous mutations in PHOX2B gene 
lead to Congenital Central Hypoventilation Syndrome (CCHS).  
The pioneer role of Phox2b in brain embryo development could explain the reason why 
mutations in PHOX2B lead to more complex pathologies, involving neurodevelopmental 
and neurocognitive disorders and autonomic impairment/dysfunction. 
At the molecular level, the pathological mutations in PHOX2B protein, principally due to 
the expansion in the 20-alanine stretch downstream the homeodomain, lead to a 
misfolded protein that has a reduced activity but shows an increase tendency to form 
aggregate and to interfere with wild type activity (Bachetti et al., 2005; Trochet et al., 
2005; Di lascio et al., 2013). 
The dissolving of “pathogenetic” PHOX2B aggregates, by means of heat shock protein 
activation shown by Di Zanni et al. (2012) and Bachetti et al. (2005), is based on the most 
common consideration that they are toxic for the cells. However, there is no evidence of 
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their in vivo existence, as they were observed only in overexpression experiments even if 
in different cell lines. Therefore, we cannot exclude that the strong interaction between 
expanded mutant proteins could be a simple over-expression artefact due to the high 
mutant proteins amount, respect to physiological conditions, or even a protective 
mechanism in order to avoid toxic effects of mutant PHOX2B. Further, Di Zanni et al. 
(2012) also observed that treatments with Curcumin and Geldanamycin, drugs able to 
dissolve the aggregates, are actually toxic for the cells, since they reduce cellular viability 
after 48hours of treatment, supporting the protective aggregation theory.  
In CCHS the anatomical abnormalities were found in Retrotrapezoid Nucleus (Dubreuil et 
al., 2008), an anatomical structure that is absent in Phox2b +/+7Ala mouse model. Recently, 
the analysis of post-mortem brain of two CCHS patients unraveled anatomical defects in 
the dorsal motor nucleus of the vagus nerve, in the mesencephalic trigeminal nucleus, in 
the serotonergic median raphe and adrenal medullary neurons and also LC neuronal loss 
(Nobuta et al., 2015). These anatomical neurodevelopmental defects are obviously 
irreparable by pharmacological treatments. However, other neural structures involved in 
breathing control, whose function depends on PHOX2B, may get beneficial effects by the 
restoration of PHOX2B activity. 
 
In 2010 the serendipitous observation of a marked chemosensitivity recovery in two CCHS 
female patients assuming Desogestrel, exclusively for a contraceptive purpose, gave us an 
interesting therapeutic perspective for the disease (Similowski and Straus, 2011). 
It is well known that progesterone has stimulant effect on respiration (Dempsey et al., 
1986; Joseph et al., 2012) and that its administration is able to reduce apnoea during 
sleep in adult women (Young et al., 2003). 
However, the mechanism through which Desogestrel could ameliorate respiratory 
symptoms in CCHS patients is largely undisclosed. It is also noterworthy that the effect of 
Desogestrel is exclusively mediated by this progestin and not by physiological 
progesterone, since women affected by CCHS did not improve hypercapnia response 
during gestation. This could be a consequence of the stronger affinity of Desogestrel for 
the progesterone receptor; three times greater than that of progesterone (Straus et al., 
2010; Wiegratz and Kuhl, 2004). 
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Our first experiments performed in T47D cell line, highlighted a clear association between 
3-KDG and PHOX2B activity, since we observed an enhancement of TLX2 promoter 
transactivation in the presence of PHOX2B, together with an increase amount of PHOX2B 
protein upon cell treatment, in both cases this effect is abolished in the presence of 
nuclear progesterone antagonist Mifepristone (RU486). 
Several functional studies support the role of nuclear progesterone receptor in the 
control of respiration, as pre-treatment with RU486 abolished positive effect of 
progesterone injection on apnoeic episodes during sleep in adult rat (Yamazaki et al., 
2005), and the enhancement of phrenic nerve activity in cats (Bayliss et al., 1987). 
Furthermore, in vivo data indicate that nuclear progesterone receptor effects on 
respiration are mainly mediated by the hypothalamus (Bayliss et al., 1990) and the 
nucleus of the solitary tract (Bayliss et al., 1987). In addition, experiments conducted on 
nuclear progesterone receptor KO mice (PRKO) and WT mice clearly indicate that 
progesterone treatment is able to increase ventilation in adult under hypercapnic 
condition, and that this effect is mediated by nuclear PR (Marcouiller et al., 2014). 
Interestingly, in these models, progesterone reduces frequency of sighs and post-sighs 
apnoeas during sleep (Marcouiller et al 2014). Sights are part of normal breathing 
(Bendixen et al., 1964) and are generated by central respiratory generator that receives 
afferents from NTS, which in turn intercepts input from pulmonary stretch receptor 
(Larrabee et al., 1946) and peripheral chemoreceptors (Glogowska et al., 1972). 
 
The data obtained in neuroblastoma cell lines revealed a strong reduction in TLX2 
promoter activity after progestin treatment in almost all the cell lines tested, with the 
exception of SK-N-BE cell line, which exclusively expresses PHOX2A , and that responded 
in a similar manner to that of T47D cells. This intriguingly result suggests that the cellular 
background, including the presence of different co-activators and co-repressors, is a 
crucial determinant of the 3-KDG effect on PHOX2B and PHOX2A pathway. 
In addition, experiments carried out in SK-N-BE(2)C cell line, stably expressing human 
PGR, have shown that the reduction in PHOX2B, PHOX2A and the protein level of other 
target genes is particularly marked in stable clone expressing high level of progesterone 
receptor B isoform together with the A isoform (SK-N-BE(2)C clone 5.8). This reduction 
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occurs, in part, also at mRNA levels, due to a reduced PHOX2B mRNA half-life. However, 
the reduced level of PHOX2B mRNA does not justify the high decrement in PHOX2 and 
PHOX2 targets protein levels, thus suggesting that 3-KDG may act also by reducing protein 
stability. This aspect is still under investigation. 
A recent study, on two postmortem CCHS cases (one PARM and one NPARM; Nabuta et 
al., 2015), reported neuronal loss within the LC, the major noradrenergic nucleus of the 
brain. Since PHOX2A gene is required for LC development, and we demonstrated that it 
interacts with both wild type and mutant PHOX2B, we tested the hypothesis that PHOX2B 
mutations may cause a dominant-negative effect on PHOX2A activity. Our results indicate 
that PHOX2B mutants do not interfere with PHOX2A transcriptional activity; on the 
contrary we measured an unexpected synergistic effect of PHOX2A and mutant PHOX2B 
heterodimers. However, we cannot exclude the possibility of new “toxic” interactions, 
due to altered recruitment of promoter-specific co-factors by mutant heterodimers , 
which could be limited by lowering also PHOX2A expression. 
 
The divergent data of the 3-KDG effect in different cell lines, suggested that in order to 
take Desogestrel in consideration as a possible therapeutic drug, a better understanding 
of brain areas expressing PGR alone or along with PHOX2B and PHOX2A is needed. 
Data available from studies obtained in young mice, and summarized in table 1, showed 
that PGR is expressed in different CNS structures (Quadros et al., 2008), but only in few of 
those PGR turned out to be co-expressed with PHOX2 proteins. 
Interestingly, the nuclus of the solitary tract (NTS) is the only structure which co-
expresses Phox2a, Phox2b and PGR (Quadros et al., 2008, Card et al., 2010, Kang et al., 
2007). The NTS neurons, located in the dorsal medulla, are known to be indispensable for 
the integration of sympathetic and respiratory responses to hypoxia, representing the 
first synaptic centre of the cardio-respiratory afferent inputs, including peripheral 
chemoreceptors, baroreceptors and pulmonary stretch receptors (Zoccal et al., 2014). 
Of particular interest are nuclei of the reticular formation, such as the Periaqueductal 
Gray and the Parabrachial nucleus, known to be involved in the autonomic control of 
respiration (Subramanian et al. 2008, Chamberlin and Saper, 1994), and in which PGR is 
express together with Phox2a (Card et al, 2010). Other Phox2a / PGR positive structures 
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have been identified in hypothalamus, in particular the Dorsomedial hypothalamic 
nucleus (DMH) in caudal hypothalamus and Ventrolateral preoptic nucleus (VLPO) in 
rostral hypothalamus, both found to be important in the control of behavioral state (for 
reviews see Saper et al., 2005; Siegel, 2006; Fuller et al., 2007). In particular, VLPO is 
involved in wake-sleep cycle regulation (Saper et al., 2005), whereas chemical stimulation 
of DMH has been associated to increased phrenic nerve stimulation (Tanaka and McAllen, 
2008). 
CCHS patients, in addition to the respiratory symptoms, also show symptoms of a 
generalized impairment of sympathetic functions. We do not know at the moment 
whether the progestin may be beneficial to restore autonomic functions adversely 
affected in the disease. 
 
Another important issue in CCHS treatment regards that PHOX2B is known to be 
necessary for the correct development of anatomical structures responsible for hypoxia 
and hypercapnia sensitivity, in particular the Carotid body (CB), NTS, petrosal 
chemoreceptor and RTN.  
As the mouse model carrying the heterozygous Phox2b +7ala mutation do not develop 
the RTN neurons, it is reasonable to expect that also in humans this structure is not 
properly developed. 
The observation of the chemosensitivity recovery in CCHS patients after 3-KDG 
assumption could therefore suggest that the ameliorated symptoms may perhaps be also 
linked to respiratory pathways apparently unrelated to PHOX2B. 
Very recently Joubert and co-workers (Joubert et al., 2016) observed an increase in 
respiratory frequency in ex vivo mouse medullary-spinal cord preparations or in vivo mice 
exposed to Etonogestrel (3-KDG), indicating that other pathways, not involving PHOX2B, 
should also be considered in 3-KDG effects. 
These data, together with our findings concerning the 3-KDG effect on PHOX2B and its 
targets and jointly with the well known positive respiratory stimulations of progestin 
drugs, indicate that 3-KDG may have a more complex effect on general ventilation in 
CCHS patients acting on different respiratory networks. 
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Table n. 1 
Adult rat: Phox2a Phox2b PGR 
Dorsal motor vagal complex 
(DVC)[medulla]: 
+ +  
Nucleus of the solitary tract (NTS) + + + 
Area postrema (AP) 
Dorsal motor vagal nucleus (DMV) 
+ 
+ 
 
+ 
+ 
 
Reticular formation: +  +/- 
Inferior salivatory nucleus +  -* 
Parabrachial nucleus, lateral 
Parabrachial nucleus, medial 
+ 
+ 
-(rare) 
- (rare) 
++ 
+/- 
Periaqueductal gray  + -* +++(not ventral) 
Gigantocellular reticular region   +/- 
Raphe pontis nucleus -  +(+) 
Pedunculopontine tegmental 
Nucleus 
  +++ 
Medulla 
Spinal nucleus of the fifth cranial 
nerve 
 
+ 
 
+( dorsomedial 
subdivision) 
 
- 
Subjacent to the fourth ventricle  +  +/-(Vestibular 
nucleus) 
Ventrolateral brainstem:    
Ventrolateral medulla  
Rostroventral medulla (RVLM) 
And pons (Trochlear and oculomotor 
nuclei) 
Retrotrapezoid nucleus (RTN) 
Superior salivary nucleus (SSN) 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
 
 
- 
Nucleus ambiguus  -(only 
embryoge
nesis) 
+  
Rostral-dorsal brainstem(pons)    
Locus coeruleus (LC) + -  
Midbrain:    
Substantia nigra, compact 
Ventral tegmental Area  
Interfascicular nucleus (VTA) 
Paranigral region (VTA) 
Retrorubral field (RRF) 
Inferior colliculus 
Anterior pretectal nucleus 
 - +/- 
++(+) 
+/- 
+/- 
+/- 
+/- 
+ 
A7 cell group (midb. And pons) + -  
Diencephalon:    
Dorsomedial hypothalamic 
nucleus(DMH) in caudal 
hypothalamus 
+ - + 
Ventrolateral preoptic nucleus 
(VLPO) in rostral hypothalamus 
+ - +(preoptic area) 
Retrochiasmatic area and 
periventricular nucleus near 
suprachiasmatic nuclei 
+ 
Scattered 
neurons 
  
100 
 
Conclusion 
Our results on ATRA and 3-KDG treatment suggest that a fine control of the PHOX2 
pathway is critical in order to ameliorate clinical condition in NB and CCHS patients.  
The reducing PHOX2B expression, as observed in 3-KDG treated SK-N-BE(2)C cells 
overexpressing PGR, could reasonably result also in the decrease of mutants expression level, 
thus limiting the pathological effects of expanded mutants. However, the divergent data 
obtained between different cell lines also indicate that these effects strictly depend on 
physiological background, including the expression of correct receptor isoforms, and co-
repressors or co-activators. The NTS seems to be the CNS structure more compelling to 
mediate 3-KGD effect since PHOX2A, PHOX2B and nuclear progesterone receptors are co-
expressed in this region.  
Taking together our results point out the existence of a specific cross-talk between ATRA 
and 3-KDG treatments and PHOX2 pathway, suggesting that the regulation of PHOX2 
proteins expression could be a common strategy into the treatment ofboth NB and CCHS.  
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Heterozygous mutations of the human PHOX2B gene, a key
regulator of autonomic nervous system development, lead to
congenital central hypoventilation syndrome (CCHS), a neuro-
developmental disorder characterized by a failure in the auto-
nomic control of breathing. Polyalanine expansions in the
20-residues region of the C terminus of PHOX2B are the major
mutations responsible for CCHS. Elongation of the alanine
stretch inPHOX2B leads to a proteinwith alteredDNAbinding,
transcriptional activity, and nuclear localization and the possi-
ble formation of cytoplasmic aggregates; furthermore, the find-
ings of various studies support the idea that CCHS is not due to
a pure loss of function mechanism but also involves a dominant
negative effect and/or toxic gain of function for PHOX2Bmuta-
tions. Because PHOX2B forms homodimers and heterodimers
with its paralogue PHOX2A in vitro, we tested the hypothesis
that the dominant negative effects of the mutated proteins are
due to non-functional interactionswith thewild-type protein or
PHOX2A using a co-immunoprecipitation assay and the mam-
malian two-hybrid system. Our findings show that PHOX2B
forms homodimers and heterodimerizes weakly with mutated
proteins, exclude the direct involvement of the polyalanine tract
in dimer formation, and indicate that mutated proteins retain
partial ability to form heterodimers with PHOX2A. Moreover,
in this study, we investigated the effects of the longest polyala-
nine expansions on the homeodomain-mediated nuclear
import, and our data clearly show that the expanded C terminus
interferes with this process. These results provide novel insights
into the effects of the alanine tract expansion on PHOX2B fold-
ing and activity.
Heterozygous mutations in the PHOX2B gene lead to con-
genital central hypoventilation syndrome (CCHS3; OMIM ID:
209880), which is characterized by a failure in the autonomic
control of breathing and an abnormal ventilatory response to
hypoxia and hypercapnia (1).
CCHS patients have a greater predisposition to Hirschsprung
disease and neuroblastoma (2, 3) as well as the symptoms of
general autonomic nervous system dysfunction (4).
The transcription factor PHOX2B (paired-like homeobox
2b, also known as PMX2B andNBPhox) is amaster regulator of
autonomic nervous system development (5), and its human
orthologue is a 314-amino acid protein that harbors a home-
odomain and two polyalanine stretches of 9 and 20 residues,
respectively, within the C-terminal domain (6, 7).
The large majority of CCHS patients carry mutations that
cause an expansion of the longer polyalanine repeat (polyala-
nine repeat expansion mutations) (2, 8) ranging from 5 to
13 alanine residues, and it has been reported that there is a
correlation between the length of the polyalanine tract and the
severity of the respiratory phenotype and autonomic dysfunc-
tion (8, 9). Non-polyalanine repeat mutations (i.e. missense,
nonsense, and frameshift mutations) are less frequent, but
they correlate with more severe respiratory symptoms,
Hirschsprung disease, and neuroblastoma.
From a functional point of view, it is well established that the
homeodomain of PHOX2B is a highly conserved 60-residue
region that contains the DNA-binding motif; furthermore, in
line with what has been observed in other homeodomain pro-
teins, the PHOX2B homeodomain may also contain nuclear
localization signals, be responsible for the formation of homo-
and heterodimers (with other homeoproteins, including its
paralogue PHOX2A), and establish protein-protein interac-
tions (10). On the contrary, the exactmolecular functions of the
polyalanine tracts remain largely unknown.
Polyalanine and, more generally, homopolymeric tracts (sin-
gle amino acid repeats) are common features of eukaryotic pro-
teins and are especially abundant in transcription factors (11,
12). Increasing experimental data show that they can modulate
transcription factor activity by acting as flexible spacer ele-
ments located between functional protein domains and there-
fore play a role in protein conformation, protein-protein inter-
actions, and/orDNAbinding (13–15). The coding triplet repeat
instability that leads to the expansion of these stretches causes a
number of human diseases (16, 17), all of which are character-
ized by protein misfolding that leads to intracellular aggrega-
tion, which may be an intrinsic tendency because, beyond a
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certain threshold, the polyalanine tracts spontaneously form
-sheets in vitro (18).
Increasingly long polyalanine tracts also lead to an increased
tendency for protein aggregation and possible toxic effects in
the case of PHOX2B (19, 20). Nuclear import defects and cyto-
plasmic aggregation are detectable only in the case of proteins
with longer expansions, whereas other defects, such as
decreased DNA binding and transcriptional activity, also char-
acterize shorter expansions (19–21). In addition to loss-of-
function defects, it has been reported that the mutant protein
with the longest expansion (13 alanines) has a dominant neg-
ative effect on the DNA binding and subcellular localization of
the wild-type protein (19, 21, 22). Furthermore, the negative
effects of PHOX2B mutant proteins on the transcriptional
activity of the wild-type protein are promoter-specific (20, 21),
but it is not clear if the observed functional effects are the result
of direct aberrant interactions between wild-type and mutant
proteins and/or with other proteins. It should be noted that the
absence of co-aggregation of the wild-type protein with
mutants with the shorter expansions, revealed by immunoflu-
orescence, does not exclude the possibility of interactions
between the non-aggregated proteins at the molecular level.
Because wild-type PHOX2B forms homodimers in vitro as well
as an important fraction of the mutants with shorter expan-
sions (7, 20), and our previous in vitro results suggest the pos-
sible formation of non-functional heterodimers (21), we
decided to test this hypothesis using a co-immunoprecipitation
assay and mammalian two-hybrid system. Furthermore, using
the same approaches, we assess the ability of mutated proteins
to form heterodimers with PHOX2A.Moreover, given the cen-
tral role of the homeodomain in DNA binding, nuclear import,
and dimerization, we also exploit the effects of the alanine tract
expansion on PHOX2B nuclear import process.
Materials andMethods
Plasmid Construction—All of the oligonucleotides used to
generate the constructs are listed in Table 1. The PCR amplifi-
cations were performed using the GC-rich PCR system (Roche
Applied Science), and all of the DNA fragments obtained by
PCR were sequenced on both strands. All of the enzymes used
for cloning were purchased from New England Biolabs.
Expression Plasmids—TheMYC-tagged PHOX2Bwild-type,
7 alanine, and 13 alanine mutant plasmids have been
described previously (19, 21, 22).
The generation of the expression plasmid HA-tagged
PHOX2B wild type (HA-PHOX2B WT) has been described
elsewhere (21). ThePHOX2Bdeletion constructs (Nter,Nter
HD, HD, HD  Cter, and Cter) were obtained by amplifying
specific regions of PHOX2B cDNA using HA-PHOX2BWT as
the PCR template. The primers used contain the EcoRI restric-
tion site, and after enzymatic digestion with EcoRI, the PCR
products were inserted into the HA-PHOX2BWT vector after
the same enzyme had been used to remove PHOX2B cDNA.
The HD Cter13Ala and the Cter13Ala constructs were
obtained by digesting the corresponding wild-type plasmids
containing the normal alanine tract with the PpuMI restriction
enzyme. The resulting 270-bp region, which encompasses the
alanine tract, was replaced by the 309-bp region obtained using
the same enzyme to digest the MYC-tagged PHOX2B13Ala
plasmid (19, 22).
The HA-PHOX2B NLS1, HA-PHOX2B NLS2, and
HA-PHOX2B 106–147 constructs were made using over-
lap extension PCR (23) with the HA-PHOX2B WT plasmid
as the template. Two chimeric primers were used for each
construct, each of which consisted of an annealing fragment
derived from one flanking region of the deletion and an
anchor fragment derived from the flanking region on the
other side of the deletion. The external primers were used to
insert the deletions in all of the PCR experiments. The first
PCR was performed using 40 ng of supercoiled plasmid con-
taining PHOX2B cDNA to amplify two partially overlapping
DNA fragments carrying the deletion. The two purified frag-
ments were then annealed and used as the template (50
ng/each) for a second PCR using the external primers to
obtain a single product. The PCR products were cloned after
double enzymatic digestion with HindIII/PpuMI in the
HA-PHOX2B WT plasmid, and the 270-bp region, which
was removed by means of PpuMI enzymatic digestion, was
subsequently inserted into the resulting plasmid after diges-
tion with the same enzyme. The HA-PHOX2B NLS1-2
plasmid was obtained by means of the same strategy using
TABLE 1
Nucleotide sequences of the synthetic primers used in the PCR amplifications to generate the deleted andmutant variants of PHOX2B
The enzyme restriction sites used for cloning are underlined.
Construct name Forward primer (5–3) Reverse primer (5-3)
PHOX2B Nter CGGAATTCCAATGTATAAAATGGAATATTC GCGAATTCTCACTTGCGCTTCTCGTTG
PHOX2B Nter HD CGGAATTCCAATGTATAAAATGGAATATTC GCGAATTCTCACTCCTGCTTGCGAAAC
PHOX2B HD CGGAATTCAGCAGCGGCGCATCC GCGAATTCTCACTCCTGCTTGCGAAAC
PHOX2B HD Cter CGGAATTCAGCAGCGGCGCATCC ATGAATTCGGCTTCCGCCGCAGG
PHOX2B Cter CGGAATTCTTCGCAAGCAGGAGCGC ATGAATTCGGCTTCCGCCGCAGG
PHOX2B NLS1 CTCAACGAGACCACTTTCACCAGTGCCCAG AAAGTGGTCTCGTTGAGGCCGCCGTG
PHOX2B NLS2 GTTCCAGCAGGAGCGCGCAGCG TCCTGCTGGAACCACACCTGGACTCGC
PHOX2B 106–147 ACCACTTTCAACCGCCGCGCCAAG CGGTTGAAAGTGGTGCGGATGCG
External primers (for NLS1,
NLS2,  NLS1-2 and 106–147)
CACAAGCTTGCTGCGGAATTGTACC CTCCATTCGCCCCGCAGCTG
GAL4 BD-/ VP16 AD-PHOX2BWT GGGGTACCATGTATAAAATGGAATATTC CCGGTACCGGCTTCCGCCGCAGG
GAL4 BD-/ VP16 AD-Nter GGGGTACCATGTATAAAATGGAATATTC CCGGTACCTCACTTGCGCTTCTCGTTG
GAL4 BD-/ VP16 AD-Nter HD GGGGTACCATGTATAAAATGGAATATTC CCGGTACCTCACTTGCGCTTCTCGTTG
GAL4 BD-/ VP16 AD-HD GGGGTACCCAGCGGCGCATCC CCGGTACCTCACTTGCGCTTCTCGTTG
GAL4 BD-/ VP16 AD-HD Cter GGGGTACCCAGCGGCGCATCC CCGGTACCGGCTTCCGCCGCAGG
GAL4 BD-/ VP16 AD-Cter GGGGTACCCGCAAGCAGGAGCGC CCGGTACCGGCTTCCGCCGCAGG
GAL4 BD-/ VP16 AD-PHOX2A GCGGCCGCCGGGCCGATGGACTACTCCTACC TTGCGGCCGCCTAGAAGAGATTGGTCTTCAGGGC
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the HA-PHOX2B NLS2 plasmid as the template and the
PHOX2B NLS1 forward and reverse primers.
The HA-PHOX2B 13Ala, HA-PHOX2B NLS1 13Ala,
HA-PHOX2B NLS2 13Ala, and HA-PHOX2B NLS1-2
13Ala constructs were generated by means of enzymatic
digestion with PpuMI and the replacement of the region
encompassing the two PpuMI restriction sites containing the
normal alanine stretch with the expanded stretch.
The MYC- and HA-tagged PHOX2A expression vectors
were obtained by cloning human PHOX2A cDNA (24) into the
EcoRI site of pCMV-MYC or pCMV-HA (Clontech).
TheMammalian Two-hybrid System Plasmids—The Check-
Matemammalian two-hybrid system kit (Promega) was used to
provide the pBIND vector containing the yeast GAL4 DNA
binding domain (BD) and Renilla reniformis luciferase under
the control of the SV40 promoter, the pACT vector containing
the herpes simplex virus VP16 activation domain (AD), and the
pG5LUC plasmid containing five GAL4 binding sites upstream
of a minimal TATA box and the firefly luciferase gene.
The plasmids encoding GAL4 BD-PHOX2B, VP16
AD-PHOX2B, VP16 AD-Nter, VP16 AD-Nter  HD, VP16
AD-HD, VP16 AD-HD  Cter, and VP16 AD-Cter were gen-
erated by means of PCR using primers containing the KpnI
restriction site. The HA-PHOX2BWT plasmid was used as the
PCR template, and the PCRproducts were cloned in the pBIND
and pACT vectors after KpnI enzymatic digestion.
TheGAL4BD-PHOX2B7Ala/13Ala/Ala and theVP16
AD-PHOX2B 7Ala/13Ala/Ala mutant plasmids were
obtained by means of PpuMI enzymatic digestion of the corre-
sponding wild-type plasmids. The 270-bp fragment between
the two PpuMI restriction sites was replaced by the corre-
sponding regions containing the expanded or deleted alanine
stretches, which were isolated from the previously described
expression plasmids HA-PHOX2B 0Ala, PHOX2B7Ala (21),
and PHOX2B13Ala (19, 22) bymeans of enzymatic digestion
using the same enzyme.
The plasmids encoding GAL4 BD-PHOX2A and VP16
AD-PHOX2A were generated by means of PCR using primers
containing the NotI restriction site. The PHOX2A in pCDNA3
plasmid was used as the PCR template (24), and the PCR prod-
ucts were cloned in the pBIND and pACT vectors after NotI
enzymatic digestion.
ReporterPlasmids—TheDBHpromoterreporterplasmidcon-
struct was obtained by cloning a 993-bpDBH regulatory region
into pGL4 basic vector (Promega), as described previously (21).
Cell Cultures, Transient Transfections, and Luciferase
Assays—The HeLa cells were grown in Dulbecco’s modified
Eagle’smedium (Lonza), and the SK-N-BE(2)C cellsweremain-
tained in RPMI 1640 without L-glutamine (Lonza). Each
medium was supplemented with 10% fetal calf serum (PAA
Laboratories), 100 units/ml penicillin (Lonza), 100g/ml strep-
tomycin (Lonza), and 2 mM L-glutamine (Lonza).
The cells were transiently transfected or co-transfected by
means of lipofection (FUGENEHD, Promega) as described pre-
viously (21, 25, 26) using 1.5  105 SK-N-BE(2)C or 5  104
HeLa cells.
In mammalian two-hybrid experiments, 80 fmol of each
expression vector were combined with 160 fmol of pG5LUC
plasmid. The luciferase assay was carried out using the Dual-
Luciferase reporter assay system (Promega) as described previ-
ously (26, 27). All of the transfections were performed in tripli-
cate, and each construct was tested in at least three
independent experiments using different batches of plasmid
preparation. The numbers of independent transfection experi-
ments are indicated in the figure legends.
Immunofluorescence—Immunofluorescence was performed
as described previously (25). HeLa cells plated on 1.7 1.7-cm2
glass coverslips were grown to 50% confluence and transfected
with the expression plasmid of interest (160 fmol of DNA). The
HA-tagged PHOX2B proteins were detected by means of pri-
mary rabbit anti-HA antibody (1:50; Sigma, catalog no. H6908)
and the secondary Alexa Fluor 488 anti-rabbit antibody (1:400;
Invitrogen, catalog no. A11034).
The GAL4 BD and VP16 AD fusion proteins (except for
VP16AD-Nter, VP16AD-NterHD, andVP16AD-HD)were
analyzed using primary chicken anti-PHOX2B antibody (1:100
(25)) and the secondary DyLight 549-conjugated donkey anti-
chicken antibody (1:200; Jackson ImmunoResearch, Inc. (West
Grove, PA), catalog no. 703-505-155). The VP16 AD-Nter,
VP16 AD-Nter  HD, and VP16 AD-HD proteins were ana-
lyzed using mouse VP16 antibody (Santa Cruz Biotechnology,
Inc., catalog no. sc-7546) and the secondary DyLight 549-con-
jugated goat anti-mouse antibody (1:400; Jackson ImmunoRe-
search, catalog no. 115-505-146). The nuclei were stained with
DAPI, and the images were acquired using an LSM 510 Meta
confocal microscope (Carl Zeiss, Inc.) with 63 Nikon Apo-
chromat lenses (1.5 numerical aperture).
All of the immunofluorescence analyses were replicated
three times, representing independent transfections, and rep-
resentative images are shown in Figs. 1, 2, 3, 6, 7, 8, and 9.
EMSAs—The EMSAs were performed as described previ-
ously (25, 28). The in vitro expression of PHOX2A, wild-type
PHOX2B, and the deletion and mutant variants was obtained
using a commercially available rabbit reticulocyte lysate system
(TNT Quick-coupled Transcription/Translation System, Pro-
mega), as described previously (25). The oligonucleotides bear-
ing the ATTA 2 and ATTA 3-4 sites of the PHOX2B promoter
have been described previously (25). The homeodomain bind-
ing site oligonucleotide corresponding to the PHOX2B binding
site in the PHOX2A promoter and the oligonucleotides PRS1
and PBD2 have been described previously (26, 29, 30). All of the
oligonucleotides were purchased from Sigma-Aldrich. The
antibodies used in EMSA experiments are the rabbit anti-HA
antibody (Sigma, catalog no. H6908) and the chicken anti-
PHOX2A and PHOX2B antibodies, previously validated and
characterized (24, 25). The EMSA experiments were replicated
at least two times, using different batches of rabbit reticulocyte
lysate.
Co-immunoprecipitation Assays and Western Blotting
Analyses—HeLa cells (8  105) were plated in 100-mm Petri
dishes and transiently transfected by means of lipofection
(FUGENEHD, Promega) with 700 fmol of each expression vec-
tor and harvested after 24 h, when the total extracts were pre-
pared for immunoprecipitation. Proteinswere extracted in lysis
buffer (25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 1 mM MgCl2, 0.2 mM phenyl-
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methylsulfonyl fluoride, Sigma protease inhibitors mixture,
and 250 units/ml Pierce universal nuclease for cell lysis
(Thermo Fisher Scientific)). Lysates were clarified by 30 min of
centrifugation at 16,000 g and 4 °C to remove cell debris and
afterward precleared using 20 l of protein G-agarose bead
slurry (Invitrogen) for 1 h under constant rotation. The pre-
cleared extracts were incubated overnight at 4 °C with 5 g of
each primary antibody (monoclonalmouse anti-MYC antibody
(Sigma-Aldrich, catalog no. M5546), polyclonal rabbit anti-HA
antibody (Sigma-Aldrich, catalog no. H6908), and preimmune
mouse or rabbit IgG (Santa Cruz Biotechnology, catalog nos.
sc-2025 and sc-2027)), and the immunocomplexes were cap-
tured by protein G-agarose bead slurry for 4 h at 4 °C with
rotation.
The beads were collected by centrifugation and gently
washed and resuspended in sample loading buffer. The immu-
nocomplexes were dissociated from the beads by boiling the
samples and then separated by SDS-PAGEand transferred onto
nitrocellulose membrane. Western blotting was performed as
described previously (24) using the primary anti-MYC (1:1000;
Sigma-Aldrich, catalog no.M5546) and anti-HA (1:500; Sigma-
Aldrich, catalog no. H6908) antibodies. All of the co-immuno-
precipitation experiments were replicated three times, repre-
senting independent transfections, and representative
immunoblotting images are shown in Figs. 1–4.
Results
PHOX2BFormsHomodimers—GSTpull-down and gel filtra-
tion chromatography experiments have previously shown that
wild-type PHOX2B protein forms homodimers in vitro (7, 20,
31). To verify these observations in a more physiological con-
text that takes into account the possible influences of the cell
environmental factors, such as interactors and post-transla-
tional modifications, we tested the ability of PHOX2B to
dimerize by co-immunoprecipitation.
To this end, we transiently transfected HeLa cells, which do
not endogenously express PHOX2B, with MYC- and
HA-tagged PHOX2B encoding plasmids, and when the pro-
teins were immunoprecipitated with the anti-MYC antibody,
the precipitated complex also contained HA-PHOX2B variant
(Fig. 1A, lane 2), indicating PHOX2B homodimer formation in
mammalian cells. As a control, protein G-agarose beads coated
with a preimmune antibody did not show HA signal after
immunoprecipitation (Fig. 1A, lane 3). This positive interaction
was confirmed by means of the anti-HA antibody immunopre-
cipitation (Fig. 2A, lane 2).
Next, we extended our analysis by examining PHOX2B self-
interactions using a mammalian two-hybrid system. Thus, we
generated PHOX2B fusion proteins respectively with the yeast
GAL4 DNA binding domain (GAL4 BD) and herpes simplex
virus VP16 activation domain (VP16 AD).
We first tested their expression and subcellular localization
by transfecting GAL4 BD-PHOX2B- and VP16 AD-PHOX2B-
encoding plasmids intoHeLa cells and analyzed the transfected
cells by means of confocal microscopy upon immunohisto-
chemistry with an antibody directed against the PHOX2B C
terminus; as shown in Fig. 1B, both the GAL4 BD-PHOX2B (a,
c, and e) and VP16 AD-PHOX2B (b, d, and f) proteins localized
diffusely in the nucleus.
The two fusion constructs were then co-transfected, alone or
in combination, together with a reporter construct containing
five GAL4 binding sites upstream of aminimal TATA box con-
trolling the firefly luciferase reporter gene (pG5LUC) into neu-
roblastoma SK-N-BE(2)C (Fig. 1C) and HeLa cells (Fig. 1D).
When VP16 AD-PHOX2B was co-transfected with the
GAL4DNAbinding domain (GAL4 BD) or the VP16 activation
domain (VP16 AD) in SK-N-BE(2)C and HeLa cells, no signif-
icant increase in luciferase activity was measured in compari-
son with the empty vectors (GAL4 BD and VP16 AD) (Fig. 1, C
and D, gray bars versus white bars), excluding nonspecific pos-
itive interactions betweenPHOX2BandVP16ADorGAL4BD.
Also, GAL4 BD-PHOX2B did not show nonspecific interac-
tions with the VP16 activation domain (VP16 AD) because
there was little if any increase (in SK-N-BE(2)C cells) or a sig-
nificant decrease (HeLa cells) in luciferase activity in compari-
son with the empty vectors (GAL4 BD and VP16 AD) (Fig. 1, C
and D, hatched versus white bars). This also indicated that
PHOX2B does not autonomously activate transcription by the
reporter construct. A decrease in luciferase activity has previ-
ously been observed in the case of other paired-type homeopro-
teins, thus suggesting that direct DNA binding by the home-
odomain is required for transactivation activity (32–34).
On the contrary, when both fusion constructs (GAL4
BD-PHOX2B and VP16 AD-PHOX2B) were co-transfected in
SK-N-BE(2)C (Fig. 1C, black bar) andHeLa cells (Fig. 1D, black
bar), there was a 3- and 8-fold increase, respectively, in lucifer-
ase activity, and the lower luciferase activitymeasured in SK-N-
BE(2)C cells was probably due to the lower transfection effi-
ciency, in comparisonwithHeLa cells. Our results thus indicate
that PHOX2B homodimers can be efficiently detected by using
both a co-immunoprecipitation assay andmammalian two-hy-
brid system.
PHOX2B Polyalanine-expanded Proteins Interact Weakly
withWild-type Protein—Mutant proteins can interferewith the
activity of the wild-type protein by forming functionally
impaired heterodimers and thus have a dominant negative
effect. Much evidence has shown that PHOX2B polyalanine-
expanded proteins can easily form aggregates, and this has been
reasonably interpreted as a consequence of an increased tend-
ency of PHOX2B to self-interact, as has been observed previ-
ously in the case of long polyalanine stretches and homopoly-
meric tracts in general (35). Previous gel filtration experiments
have also shown that an important fraction of themutants with
shorter expansions retains the ability to form dimers, whereas
there is virtually no formation of species corresponding to the
wild-type dimers in the presence of proteins with increasingly
long polyalanine tracts (20), and both in vitro and in vivo exper-
iments suggest the existence of interactions between wild-type
and mutant proteins (20–22).
To test the ability of mutant proteins to heterodimerize, we
transiently transfected HeLa cells with HA-tagged PHOX2B
WT plasmid in combination with MYC-tagged PHOX2B vari-
ants carrying themost frequently identified polyalanine expan-
sion in CCHS patients (7 alanine) or the longest expansion
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(13 alanine) and examined their binding potential by co-im-
munoprecipitation assays.
Our results revealed that mutant proteins immunoprecipi-
tated with PHOX2B wild-type protein and that there was a
progressively weaker interaction of the mutant proteins as a
function of the length of the expansion (Fig. 2A, lanes 5 and 8
versus lane 2). Moreover, we observed a reduced amount of
mutant proteins in total cell lysates in comparison with wild-
type protein (Fig. 2A, lanes 4 and 7 versus lane 1), due to their
decreased solubility after detergent extraction, as confirmed by
the higher proportion of mutant proteins in the insoluble frac-
tion (data not shown and previously reported (22)). To exclude
FIGURE 1.Homodimerization of PHOX2Bwild-type protein. A, representative immunoblotting images of co-immunoprecipitation ofMYC- and HA-tagged
PHOX2B proteins in transfected HeLa cells. Cell extracts were immunoprecipitated with anti-MYC antibody or control immunoglobulin (IgG) and immuno-
blotted with anti-MYC (top) and anti-HA antibodies (bottom). B, representative immunofluorescence images of the localization of the GAL4 BD- and VP16
AD-tagged PHOX2B WT fusion proteins in transfected HeLa cells stained using anti-PHOX2B antibody (c and d). The nuclei were visualized using DAPI (a and
b) and merged with the proteins detected by the anti-PHOX2B antibody (e and f). Scale bars, 10 m. C and D, luciferase assays. The bars indicate the
transcriptional activity of the pG5LUC reporter construct upon co-transfection in neuroblastoma SK-N-BE(2)C (C) or HeLa cells (D) with a combination of
equimolar amounts of a vector containing the cDNA of wild-type protein fused to GAL4 BD (GAL4 BD-PHOX2BWT) and the empty vector containing VP16 AD
(hatched bars) or with a combination of equimolar amounts of both GAL4 BD and VP16 wild-type fusion proteins (black bars). Nonspecific interactions were
excluded upon co-transfection of PHOX2B fused to VP16 AD with VP16 AD or GAL4 BD (light and dark gray bars). The background level of firefly luciferase
expression fromthepG5LUCvectorwasdetermineduponco-transfectionwithempty vectors containingGAL4BDandVP16AD (white bars). The results are the
means S.D. (error bars) of the transcriptional activity of the constructs detected in at least three experiments performed in triplicate (C andD, n 5) and
are expressed as -fold increases over the activity of the reporter plasmid co-transfected with the GAL4 BD-PHOX2B WT protein ( 1). *, significant
differences from the activity of the wild-type protein fused to GAL4 BD (ANOVA, Tukey’s test, p 0.05); ***, significant differences from the activity of
the wild-type protein fused to GAL4 BD (ANOVA, Tukey’s test, p  0.001).
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the possibility that the lower signals obtained with the mutants
in co-immunoprecipitation experiments were due to the
decreased protein solubility and to confirm our data, we
extended our analysis by using the mammalian two-hybrid sys-
tem. Co-transfection experiments of VP16 AD-PHOX2B
7Ala or VP16 AD-PHOX2B13Ala with GAL4 BD-PHOX2B
WT showed no functional interactions between the mutants
and wild-type protein in SK-N-BE(2)C cells (Fig. 2C, cross-
hatched bars versus hatched bar) and only slight and not statis-
tically significant interactions in HeLa cells, with respect to
PHOX2BWT and VP16 AD (Fig. 2D, cross-hatched bars versus
hatched bar).
Immunofluorescence analysis ofHeLa cells transiently trans-
fectedwithVP16AD-PHOX2B7Ala andVP16AD-PHOX2B
13Ala showed that both mutants localized completely in the
nucleus (Fig. 2B, a–f), thus suggesting that the insertion of the
nuclear localization signal encoded by the pACT vector is suf-
ficient to force the mutant proteins into the nucleus, particu-
larly the 13 alanine mutants, which usually have a partial
cytoplasmic localization (19–21), and excluding the possibility
that the reduced capability of the mutant proteins to interact
with the wild-type protein may be due to their improper
localization.
To evaluate the ability of the mutants to form homodimers,
we fused GAL4 BD to PHOX2B carrying 7 or 13 alanine
expansions. Unlike the VP16 fusion proteins, the GAL4 BD
fusion proteins were not completely detected in the nucleus,
thus confirming their tendency to mislocalize in the cytoplasm
FIGURE2.HeterodimerizationofPHOX2Bpolyalanine-expandedmutantswithwild-typeprotein.A, representative immunoblotting imagesofco-immunopre-
cipitation of HA-tagged PHOX2B protein alongwithMYC-tagged PHOX2B polyalanine-expandedmutants in transfected HeLa cells. Cell extracts were immunopre-
cipitatedwith anti-HA antibody or control immunoglobulin (IgG) and immunoblottedwith anti-HA (top) and anti-MYC antibodies (bottom). B, representative immu-
nofluorescence images of the localization of the VP16 AD-PHOX2B 7Ala and VP16 AD-PHOX2B 13Ala fusion proteins in transfected HeLa cells stained using
anti-PHOX2Bantibody (candd). ThenucleiwerevisualizedusingDAPI (aandb) andmergedtotheproteinsdetectedbytheanti-PHOX2Bantibody (eand f).Scalebars,
10m.C andD, luciferase assays. The bars indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in neuroblastoma SK-N-BE(2)C
(C) orHeLacells (D)withavectorcontaining thecDNAofwild-typeprotein fusedtoGAL4BD(GAL4BD-PHOX2BWT) incombinationwith theemptyvectorcontaining
VP16AD (hatched bars), the VP16wild-type fusion protein (black bars), or the VP16-PHOX2B fusion protein carrying polyalanine expansions (cross-hatched bars). The
results are themeans S.D. (error bars) of the transcriptional activity of the constructs detected in at least three experiments performed in triplicate (C andD, n 5)
and are expressed as -fold increases over the activity of the reporter plasmid co-transfectedwith the GAL4 BD-PHOX2BWT protein ( 1). ***, significant differences
from the activity of thewild-type protein fused to GAL4 BD (ANOVA, Tukey’s test, p 0.001).
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and indicating that the nuclear localization signal encoded by
pBIND vector is weaker and unable to counteract their nuclear
import defects (Fig. 3A, a–f).
In SK-N-BE(2)C cells co-transfection experiments along
with pG5LUC plasmid, we found a significant increase in lucif-
erase activity, but the strength of the interactions in mutants
forming homodimers was weaker than those observed in wild-
type homodimers, probably due to the partialmislocalization of
the GAL4 BD fusion proteins in the cytoplasm: 1.7- and 2-fold
increases in the case of the7 alanine and13 alanine mutant
homodimers, respectively (Fig. 3, B and C, compare black bars
with black bar in Fig. 1C). Further, it should be noted that our
data concerning interactions among mutants may not allow us
to distinguish the formation of dimers and oligomers, but the
measured luciferase activities apparently correlate with the
increasing propensity of the expanded protein to aggregate as a
function of the length of the polyalanine tract. Interactions
among mutants were confirmed by co-immunoprecipitation
(Fig. 3D, lanes 5 and 11), and the signal obtained with the13
alanine mutant, compared with its respective input signal, was
stronger than that shown by the 7 alanine mutant, thus sug-
gesting, again, a correlation between the increasing formation
of oligomers and the length of the polyalanine tract (Fig. 3D,
lane 5 versus lane 4 and lane 11 versus lane 10).
Becauseprotein-protein interactionscanbedirection-depen-
dent, we also assessed the dimerization of the mutants and
FIGURE 3. Homodimerization of PHOX2B polyalanine-expanded mutants. A, representative immunofluorescence images of the localization of the GAL4
BD-PHOX2B 7Ala and GAL4 BD-PHOX2B 13Ala fusion proteins in transfected HeLa cells stained using anti-PHOX2B antibody (c and d). The nuclei were
visualized usingDAPI (a and b) andmergedwith the proteins detected by the anti-PHOX2B antibody (e and f). Scale bars, 10m. B and C, luciferase assays. The
bars indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in neuroblastoma SK-N-BE(2)C cells with a vector containing
the cDNA of PHOX2B7Ala fused to GAL4 BD (GAL4 BD-PHOX2B7Ala in B) or the cDNA of PHOX2B13Ala fused to GAL4 BD (GAL4 BD-PHOX2B13Ala in
C), in combination with the empty vector containing VP16 AD (hatched bars), VP16 wild-type fusion protein (cross-hatched bars), or VP16-PHOX2B fusion
protein carrying7 (Fig. 3B) or13 (Fig. 3C) alanine expansions (black bars). The results are the means S.D. (error bars) of the transcriptional activity of the
constructs detected in at least three experiments performed in triplicate (B and C, n 4) and are expressed as -fold increases over the activity of the reporter
plasmid co-transfected with the GAL4 BD-PHOX2B7Ala protein or the GAL4 BD-PHOX2B13Ala protein ( 1). ***, significant differences from the activity
of the PHOX2B protein7 or13 alanine fused to GAL4 BD (ANOVA, Tukey’s test, p 0.001). D, representative immunoblotting images of co-immunopre-
cipitationofHA-taggedPHOX2Bpolyalanine-expandedmutants alongwithMYC-taggedPHOX2Bwild-type andmutant variants in transfectedHeLa cells. Cell
extracts were immunoprecipitated with anti-HA antibody or control immunoglobulin (IgG) and immunoblotted with anti-HA (top) and anti-MYC antibodies
(bottom).
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wild-type protein in the opposite orientation, but once again,
we observed no functional interactions with the wild-type pro-
tein (Fig. 3, B and C, cross-hatched bars). However, in accord-
ance with our previous co-immunoprecipitation experiments
and those performed in HeLa cells using the mammalian two-
hybrid system, a small proportion of the wild-type protein was
immunoprecipitatedwith bothmutants (Fig. 3D, lanes 2 and 8).
These data indicate that the mutant proteins partially form
homodimers and interact very weakly with the wild-type pro-
tein and that this was unlikely to be due to the incorrect local-
ization of the mutants. However, the partial discrepancy
between biochemical and luciferase data did not exclude the
possibility that heterodimers are unable to reconstitute a func-
tional transcription factor and thus stimulate transcription
from the reporter gene.
PHOX2B Polyalanine-expanded Proteins Retain a Partial
Ability to Interact with PHOX2A—GST pull-down and EMSA
experiments have previously shown that PHOX2B protein and
its paralogue PHOX2A form heterodimers in vitro (7, 20, 31).
Overexpression of PHOX2A with the PHOX2B 13 alanine
mutant did not show co-aggregation or trapping of PHOX2A in
the cytoplasm (20). We decided to test the ability of mutant
proteins to heterodimerize with PHOX2A by both co-immu-
noprecipitation and the mammalian two-hybrid system.
When the MYC-tagged version of PHOX2A together with
HA-tagged PHOX2A or PHOX2B WT were overexpressed in
HeLa cells, immunoprecipitation with the anti-MYC antibody
showed interaction with bothHA-PHOX2A andHA-PHOX2B
(Fig. 4A, lanes 2 and 5), thus confirming the formation of
PHOX2A homodimers and PHOX2A-PHOX2B heterodimers
in mammalian cells. When we tested the ability of PHOX2B
mutant proteins to interact with PHOX2A, similarly to our
observations on PHOX2B-mutant heterodimer formation, the
polyalanine-expanded tract reduced the solubility of PHOX2B
mutants in comparison with wild-type protein and even more
compared with PHOX2A (Fig. 4, A (lanes 1 and 4) and B (lanes
1, 4, and 7)) and also their binding to PHOX2A (Fig. 4B, lanes 5
and 8 versus lane 2). To exclude an effect of the protein extrac-
tion procedure on the reduced interaction between PHOX2A
and mutant PHOX2B proteins, we tested homo- and het-
erodimer formation by the mammalian two-hybrid system. To
this end,we fusedGAL4BDandVP16AD toPHOX2Aand first
measured the ability of PHOX2A to formhomodimers and het-
erodimers with PHOX2B. As shown in Fig. 4C, the luciferase
activity measured when the GAL4 BD-PHOX2A protein was
co-transfected with the VP16-counterpart was2-fold greater
than that obtained using PHOX2B fusion constructs (Fig. 4C,
compare white bar with black bar), thus suggesting that
PHOX2A forms homodimers more efficiently than PHOX2B.
When we assessed the heterodimerization of PHOX2A with
PHOX2B, we observed that their interaction is stronger than
thatmeasured in PHOX2Bhomodimers (Fig. 4C, cross-hatched
and gray bars versus black bar) and direction-dependent (Fig.
4C, cross-hatched versus gray bar).
Co-transfection experiments of GAL4 BD-PHOX2A
along with VP16-PHOX2B mutant fusion proteins (VP16
AD-PHOX2B7Ala andVP16AD-PHOX2B13Ala) showed
that the polyalanine expansions severely affect the ability of
PHOX2B to form heterodimers with PHOX2A (Fig. 4C,
hatched bars versus gray bar). Nevertheless, the strength of the
interactions measured between PHOX2A and the PHOX2B
mutants was comparable with or slightly weaker than that of
PHOX2A homodimers (Fig. 4C, hatched bars versus white bar)
and even higher than that of PHOX2B homodimers (Fig. 4C,
hatched bars versus black bar). The above experiments indicate
that PHOX2Bmutants retain a partial ability to heterodimerize
with PHOX2A and, therefore, suggest the possible formation of
heterodimers (PHOX2A-PHOX2Bmutants) with an efficiency
comparable with that of PHOX2A homodimers. To investigate
whether the relative strong binding of mutants to PHOX2A
might compete with normal PHOX2A homodimerization,
we performed competition experiments by co-transfecting
equimolar amounts of PHOX2BWTormutants encoding plas-
mids together with GAL4 BD- and VP16 AD-tagged PHOX2A.
Whereas PHOX2Bwild-type protein increased luciferase activ-
ity2-fold (Fig. 4D, black bar versus white bar), both mutants
showed a slight but not significant increase of luciferase activity
(Fig. 4D, hatched bars versus white bar), thus suggesting that
PHOX2Ahomodimer formation is not affected by the presence
of PHOX2Bmutants. A possible interpretation of the increased
luciferase activity in the presence of thewild-type protein is that
PHOX2B might stabilize PHOX2A homodimer formation
and eventually promote transcriptional complex assembly.
Remarkably, a similar increase in PHOX2B homodimer activity
occurred in the presence of the wild-type protein (Fig. 4E, black
bar versus white bar), whereas a slight reduction was measured
in the presence of PHOX2Bmutants (Fig. 4E, hatched bars ver-
suswhite bar). Our data thus indicate that PHOX2Bmutants do
not significantly interfere with either PHOX2B or PHOX2A
homodimerization.
PHOX2B Polyalanine-expanded Proteins Do Not Interfere
with PHOX2A-mediated Transactivation of the DBH Promoter
and, Conversely, Interact Synergistically—Given that PHOX2B
mutants retain a partial ability to heterodimerize with
PHOX2A, we tested whether PHOX2B mutants might alter
PHOX2A-mediated transactivation of the DBH (dopamine--
hydroxylase) promoter, a well characterized PHOX2A and
PHOX2B target gene (7, 29, 30). As reported previously (19–
21), the mutant proteins showed a marked reduction in their
ability to induce the correct activation of the DBH reporter
construct (Fig. 5A, bars 3 and 4 versus bar 2), and co-transfec-
tion of the polyalanine-expanded proteins with the wild-type
protein led to luciferase activity similar to that of the normal
PHOX2B alone (Fig. 5A, bars 5 and 6 versus bar 2). When the
DBH reporter construct was co-transfected together with
PHOX2A, we measured a greater induction by PHOX2B WT
protein in comparison with PHOX2A (Fig. 5A, bar 2 versus bar
8), different from that previously reported (7, 29, 30); this dis-
crepancy could possibly be due to the use of a different regula-
tory region (993 bp versus 232 bp long) and/or reporter plasmid
(pGL4 versus pGL3 vector). Moreover, the combination of
PHOX2AandPHOX2B increasedDBH-driven luciferase activ-
ity to a slightly (but not significant) lower extent than that
obtained with PHOX2B alone (Fig. 5A, bar 7 versus bar 2),
confirming that the two factors act independently on the DBH
promoter (7).
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Interestingly, the luciferase activity measured when PHOX2A
was co-transfected with the 7 alanine mutant protein was
lower but more comparable with that obtained using the
wild-type counterpart (23- and 32-fold over the empty vec-
tor, respectively), suggesting a (novel) synergistic interaction
between the two proteins (Fig. 5A, bar 9 versus bar 7). A
lower synergistic interaction was observed by combining
the 13 alanine mutant with PHOX2A (Fig. 5A, bar 10)
although not statistically significant.
Because PHOX2B mutants showed diminished DNA bind-
ing (20, 21), we tested by EMSAs whether the observed tran-
scriptional effects correlated with alterations in their DNA
binding properties in the presence of PHOX2A; we used the
oligonucleotide corresponding to the site in theDBH promoter
to which PHOX2A/2B bind as dimers (30). As previously
reported with other PHOX2B binding sites (20, 21), the expan-
sion of the polyalanine tract progressively reduced DNA
binding (Fig. 5B, lanes 9 and 12 versus lane 6), with the DNA-
13 alanine mutant complex severely affected and hardly
detectable.
The retarded band obtained with the in vitro expressed
PHOX2A protein was undetectable in this set of experiments
FIGURE 4. Homodimerization of PHOX2A protein and its heterodimerization with PHOX2B wild-type protein and with polyalanine-expanded
mutants. A and B, representative immunoblotting images of co-immunoprecipitation of MYC-tagged PHOX2A along with HA-tagged PHOX2A, PHOX2B (A),
and PHOX2B polyalanine-expanded mutants (B) in transfected HeLa cells. Cell extracts were immunoprecipitated with anti-MYC antibody or control immu-
noglobulin (IgG) and immunoblotted with anti-MYC (top) and anti-HA antibodies (bottom). H.E., higher exposure. C, luciferase assays. The bars indicate the
transcriptional activity of the pG5LUC reporter construct upon co-transfection in HeLa cells with a vector containing the cDNA of wild-type protein fused to
GAL4 BD (GAL4 BD-PHOX2B WT) in combination with the VP16 wild-type fusion protein (black bar) or the VP16-PHOX2A (cross-hatched bar); white, gray, and
hatched bars indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in HeLa cells with a vector containing the cDNA of
PHOX2A fused to GAL4 BD (GAL4 BD-PHOX2A) in combinationwith the VP16-PHOX2A fusion protein (white bar), VP16-PHOX2Bwild-type fusion protein (gray
bar), or the VP16-PHOX2B fusion proteins carrying polyalanine expansions (hatched bars). The results are the means S.D. (error bars) of the transcriptional
activity of the constructs detected in at least three experiments performed in triplicate (n  4) and are expressed as -fold increases over the activity of the
reporter plasmid co-transfected with the GAL4 BD-PHOX2BWT protein in combination with the VP16-PHOX2B wild-type fusion protein ( 1). ***, significant
differences from the luciferase activity due to the wild-type protein homodimerization (ANOVA, Tukey’s test, p 0.001). D and E, luciferase assays. The bars
indicate the transcriptional activity of the pG5LUC reporter construct upon co-transfection in HeLa cells with a vector containing the cDNA of PHOX2A fused
to GAL4 BD (GAL4 BD-PHOX2A) in combination with the VP16-PHOX2A fusion protein (D,white bar) or the cDNA of wild-type protein fused to GAL4 BD (GAL4
BD-PHOX2BWT) in combinationwith theVP16wild-type fusionprotein (E,white bar).Black andhatched bars indicate the transcriptional activity of thepG5LUC
reporter upon the co-transfection of the above plasmids with equimolar amounts of a vector encoding PHOX2BWT (black bars) or PHOX2Bmutants (hatched
bars). The results are the mean values S.D. (error bars) of the transcriptional activity of the constructs detected in at least three experiments performed in
triplicate (D and E, n 3) and are expressed as -fold increases over the activity of the reporter plasmid co-transfectedwith the GAL4 BD-PHOX2A protein ( 1;
D) or the GAL4 BD-PHOX2BWT protein ( 1; E). ***, significant differences from the luciferase activity due to PHOX2B or PHOX2A homodimerization (ANOVA,
Tukey’s test, p 0.001).
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(Fig. 5B, lane 3), probably reflecting the relative low affinity of
this consensus site and/or the lower binding ability of the in
vitro expressed protein compared with the PHOX2A-contain-
ing nuclear lysates (24, 30, 36, 37); however, a strong ultrare-
tarded band could be obtained in the presence of the anti-
PHOX2A antibody (Fig. 5B, lane 5).
This effectwas not due to the interaction of the antibodywith
other proteins contained in the reticulocyte lysate, because we
had previously shown that both PHOX2A and PHOX2B anti-
bodies did not recognize any protein in the lysate (24, 25), but it
is in line with previous evidence showing that the antibodymay
stabilize the interactions between PHOX2A and PHOX2B and
their cognate DNA binding sites (21, 24, 25, 36). No specific
band was detectable in the presence of reticulocyte lysate pro-
grammedwith the empty vector pcDNA3 (Fig. 5B, lane 2), thus
excluding nonspecific interactions of the lysate with this probe.
When PHOX2A was combined with PHOX2B, a more
intense retarded band than that with the PHOX2B wild-type
protein alone was obtained (Fig. 5B, lane 15 versus lane 6), and
the antibody directed against PHOX2A supershifted a more
intense band than that observed using the PHOX2A protein
alone (Fig. 5B, lane 17 versus lane 5), suggesting that het-
erodimers formed of both proteins have a higher DNA binding
affinity. Interestingly, a band is still visible in the presence of the
antibody against PHOX2A, indicating that only a fraction of the
PHOX2B protein forms heterodimers with PHOX2A (Fig. 5B,
lane 17). Similar to the band obtained with the wild-type pro-
tein, the retarded bands observed when the 7 and the 13
alanine mutants were mixed with PHOX2A were more intense
than those detected with the expanded proteins alone (Fig. 5B,
lane 19 versus lane 9 and lane 23 versus lane 12). Notably, more
intense supershifted bands were observed using the antibody
against the PHOX2Bmutants, indicating a partial rescue of the
DNA binding of the mutants in the presence of PHOX2A (Fig.
5B, lane 22 versus lane 11 and lane 26 versus lane 14).
The Dimerization Domain Encompasses the Homeodomain
and theC-terminal Region of PHOX2BandDoesNot Involve the
Alanine Stretch—Despite the predictable central role of the
homeodomain in PHOX2B dimerization, because our data
from mammalian two-hybrid system experiments indicated
that PHOX2B carrying polyalanine-expanded stretches was
unable to interact with wild-type protein but at least partially
conserved an ability to homodimerize, we estimated the
involvement of the alanine tract in dimer formation by gener-
FIGURE 5. Molecular effects of co-expressing the polyalanine-expanded mutants and PHOX2A on their transcriptional activity and DNA binding
properties. A, luciferase assays. The bars indicate the transcriptional activity of DBH promoter reporter construct upon co-transfection in HeLa cells with
expression vectors containing the cDNA of PHOX2BWT protein (bar 2) or of PHOX2A (bar 8) or carrying the expanded polyalanine tracts (bars 3 and 4); bars 5,
6, 7, 9, and 10 indicate the transcriptional activity of DBH promoter reporter construct upon co-transfection in HeLa cells with a combination of equimolar
amounts of the indicatedexpressionvectors. pcDNA3 indicates theempty vector usedasnegative control (bar 1). The results aremeanvaluesS.D. (error bars)
of the transcriptional activity of the constructs of at least three experiments performed in triplicate (n 3) and are expressed as -fold increases over the activity
of the reporterplasmidco-transfectedwith theemptyvector (1). ***, significantdifferences fromthe luciferase activityof the reporterplasmidco-transfected
with PHOX2A-encoding vector (ANOVA, Tukey’s test);n.s., not significant (ANOVA, Tukey’s test).B, gel shift assays using theoligonucleotideprobe correspond-
ing to a region of theDBHpromoter containing theATTA coremotif known to bind PHOX2A and PHOX2B. Top, sequence of the oligonucleotide used as probe;
the ATTA core motif is underlined, and the incomplete motif is in italic type. The labeled probe was incubated with in vitro expressed PHOX2A (lanes 3–5),
PHOX2B wild-type protein (lanes 6–8), PHOX2B7Ala (lanes 9–11), PHOX2B13Ala proteins (lanes 12–14), or a combination of equimolar amounts of the
indicated proteins (lanes 15–26). The in vitro translated pcDNA3 empty vector was used as a control to exclude nonspecific interactions (lane 2). The compe-
titions were carried out by adding a molar excess of unlabeled oligonucleotide (lanes 4, 7, 10, 13, 16, 20, and 24). Supershift experiments were performed by
preincubating the in vitro expressed proteins with anti-PHOX2A (lanes 5, 17, 21, and 25) or anti-PHOX2B antibodies (lanes 8, 11, 14, 18, 22, and 26). The Roman
numeraland theasteriskon the left indicate the specific retardedcomplexesobtainedand the supershifted complexes containingPHOX2AorPHOX2B. The free
probes are shown at the bottom of the gels.
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ating two constructs expressing a polyalanine-deleted PHOX2B
protein fused to the GAL4 BD or VP16 AD domain (GAL4
BD-PHOX2B Ala and VP16-PHOX2B Ala). As shown in
Fig. 6A, the deletion of the polyalanine tract did not affect the
intracellular localization of the proteins, as previously reported
by Di Lascio et al. (21). The luciferase activity measured when
the GAL4 BD-PHOX2B WT protein was co-transfected with
the VP16-polyalanine-deleted protein was comparable with or
even slightly greater than that obtained using the wild-type
counterpart, thus suggesting that the deleted alanine tract does
not affect the ability of PHOX2B to dimerize (Fig. 6B, compare
black bar with cross-hatched bar). We likewise also detected
strong homodimerization with the GAL4 BD-PHOX2B Ala
and VP16-PHOX2B Ala fusion proteins, thus confirming the
small contribution of the alanine stretch to the dimerization
properties of PHOX2B (Fig. 6C, black bar).
To map the protein dimerization domain, a series of VP16
fusion constructs containing fragments of PHOX2B protein
were generated on the basis of its homeodomain boundaries
(Fig. 7B). We first used immunofluorescence to check the
expression and localization of the deleted proteins. The VP16-
PHOX2B 1–157 containing the homeodomain and the N-ter-
minal region (Fig. 7A, d–f; Nter  HD), VP16-PHOX2B
98–157 corresponding to the homeodomain (Fig. 7A, g–i; HD),
VP16-PHOX2B 98–314 including the homeodomain and the
C-terminal region (Fig. 7A, l–n; HD  Cter), and the VP16-
PHOX2B 155–314 construct containing the C-terminal region
(Fig. 7A, o–q; Cter) all predominantly localized in the nucleus.
Unexpectedly, the proteins containing the N-terminal region
(i.e. Nter and Nter  HD) showed a very strong tendency to
aggregate in the cytoplasm (Fig. 7A, a–c) and nucleus (Fig. 7A,
d–f), respectively.
We therefore co-transfected the deleted proteins (excluding
the construct containing the N-terminal region because it is
localized in the cytoplasm) with the GAL4 BD-PHOX2B WT
protein. A significant increase in luciferase activity was
observed only with the fragment corresponding to theC-termi-
nal region and homeodomain (2B 98–314), but it was less than
that obtained using the full-length protein (Fig. 7B, compare
cross-hatched barswith black bar); luciferase activity was com-
parable with that of the background in the case of the C-termi-
nal fragment alone (2B 155–314) and only 2-fold above the
background in the case of the fragment containing the N-ter-
minal region and homeodomain (2B 1–157).
The findings of previous studies of other homeoproteins sug-
gest that the region at the end of the homeodomain (helix III)
might be critical for dimer formation (34, 38). Bearing in mind
the spotlike distribution of the protein lacking the C-terminal
region (Nter  HD) that could interfere with this process, we
generated a deletion construct missing the region at the end of
the homeodomain (encompassing amino acids 148–155). The
obtained protein did not interact with the wild-type protein
but, once again, aggregated in the nucleus (data not shown).
Furthermore, the luciferase activity of the VP16 AD-HD con-
struct (corresponding to the homeodomain) was comparable
with that of the background and that obtained using the C-ter-
minal fragment alone (Fig. 7B, 2B 98–157), thus suggesting that
the presence and integrity of both domains are required for
PHOX2B dimerization. We also found slightly lower luciferase
activity in the absence of the N-terminal domain, although not
FIGURE 6. Homodimerization of PHOX2B protein lacking the polyalanine tract and its heterodimerization with wild-type protein. A, representative
immunofluorescence images of the localization of the GAL4 BD- and VP16 AD-PHOX2B Ala fusion proteins in transfected HeLa cells stained using anti-
PHOX2Bantibody (c andd). Thenucleiwere visualizedusingDAPI (a andb) andmergedwith theproteins detectedby the anti-PHOX2Bantibody (e and f). Scale
bars, 10 m. B and C, luciferase assays of heterodimerization with the WT protein (B) or homodimerization (C) of PHOX2B Ala protein. The bars indicate the
transcriptional activity of the pG5LUC reporter construct in HeLa cells upon co-transfection with a vector containing the cDNA of wild-type protein fused to
GAL4 BD (GAL4 BD-PHOX2BWT; B) or a vector containing the cDNA of the deleted protein fused to GAL4 BD (GAL4 BD-PHOX2B Ala; C) in combination with
the empty vector containing VP16 AD (hatched bars), VP16 wild-type fusion protein (cross-hatched bars), or VP16-PHOX2B fusion protein deleted of the
polyalanine stretch (black bars). The results are the means  S.D. (error bars) of the transcriptional activity of the constructs detected in at least three
experiments performed in triplicate (n  5) and are expressed as -fold increases over the activity of the reporter plasmid co-transfected with the GAL4
BD-PHOX2BWT protein (B) or GAL4 BD-PHOX2BAla protein (C) ( 1). ***, significant differences from the activity of the wild-type protein fused to GAL4 BD
(B) or the GAL4 BD-PHOX2B Ala (C) (ANOVA, Tukey’s test, p 0.001).
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FIGURE 7. Mapping of the PHOX2B dimerization domain and contribution of the N- and C-terminal domains to dimerization and DNA binding of
PHOX2B. A, representative immunofluorescence images of the localization of the VP16 AD-PHOX2B deleted fusion proteins (VP16 AD-Nter, VP16 AD-Nter
HD, VP16 AD-HD, VP16 AD-HD Cter, VP16 AD-Cter) in transfected HeLa cells stained using anti-VP16 (b, e, and h) or anti-PHOX2B antibody (m and p). The
nuclei were visualized using DAPI (a, d, g, l, and o) andmerged with the proteins detected by the anti-VP16 and anti-PHOX2B antibodies (c, f, i, n, and q). Scale
bars, 10m. B, luciferase assays. The bars indicate the transcriptional activity of the pG5LUC reporter construct in HeLa cells upon co-transfectionwith a vector
containing the cDNA of wild-type protein fused to GAL4 BD (GAL4 BD-PHOX2BWT) in combination with the empty vector containing VP16 AD (hatched bar),
VP16wild-type fusion protein (black bar), or VP16-PHOX2Bdeleted fusionprotein shownon the left (cross-hatched bars). The results are themean values S.D.
(error bars) of the transcriptional activity of the constructs detected in at least three experiments performed in triplicate (n  4) and are expressed as -fold
increases over the activity of the reporter plasmid co-transfected with the GAL4 BD-PHOX2BWT protein ( 1; hatched bar). *, significant differences from the
activity of the wild-type protein fused to GAL4 BD (ANOVA, Tukey’s test, p 0.05); ***, significant differences from the activity of the wild-type protein fused
to GAL4 BD (ANOVA, Tukey’s test, p 0.001); n.s., not significant (ANOVA, Tukey’s test). C and D, gel shift assays using oligonucleotide probes corresponding
to two regions of the PHOX2B promoter (C) or a region of the PHOX2A andDBH promoters (D) containing the ATTA coremotifs known to bind PHOX2B. At the
top, the sequences of the oligonucleotides used as probes; the ATTA coremotif is underlined, and the incompletemotif is in italic type. The labeled probeswere
incubated with in vitro expressed HA-tagged PHOX2B wild-type protein (lanes 1–3 and 11–13), PHOX2B HD Cter (lanes 4–6 and 14–16), or PHOX2B Nter
HDproteins (lanes 7–9 and 17–19). The in vitro translated pcDNA3 empty vectorwas used as a control to exclude nonspecific interactions (lanes 10 and 20). The
competitions were carried out by adding amolar excess of unlabeled oligonucleotide (lanes 2, 5, 8, 12, 15, and 18). Supershift experiments were performed by
preincubating the in vitro expressed proteins with anti-HA antibody (lanes 3, 6, 9, 13, 16, and 19). The Roman numerals on the left indicate the specific retarded
complexes obtained using in vitro expressed PHOX2B wild-type protein (I and II) or PHOX2B HD  Cter (Ia and IIa); the asterisks indicate the supershifted
complexes containing PHOX2B. The free probes are shown at the bottom of the gels.
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statistically significant compared with that obtained with the
full-length protein, thus not excluding the possibility that the
N-terminal domain may also play a role in the dimerization
process.
We also evaluated the role of the C-terminal and N-terminal
domains in dimer formation and DNA binding using EMSAs
and radiolabeled oligonucleotides corresponding to the
PHOX2B promoter region containing ATTA core motifs
known to bind PHOX2B (ATTA 2 and ATTA 3-4 motifs) (21,
25), the probe corresponding to the PHOX2Bbinding site in the
PHOX2A promoter (26, 39), and the PRS1 oligonucleotide cor-
responding to a region within domain IV of theDBH promoter
(29).
Incubation of the wild-type protein with each radiolabeled
oligonucleotide caused the appearance of specific retarded
bands (complexes I and II) that could be competed by a molar
excess of cold oligonucleotide and supershifted by the anti-HA
antibody (Fig. 7, C and D, lanes 1–3 and 11–13, *). Conversely,
DNAbinding of theC terminus-deleted protein (NterHD) to
all of the probes was severely affected (Fig. 7,C andD, lanes 7–9
and 17–19), although a weak complex could be detected in the
presence of the HA antibodies (Fig. 7C, lanes 9 and 19, ***) with
the exception of the ATTA 3-4 motif, which suggests that the
antibodymay stabilize interactions between the truncated pro-
tein and DNA. The behavior of the N terminus-deleted protein
(HD Cter) was different; the migration of complexes I and II
was faster because of the smaller size of the protein (complexes
Ia and IIa), and the deleted protein retained a partial ability to
bind DNA (Fig. 7, C and D, lanes 4–6 and 14–16), with com-
plex Ia being the most affected. The same oligonucleotide
shown in Fig. 7D (corresponding to a region of the DBH pro-
moter and containing two homeodomain binding sites) has
previously been used with PHOX2A protein in EMSA experi-
ments (30), and it is worth noting that two DNA-protein com-
plexes were observed: one formed when PHOX2A binds a sin-
gle site as a monomer and another more retarded complex
when two PHOX2A molecules simultaneously bind both sites
(probably as monomers). We obtained a similar pattern (com-
plex I and II) using the PHOX2B promoter (ATTA 3-4 motifs)
and the DBH promoter probes, both of which contain two
ATTA motifs in tandem position with seven and six interven-
ing bases, respectively (underlined in Fig. 7, C and D), thus
suggesting that PHOX2B binds to those sites in the DBH and
PHOX2B promoters mainly as a monomer. Moreover, the
authors also showed that PHOX2A binds two other probes as a
dimer containing a single motif and a second potential incom-
plete motif with three intervening bases. Because comparison
of the nucleotide sequences of the probes containing theATTA
2 site of the PHOX2B promoter and the homeodomain binding
site of the PHOX2A promoter revealed the presence of one
conserved ATTA motif close to a second incomplete motif (in
italic type in Fig. 7, C and D), we can reasonably speculate that
the more intense retarded band observed in our experiments
was probably formedby the binding of PHOX2Bas a dimer (Fig.
7,C andD, lane 1, complex I). This suggests that theHDCter
protein retained its ability to bind DNA as a monomer (com-
plex IIa) but only partially as a dimer (complex Ia). Interest-
ingly, the antibody against the HA tag fused to the HD Cter
protein supershifted a more intense band than that obtained
using the PHOX2B WT-HA protein, thus suggesting that the
deletion of the N-terminal domain affected the dimer DNA
binding affinity but not its formation (Fig. 7,C andD, lane 6, **).
Notably, faint bands were also observed using the Nter  HD
protein, thus suggesting that it might form dimers in vitro (Fig.
7, C and D, lane 9, ***).
The Polyalanine-expanded Tract Interferes with Each Local-
ization Signal and Blocks PHOX2B Homeodomain-mediated
Import—Our results show that dimerization is impaired when
the polyalanine stretch is elongated. Given that previous exper-
iments have shown that nuclear import and DNA binding are
also progressively reduced by polyalanine tract expansion (19–
21) and that the homeodomain presumably plays a central role
in all PHOX2B functions (i.e. nuclear import, DNA binding,
and dimerization), we further characterized the role of the
C-terminal region inmodulating homeodomain activity, focus-
ing our attention on nuclear import process.
Nuclear localization sequences (NLSs) are quite variable but
generally consist of basic residues (40), and in the case of home-
odomain proteins, an NLS is often found within or adjacent to
the homeodomain itself (41–45). The PHOX2B protein con-
tains two stretches of highly basic amino acids at both ends of
the homeodomain (encompassing amino acids 95–102 and
148–155, respectively; Fig. 9A). To clarify further the nuclear
import of PHOX2B, we identified and characterized PHOX2B
NLSs. To confirm the role of the homeodomain in nuclear
import of the protein, we cloned the same fragments of the
PHOX2B protein (downstream of the smaller HA tag) as those
used in the mammalian two-hybrid experiments (Fig. 8A) to
exclude the possible effects of the heterologous nuclear signal
of the VP16 AD tag on protein import and analyzed their sub-
cellular localization by means of immunohistochemistry. We
detected cells transfected with all of the truncated constructs
except for Nter (corresponding to the N-terminal region),
which was only detectable when a MYC tag was cloned down-
streamof theNter region (Fig. 8B, panels d-f), probably because
it makes the protein more stable. This confirms that, as previ-
ously reported by Wu et al. (46), the N-terminal domain of
PHOX2B is extremely unstable.
Nuclear stainingwas only observedwhen the expressed trun-
cated proteins were those containing the homeodomain and
lacking the C-terminal (NterHD) or N-terminal region (HD
 Cter) (Fig. 8B, g–i and o–q), thus confirming that the HD is
required for nuclear localization (47). Moreover, the HD per se
localized in the nucleus, whereas the Nter and Cter regions
were excluded from it, thus indicating that the HD is both
required and sufficient for nuclear import (Fig. 8B, compare l–n
(HD) with d–f (Nter) and r–t (Cter)). It is worth noting that all
of the cells transfected with one of the two constructs contain-
ing the N-terminal domain (Nter and NterHD, Fig. 8B, d–i)
showed very strong cytoplasmic and nuclear aggregation,
respectively, thus suggesting that the C-terminal portion of
PHOX2Bplays a role in keeping the protein in a soluble state, as
in the case of the wild-type protein (Fig. 8B, a–c) and the trun-
cated constructs containing the C terminus (Fig. 8B, o–t).
Remarkably, the peculiar dotlike pattern of theNterHDpro-
tein showed that the truncated protein is localized in specific
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foci, corresponding to nuclear regions with weak DAPI stain-
ing, which seem to be distinct from the nucleoli surrounded by
a characteristic ring of DAPI-positive chromatin (marked with
asterisks in Fig. 8B, enlarged view of the indicated area in i).
To characterize the role of the two stretches of basic residues
at both ends of the homeodomain, we first generated a con-
struct encoding a protein carrying the deletion of the entire HD
except for the two putative NLSs (PHOX2B 106–147, Fig.
9B). As shown in Fig. 9B (a–c), the deletion did not affect
nuclear localization, thus suggesting that the two regions (or at
least one) are required for PHOX2B nuclear import. To exam-
ine the functional role of each NLS motif in PHOX2B nuclear
localization, we introduced deletions into the PHOX2B expres-
sion vector that eliminated one or both stretches.
Deletion of the proximal NLS (PHOX2B NLS1) led to
nuclear staining of the fusion protein with substantial cytoplas-
mic fluorescence (Fig. 9B, d–f), whereas deletion of the NLS2
region (PHOX2B NLS2) led to a more marked cytoplasmic
localization (Fig. 9B, g–i). However, in both cases, the DAPI
staining was distorted, and we observed nuclear inclusions cor-
responding to DAPI-negative regions that resembled the find-
ings obtained when the Nter  HD deletion construct was
overexpressed (compare Fig. 9B, d–i, with Fig. 8B, g–i).
PHOX2B carrying deletions of both NLS motifs (PHOX2B
NLS1–2) accumulated in the cytoplasm around the nucleus
(Fig. 9B, l–n), thus confirming that the concerted action of both
regions is required for the nuclear localization of the protein.
To assess the effects of the polyalanine expansions on the
homeodomain-mediated nuclear import, we inserted the lon-
gest polyalanine expansion (13) into the constructs carrying
the single or double NLS deletion. As shown previously (19–
21), the cells transfected with the13 alanine mutant showed
cytoplasmic staining and aggregation as well as nuclear staining
(Fig. 9C, a–c). Unlike the wild type, the combined presence of
the expanded polyalanine tract and the deletion of just oneNLS
(PHOX2B 13Ala NLS1 and PHOX2B 13Ala NLS2) is
almost sufficient to completely block protein import (Fig. 9,
compare C (d–i) with B (d–i)).
Moreover, after deletion of theN-terminal domain, the pres-
ence of the C-terminal portion carrying the expanded polyala-
nine tract directed the homeodomain to a subcellular localiza-
tion that was different from that of its normal counterpart,
which was localized exclusively inside the nucleus (Fig. 8B,
o–q); a fraction of the truncated protein was in the cytoplasm
and formed aggregates (Fig. 9D, d–f), thus suggesting that the
expanded C terminus actively interferes with the correct fold-
ing of the homeodomain, leading to aggregation. Interestingly,
the expanded C-terminal domain localized diffusely in the
cytoplasm, like the C-terminal carrying the normal polyalanine
tract (Fig. 8B, r–t), thus indicating that the polyalanine tract per
se does not massively aggregate (Fig. 9D, a–c). The above
experiments indicate that the nuclear import of the protein is
regulated by the homeodomain and that the expanded C termi-
nus interferes with this process.
Discussion
In the first part of this study, we analyzed the dimerization
properties of PHOX2Bwild-type andmutant proteins and their
possible interactions in a cell model using co-immunoprecipi-
tation and a mammalian two-hybrid system. The analyses con-
firmed the formation of wild-type homodimers, as already
shown in vitro (7, 20), and the formation of mutant homo-
dimers/oligomers (although the interactions observed by mea-
suring luciferase activity in mammalian two-hybrid experi-
ments were weaker than those observed in the homodimers of
wild-type protein, probably due to the partial mislocalization of
the GAL4 BD-tagged expanded proteins) and indicated that
FIGURE 8. Contribution of the N- and C-terminal domains to nuclear
import of PHOX2B. A, schematic representation of wild-type PHOX2B pro-
tein and its truncated constructs. All constructswere fusedN-terminally to an
HA epitope tag.Numbers correspond to the amino acids residues of PHOX2B.
B, representative immunofluorescence images of the localization of
HA-PHOX2B truncated fusion proteins. HeLa cells were transfected with the
HA-tagged proteins and analyzed 48 h after transfection by means of immu-
nofluorescence using anti-HA antibody (b, e, h, m, p, and s); the nuclei were
visualized using DAPI (a, d, g, l, o, and r) and merged with the proteins
detected by the anti-HA antibody (c, f, i, n, q, and t). On the right of i, an
enlarged view of the indicated area is shown; the asterisks indicate the
nucleoli.
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expanded PHOX2B mutants interact weakly with wild-type
protein.
As in the case of wild type-mutant heterodimers, we detected
functional weak interactions only in HeLa cells by themamma-
lian two-hybrid system, and taking into account that this exper-
imental approach forces proteins into the nucleus and converts
an interaction into a defined transcriptional readout, we also
considered the possibility that the tendency to aggregation
FIGURE 9. Identification of PHOX2BNLSs and effects of the polyalanine-expanded tract on PHOX2B nuclear import. A, schematic representation of the
PHOX2B protein showing the sequence of the homeodomain and the two putative NLSs (underlined). B, top, schematic representation of PHOX2B carrying
deletions of the proximal NLS (NLS1), distal NLS (NLS2), both (NLS1-2), or the entire HD except for the NLSs (106–147). Black boxes, NLSs. Bottom,
representative immunofluorescence imagesof the subcellular localizationofHA-taggedPHOX2Bdeletionproteins in transfectedHeLa cells stainedbyanti-HA
antibody (b, e, h, andm); the nuclei were visualized using DAPI (a, d, g, and l) andmergedwith the HA-PHOX2B deleted proteins detected by anti-HA antibody
(c, f, i, and n). Scale bars, 10 m. C, representative immunofluorescence images of the subcellular localization of HA-tagged PHOX2B carrying 13 alanine
expansions (PHOX2B 13Ala) and the expanded deletion proteins (PHOX2B 13Ala NLS1, PHOX2B 13Ala NLS2, and PHOX2B 13Ala NLS1-2) in
transfectedHeLa cells stainedbyanti-HAantibody (b, e,h, andm). Thenucleiwere visualizedusingDAPI (a,d,g, and l) andmergedwith theHA-PHOX2Bdeleted
proteins detected by anti-HA antibody (c, f, i, and n). Scale bars, 10 m. D, representative immunofluorescence images of the localization of the expanded
HA-PHOX2B truncated fusion proteins. HeLa cells were transfected with the HA-tagged proteins and analyzed 48 h after transfection by means of immuno-
fluorescence using anti HA antibody (b and e); the nuclei were visualized using DAPI (a and d) andmergedwith the proteins detected by the anti-HA antibody
(c and f). Scale bars, 10 m.
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shown by the expanded proteins could interfere with the cor-
rect folding of the VP16-tagged expanded proteins or that the
formation of heterodimers do not reconstitute a functional
transcription factor. However, we reasonably excluded both
hypotheses because we were able to detect the formation of
mutant homodimers and heterodimers with PHOX2A,
although we cannot rule out the possibility that oligomers are
formed, because two-hybrid systems have been successfully
used to study the oligomerization of aggregation-prone pro-
teins (particularly polyglutamine- and polyalanine-expanded
proteins), thus suggesting that this assay is not intrinsically
impaired by protein aggregation (35, 48). Interestingly, our data
indicate that also the mutant with short (7) alanine expan-
sion, although still able to partially form homodimers in vitro
(20), dramatically reduces its ability to dimerize with its wild-
type counterpart. Moreover, the same defects have been
observed with the mutant carrying the longest expansion (13
alanine), and the slightly higher luciferase activity measured
may correlate with its partial ability to sequester the wild-type
protein in the nuclear and cytoplasmic aggregates (19, 21, 22).
Therefore, our data exclude the idea that polyalanine-expanded
mutants can form strong dimers with wild-type protein and
that the formation of non-functional heterodimers may play a
major role in CCHS pathogenesis.
In this study, we also analyzed the dimerization properties of
PHOX2A and its ability to form heterodimers with PHOX2B
wild-type and mutant proteins. Co-immunoprecipitation
experiments showed similar interactions among PHOX2B
mutated proteins and the wild-type counterpart or PHOX2A,
but conversely, themammalian two-hybrid system showed that
PHOX2B and PHOX2A appear to have different interaction
properties. Although the homeodomains of PHOX2B and
PHOX2A are identical, we measured significantly different
strengths of the interactions in the respective homodimers, and
interestingly, our data indicate that the formation of PHOX2A-
PHOX2B heterodimers is direction-dependent, suggesting a
role for other domains of the proteins in modulating these
interactions. Several lines of evidence in vivo showed that the
two proteins are not functionally equivalent, and given that
their C-terminal domains are very different and the role of the
C-terminal domain of PHOX2B in homodimerization, it is rea-
sonable to suppose that the formation of homo- or het-
erodimersmay be responsible for the creation of different inter-
faces for differential binding of cofactors. Moreover, the partial
ability of PHOX2B mutated proteins to form heterodimers
with PHOX2A, with a comparable affinity with PHOX2A
homodimers (at least for shorter expansions), suggests the
possible presence of species of dimers that differ from con-
ventional homo- and heterodimers.
The hypothesis that PHOX2Bmutantsmay inhibit PHOX2A
function in a dominant negative manner was first suggested by
Trochet et al. (20); however, in that study, PHOX2A nuclear
localization was not affected by the overexpression of13 ala-
nine mutant. Moreover, the recent data reporting specific
defects in locus coeruleus development in two human cases of
CCHS (one of which carried the7 alanine mutation) (49) and
the finding that PHOX2A is required for LC differentiation (50)
have favored, once again, the hypothesis that PHOX2Bmutant
proteins may exert dominant negative effects on PHOX2A
function. Our results with the DBH promoter suggest that
PHOX2B mutants do not interfere with the transcriptional
activity of PHOX2A, but, conversely, PHOX2A is able to syn-
ergize with PHOX2B mutants (and this effect is clearly evident
at least with the 7 alanine mutant). This observation was
unexpected and uncovers additional interesting characteristics
of PHOX2Bmutants that open the possibility that theymay not
be simply misfolded and non-functional molecules. Our data
indicate first that, despite the reduced transcriptional activity,
probably due to the diminished DNA binding, they have a (par-
tial) conserved ability to interact with other components of the
transcriptional complex and transcriptional activators and, sec-
ond, that their defects can be partially counteracted by the
interaction with molecules (such as PHOX2A) able to tether
them to the promoter of target genes. However, because the
nature of the interactors could vary according to the promoter,
and we cannot exclude the possibility of new “toxic” interac-
tions, the possible protective role of PHOX2A needs to be fur-
ther elucidated and investigated. Although we are probably
underestimating the interactions among mutants, because of
the partial mislocalization of the GAL4 BD-tagged expanded
proteins, our findings indicate that themutants are able to form
homodimers, and both the homeodomain and the C terminus
are required; therefore, we can reasonably hypothesize that the
expansion causes a conformational change in the C-terminal
domain that partially blocks interactions between mutant and
wild type but not those between mutants (or between mutants
and PHOX2A) and that a strong structural constraint on the
length of the polyalanine tract is necessary to impose the cor-
rect spatial distance and orientation between the homeodo-
main and the C-terminal region.
Our findings on PHOX2B nuclear import also support the
idea of cross-talk between the homeodomain and the C termi-
nus insofar as they show that PHOX2B has two strong func-
tional cooperative NLSs in the homeodomain (a weaker NLS1
in theN-terminal arm and a strongerNLS2 in helix III) and that
the polyalanine expansion alters their functionality. In line with
this, we found that the polyalanine-expanded tract per se does
not lead to visible intracellular aggregation because the cyto-
plasmic signal of the C terminus with the expanded polyalanine
tract was diffuse and comparable with that of the wild-type
counterpart, and the addition of the homeodomain to the
expanded C terminus not only strongly shifts the protein into
the nucleus, but also causes its partial aggregation in the cyto-
plasm. Because the homeodomain itself apparently does not
aggregate, this suggests that the expanded C terminus actively
interferes with its correct folding. Nuclear transport is a highly
regulated process, and the proteins to be transported into or out
of the nucleus are bound by transport receptors that recognize
the NLSs in the cargo protein. One mechanism regulating pro-
tein nuclear import is to modulate the binding affinity of the
transport receptor for the NLS cargo, which may occur in var-
ious ways: (i) the intermolecular masking of the NLS by a sec-
ondmacromolecule; (ii) the intramolecularmasking of theNLS
as a result of a post-translational modification within the NLS;
and (iii) the intramolecular/interdomain masking of the NLS
due to the protein taking on an inhibitory conformation. We
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favor the idea that the normal C terminus adopts an “open”
conformation that allows the homeodomain to function cor-
rectly and is thenmasked by the expanded C terminus in such a
way as to prevent dimerization, DNA binding, and nuclear
localization. A similar mechanism has been proposed for
another homeoprotein containing an alanine stretch (extra-
denticle, the Drosophila homologue of PBX1A), and interest-
ingly, the authors suggest that the stretch itself might be impor-
tant for maintaining the correct conformation for protein
nuclear localization (51). Another possible mechanism is the
decreased release in the nucleus of the mutated cargo by trans-
port receptors, as already reported for another homeoprotein
(ARX) (52).
Unexpectedly, our findings indicate that, although unstable,
the N-terminal region of the protein massively aggregates. Fur-
thermore, the addition of the homeodomain to the N-terminal
portion of PHOX2B is sufficient to stabilize it (thus forcing the
protein into the nucleus) but apparently does not block the
aggregation process. In agreement with our data, it has been
shown that the K155X mutant (found in a CCHS patient),
which lacks the entire C terminus, aggregates in both the
nucleus and the cytoplasm. This is probably because of the
absence of the last three residues of the homeodomain, which,
as has been previously shown, are important for theNLS2 activ-
ity (31). Alternatively, as the truncated proteins accumulate in
nuclear regions with weak DAPI staining, which seem to be
distinct from the nucleoli surrounded by a characteristic ring of
DAPI-positive chromatin, we cannot rule out the possibility
that, instead of aggregating, the truncated protein is localized in
specific foci. The different pattern observed with the HD 
Cter protein, which was indistinguishable from that of the full-
length protein, suggests that the C-terminal domain plays a
major role in protein solubility and, possibly, protein targeting
to the proper subnuclear regions. This is probably a result of
greater DNA binding affinity, as supported by the findings of
our in vitro gel shift experiments showing that the deletion
of the C-terminal domain greatly decreases protein DNA bind-
ing affinity. In line with this idea is the fact that the two other
mutants we tested, which completely lacked DNA binding (i.e.
PHOX2BNLS1 and PHOX2BNLS2), showed defective sub-
nuclear localization. It has been shown that DNA plays a role in
regulating the nuclear distribution of other transcription fac-
tors, includingmembers of families of proteins bearing a home-
odomain. An intriguing possibility is that, as the DNA binding
of polyalanine-expanded proteins progressively decreases as a
function of the length of the polyalanine tract, the subnuclear
localization of mutants might be slightly different, although by
immunofluorescence, the nuclear pattern of proteins with
shorter polyalanine expansions is virtually identical to that of
wild-type protein. Nuclear import defects and cytoplasmic
aggregation are detectable only in the case of proteins with
longer expansions, and our previous data indicated that the
formation of aggregates is dependent on protein abundance
(21, 53). Much evidence regarding other polyalanine proteins,
suggests that massive overexpression of the protein might trig-
ger the aggregation process and prevent nuclear import per se.
Moreover, there are no data on in vivo aggregation of PHOX2B
protein available, and the debate concerning the involvement of
aggregates and their toxicity in CCHS is still open. Neverthe-
less, our data indicate that the expansion of the polyalanine
tract diminishes the efficiency of the homeodomain-mediated
protein nuclear import, in comparison with wild-type protein,
and together with previous data, our findings indicate that the
C-terminal domain is an importantmodulator ofDNAbinding,
homeodomain-mediated dimerization, and solubility of the
protein and that the length of the polyalanine tract is critical to
drive the folding of theC-terminal domain,whichwould in turn
influence the spatial orientation of the homeodomain and all of
its functions.
Moreover, our data exclude the possibility that the formation
of non-functional heterodimers between the wild-type protein
and mutants with both short and long expansions may play a
major role in CCHS pathogenesis. On the other hand, our find-
ings suggest that PHOX2B mutants may form heterodimers
with PHOX2A, with biochemical properties possibly different
from those of the homodimers.
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a b s t r a c t
PHOX2B and its paralogue gene PHOX2A are two homeodomain proteins in the network regulating the
development of autonomic ganglia that have been associated with the pathogenesis of neuroblastoma
(NB), because of their over-expression in different NB cell lines and tumour samples. We used the SK-N-
BE(2)C cell line to show that all-trans retinoic acid (ATRA), a drug that is widely used to inhibit growth
and induce differentiation in NBs, regulates both PHOX2A and PHOX2B expression, albeit by means of
different mechanisms: it up-regulates PHOX2A and down-regulates PHOX2B. Both mechanisms act at
transcriptional level, but prolonged ATRA treatment selectively degrades the PHOX2A protein, whereas
the corresponding mRNA remains up-regulated. Further, we show that PHOX2A is capable of modulating
PHOX2B expression, but this mechanism is not involved in the PHOX2B down-regulation induced by
retinoic acid. Our ﬁndings demonstrate that PHOX2A expression is ﬁnely controlled during retinoic acid
differentiation and this, together with PHOX2B down-regulation, reinforces the idea that they may be
useful biomarkers for NB staging, prognosis and treatment decision making.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
A neuroblastoma, one of the most frequent tumours of child-
hood, is caused by the arrested differentiation of neural crest
sympatho-adrenal progenitor cells [1]. PHOX2B, and its paralogue
PHOX2A, are two homeodomain transcription factors that play a
pivotal role in the development of the autonomic nervous system
and speciﬁcation of the neurotransmitter phenotype by control-
ling the expression of the two enzymes responsible for nora-
drenaline biosynthesis (tyrosine hydroxylase [TH] and dopamine-
β-hydroxylase [DβH]), and thus directing neurons towards their
terminal noradrenergic differentiation [2,3]. PHOX2B also mod-
ulates its own expression by means of an auto-regulatory me-
chanism [4] and the expression of PHOX2A [5,6], whereas PHOX2A
regulates the expression of the human α3 nAChR subunit gene [7].
Both therefore play a primary role in controlling a number of the
molecular determinants of autonomic neurons.
PHOX2A and PHOX2B are also involved in coordinating cell
cycle exit and the differentiation of neural progenitors during
sympathetic neuronal differentiation [8] as a result of their ability
to induce the transcription of p27Kip1 [9–11], a cyclin-dependent
kinase inhibitor (CKI) whose expression is also regulated by re-
tinoic acid (RA) at post-translational level [12], followed by
PHOX2B down-regulation during ﬁnal neuronal differentiation
[13].
Recently, the PHOX2A gene has been localised to near the de-
letion breakpoint of a number of 11q-deleted NB specimens [14],
and microarray expression analysis has shown that it is one of nine
noradrenaline biosynthesis pathway genes whose expression is
reduced in unfavourable NB tumours [14]. However, the possible
contribution of PHOX2A to the pathogenesis of NB is not univocal
as it is over-expressed in a number of NB tumours and cell lines
[15]. As no mutations have been observed in the PHOX2A reg-
ulatory or coding regions of tumour samples [14,16], it is likely
that this gene is involved in the pathogenesis of NB when its
Contents lists available at ScienceDirect
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expression is deregulated in either direction.
The pathogenetic role of PHOX2B in NB is supported by the
presence of heterozygous mutations in familial, sporadic and
syndromic cases of NB, and its over-expression in tumour samples
and NB cell lines, sometimes associated with other neurochristo-
pathies such as Congenital Central Hypoventilation Syndrome
(CCHS) and Hirschprung's disease (HSCR) [16–23], but the under-
lying mechanisms are still largely unknown. In vitro and in vivo
studies have linked the PHOX2B mutations associated with NB
with the impaired differentiation of immature sympathetic neu-
rons that can proliferate, and aberrant differentiation towards the
glial lineage [10,24]. PHOX2B over-expression leads to contra-
dictory results as some studies indicate that it inhibits the pro-
liferation of motoneuron progenitors and of immature sympa-
thetic neurons [8,10,16] and promotes the differentiation of hu-
man NB cells after treatment with RA [16], whereas conditional
Phox2b knockout studies have revealed that Phox2b is required for
the proliferation of immature sympathetic neurons [25], and Alam
et al. [13], and Ke et al. [23] have shown that a high level of
PHOX2B promotes neuroblastoma cell proliferation and xenograft
tumour growth in the TH-MYCN murine model, and that this
correlates with a high level of MYCN expression. Furthermore, the
presence of aberrant Phox2b expression in a zebraﬁsh model has
shown that the correct amount of the Phox2b gene is important for
the differentiation of sympathetic neurons [26].
Vitamin A (retinol) profoundly affects various biological pro-
cesses during development and adulthood. Most of its actions are
mediated by its metabolic product, retinoic acid, which binds to
speciﬁc nuclear receptors: heterodimers of retinoic acid receptors
(RARs) α, β and γ, and retinoid X receptors (RXRs) α, β and γ. These
ligand-activated receptors regulate gene transcription by binding
to retinoic acid responsive elements (RAREs) in the promoter re-
gions of responsive genes [27]. At embryological level, retinoids
control the proliferation, migration and differentiation of neural
crest-derived progenitors and, in developing sympathetic neurons,
RA cooperates with Bone morphogenetic protein-2 (BMP-2) to
make cells responsive to neurotrophic factors such as glial derived
neurotrophic factor (GDNF) and neurotrophin 3 (NT3) [28,29]. The
pleiotropic effects of RA on the regulatory network governing
sympathetic neuron differentiation are well known, but very little
is known about its effect on the transcription factors (such as
MASH1, PHOX2A and PHOX2B) that play a fundamental role in this
process. In vitro, retinoids arrest cell growth in the G1 phase of the
cell cycle, and induce differentiation in human NB cell lines [30,31]
along neuronal- or glial-like lineages depending on the cell line
[32] by regulating, for example, the expression of p27Kip1, a target
gene of PHOX2A and PHOX2B that has major functions in con-
trolling the cell cycle.
As the target genes mediating retinoid-induced differentiation
are largely unknown, and the molecular mechanisms by which RA
regulates the different signalling pathways necessary for retinoid-
induced cellular differentiation in various tissues and at different
times are poorly understood, we tested the hypothesis that there
may be a direct regulatory link between RA and PHOX2A and
PHOX2B expression/activity in the SK-N-BE(2)C NB cell line. The
ﬁndings show that the retinoic-acid induced differentiation of SK-
N-BE(2)C cells is accompanied by a differential regulation of
PHOX2A and PHOX2B expression, with up-regulation of PHOX2A
mRNA followed by the disappearance of PHOX2A protein (the
mRNA remains stably expressed), and a marked decrease in the
expression of PHOX2B mRNA and protein, thus suggesting that
their expression must be ﬁnely controlled during RA-induced
differentiation, reinforcing the idea that they may be useful bio-
markers for NB staging, prognosis and treatment decision making.
2. Material and methods
2.1. Cell lines and cultures
The SK-N-BE(2)C and IMR32 human neuroblastoma cell lines
were grown in RPMI 1640, 10% fetal calf serum, 100 units/ml pe-
nicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine (Lonza).
All-trans retinoic acid (ATRA; Sigma-Aldrich, St.Louis, Missouri,
USA), dissolved in 100% EtOH, was added at a ﬁnal concentration
of 10 μM for the times described in the and the medium was
changed every day. Each treatment was carried out in duplicate
and repeated at least three times in independent experiments
using different batches of ATRA. Cycloheximide (Sigma-Aldrich, St.
Louis, MO, USA) was added at a ﬁnal concentration of 10 μg/ml
before or after ATRA for the times described in the The proteasome
inhibitor MG-132 (8 μM; Calbiochem, Darmstadt, Germany) was
added for eight and 24 h after initial treatment with ATRA for 24
and 48 h.
2.2. Total RNA extraction, reverse transcription, and quantitative
real-time PCR
Total RNA was extracted and reverse transcribed, and gene ex-
pression was quantitatively analysed as described by Benfante et al.
[33] with minimal modiﬁcations. The TaqMan
s
primer and probe as-
says (Life Technologies, Inc., Carlsbad, CA, USA) were PHOX2A (ID
#Hs00605931_mH) and PHOX2B (ID #Hs00243679_m1), and glycer-
aldehyde-3-phosphate dehydrogenase (GADPH; ID# Hs99999905_m1)
was used as an endogenous controls after its compatible with the
other assays had been conﬁrmed. The results were calculated using
the 2ΔCT and the 2ΔΔCT methods in order to allow the normal-
isation of each sample to the endogenous control, and comparison
with the calibrator of each experiment (set to a value of 1) as described
in the ﬁgure legends.
2.3. Nuclear run-on
Nuclear run-on transcription was performed in accordance
with the protocol described by Patrone et al. [34]. The nuclei
(5107) were prepared from SK-N-BE(2)C cells treated for 24 h
with ATRA or vehicle. RNA was synthesised in vitro by adding an
equal volume of transcription buffer containing 0.4 mM biotin-16-
UTP (Roche Diagnostics SpA, Monza, Milan, Italy), and the biotin-
labelled RNA was isolated by means of streptavidin-coated mag-
netic beads (Dynabeads M-280 Streptavidin, Dynal Biotech ASA,
Oslo, Norway). Gene expression was quantitatively analysed by
reverse transcribing 8 ml of the nuclear RNA sample and 1 mg of the
total RNA sample and using real-time PCR.
2.4. Chromatin immunoprecipitation and qPCR
Chromatin immunoprecipitation was carried out as previously
described [4]. Chromatin was incubated overnight at 4 °C with
5 mg of anti-PHOX2A antibody (Davids Biotechnologie, Regensburg,
Germany), and chicken pre-immune IgY (Davids Biotechnologie),
and the immunocomplexes were collected on monoclonal anti-
chicken IgY-agarose beads or protein G/agarose bead slurry (In-
Vitrogen, Carlsbad, CA, USA) pre-adsorbed with 20 mg/ml tRNA and
10 mg/ml salmon sperm DNA (Sigma-Aldrich). After washes and
elution, the cross-linking was reversed by heating to 65 °C over-
night, and the samples were puriﬁed on columns (High Pure PCR
product puriﬁcation kit, Roche Diagnostics SpA, Italy). For the PCR
detection of the immunoprecipitated chromatin, 5% of the puriﬁed
DNA was used as a template to amplify the PHOX2B promoter
using the primers ChIP[2 bprom] UP, 5′-CAA GCT TAT TTC CAA GTA
GTG TGA TTG AAT-3′, and ChIP[2bprom] LOW, 5′-GCC TCC TAT
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GAG ATG CCT TGT CTG A-3′. The DNA samples were heated to
95 °C for 2 min, followed by 47 cycles of heating at 95 °C for 30 s,
annealing at 64 °C for 30 s, and extension at 72 °C for 30 s. For
quantitative analysis, the immunoprecipitated chromatin was
ampliﬁed by means of SYBR-Green chemistry (Life Technologies,
Inc.) using the primers #UP, 5′-GCT CGG TGC GTA ATG GTG TGG
TA-3′ and #LOW, 5′-GGT TGG TCT TAT TGC TGG CGC TT-3′, and
quantitatively analysed using the ABI Prism™ 7000 Sequence
Detection System (Applied Biosystems, CA, USA) and SDS software,
version 1.2.3.
2.5. shRNA
PHOX2A expression was silenced by means of the transient
transfection of a plasmid (MISSIONs shRNA, Cod. SHCLNG-
NM_005169, TRCN0000013543, Clone ID:NM_005169.2-
1260s1c1) containing an shRNA targeting the 3′-UTR region of
PHOX2A (Sequence: CCG GCC TTC TAG CTT GGC CTT CTT TCT CGA
GAA AGA AGG CCA AGC TAG AAG GTT TTT) and the results were
analysed as described in the SHC002 MISSIONs pLKO.1-puro Non-
Mammalian shRNA Control Plasmid DNA (Sigma-Aldrich) was
used as the control.
2.6. Electrophoretic mobility shift assays (EMSAs)
The EMSAs were performed as described by Terzano et al. [35]
and Cargnin et al. [4]. The oligonucleotides spanning the ATTA
sites in the PHOX2B promoter have been described by Cargnin
et al. [4] and all of the oligonucleotides were purchased from
Sigma Aldrich.
2.7. Plasmid construction
The β-RARE luc construct was obtained by cloning the con-
sensus RARE from the β2 RA receptor subunit promoter [36] up-
stream of the SV40 promoter (Promega Madison, WI, USA). The
oligonucleotide sequence was 5′-TCG AGT AAG GGT TCA CCG AAA
GTT CAC TCG CAC-3′, in which the RARE sequence is underlined.
Some of the reporter constructs containing regions of the
PHOX2A promoter have been previously described by Flora et al.
[5]. However, as these regions were cloned into the pGL3basic
vector backbone and this was unspeciﬁcally transactivated by
ATRA treatment, we re-cloned fragments of the human PHOX2A 5′-
ﬂanking region into the ATRA-unresponsive pGL4basic plasmid
(Promega) upstream of the Fireﬂy luciferase gene. Details con-
cerning the plasmid construction are available in the Supplemen-
tary Material. The PHOX2A expression vector was obtained by
cloning human PHOX2A cDNA [7] into the EcoRI site of pCMV-myc
(Clontech Laboratories Inc., Mountain View, CA, USA). All of the
constructs were checked by means of restriction analysis and
partial sequencing.
2.8. Transfections and luciferase assays
The transfection experiments were performed by means of li-
pofection as described by Flora et al. [37] using 1.6105 SK-N-BE
(2)C cells. Luciferase was assayed using the Dual Luciferase Re-
porter Assay System as previously described [5,38].
2.9. Protein preparation, immunoprecipitation and western blot
analysis
The total protein extracts were obtained from sub-conﬂuent
cells using the freeze and thaw method as described by Benfante
et al. [33] and the nuclear extracts were prepared as previously
described [35].
For immunoprecipitation, SK-N-BE(2)C cells were harvested
after being treated with ATRA and MG-132 as described in the by
means of centrifugation at 7000 rpm for 5 min. The pellet was
resuspended in 150 ml lysis buffer containing non-ionic detergent
(1% Triton X-100, 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 2 mM
EDTA, 0.5 mM DTT, 0.2 mM PMSF, and the Sigma-Aldrich protease
inhibitors cocktail), and incubated for one hour at 4 °C on a ro-
tating wheel. The extracts were then clariﬁed by means of 30 min
centrifugation at 13,200 rpm/4 °C, and pre-cleared using protein
G/agarose bead slurry (InVitrogen) and chicken pre-immune IgY
(Santa Cruz Biotechnology, Inc., Dallas, Texas, USA). Three milli-
grams of the pre-cleared extracts were incubated overnight at 4 °C
with 5 μg polyclonal chicken anti-PHOX2A antibody (Davids Bio-
technologie), or pre-immune chicken IgY (Santa Cruz Biotechnol-
ogy) and the immunocomplexes were captured by protein G/
agarose bead slurry (InVitrogen). Because of the poor binding of
chicken antibodies to protein G, a bridging antibody (rabbit anti-
chicken IgG, Upstate, Lake Placid, NY, USA) was added to enhance
the capture of the immunocomplexes. The beads were collected by
means of centrifugation, gently washed, and resuspended in
sample loading buffer, and the immunocomplexes were dis-
sociated from the beads by boiling the samples.
The proteins were separated by means of 10% SDS-PAGE and
transferred to a nitrocellulose membrane (Schleicher & Schuell
BioScience GmbH, Dassel, Germany), and Western blotting was
carried out as previously described [7] using the chicken anti-
PHOX2A [7], mouse monoclonal anti-PHOX2B (B-11), rabbit anti-
Sp1 (Santa Cruz Biotechnology), mouse anti-β-tubulin (Sigma-Al-
drich) and mouse anti-Ubiquitin (BIOMOL GmbH, Hamburg, Ger-
many) as primary antibodies; the secondary antibodies (rabbit
anti-chicken, Davids Biotechnologie; goat anti-rabbit and anti-
mouse, Pierce Biotechnology Inc., Rockford, ME, USA) were con-
jugated with horseradish peroxidase. The bands were revealed
using Super Signal West Dura (Pierce Biotechnology Inc.), with
standard molecular weights (New England Biolabs Inc., Beverly,
MA USA) being loaded in parallel.
2.10. Data analysis
NIH Image 1.61/fat software was used for the densitometric
analysis of the signals obtained from the Western blots. The results
are given as the mean values of at least three independent ex-
periments, and standard deviation (SD) or standard error (SEM) as
indicated in the The data were analysed by means of a paired two-
tailed Student's t test or one-way ANOVA using GraphPad Prism
5 Software (GraphPad Software, Inc.) as described in the; p values
of o0.05 were considered signiﬁcant.
3. Results
3.1. Effects of ATRA on PHOX2A and PHOX2B expression
The effect of ATRA on the expression of PHOX2A and PHOX2B
was studied using the SK-N-BE(2)C NB cell line, a very well-char-
acterised model of RA-induced neuronal differentiation [39]. Its
differentiation potential was tested by treating the cells with
10 μM ATRA for different periods of time, evaluating their mor-
phology and the differential expression of some target genes, and
measuring the responsiveness of a reporter construct in which
transcription was driven by the RARE. Phase-contrast microscopy
showed that the morphology of the SK-N-BE(2)C cells started
changing after 24 h of ATRA exposure (Fig. S1A, panel b), and
neurite outgrowth was clearly evident after 72 h (Fig. S1A, panel
c); exposure to the vehicle alone did not affect their morphology at
any time (Fig. S1A, panels d and e), leaving them indistinguishable
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from the control (Fig. S1A, panel a).
At molecular level, ATRA-induced SK-N-BE(2)C cells differ-
entiation is characterised by changes in the expression of some
target genes, including HASH1 [40,41], and Northern blot analysis
of RNA from the cells treated with ATRA for different times re-
vealed a unique transcript of approximately 3 Kb encoding HASH1
(Fig. S1B, lanes 1, 2 and 4), which was observed in all of the tested
NB cells, whereas no signal was observed in the HeLa cells (Fig.
S1B, lane 3). After 24 h exposure to ATRA, the expression of the
transcript became barely detectable (Fig. S1B, lane 5) and re-
mained very low for up to 96 h (Fig. S1B, lanes 6–8). This is in line
with the ﬁndings of Söderholm et al. [41] and, together with the
morphological data, indicates that the most relevant biological
responses of neuroblastoma cells to ATRA exposure were com-
pletely reproducible under our experimental conditions.
The responsiveness of SK-N-BE(2)C cells to ATRA was also tes-
ted by means of the transient transfection of a reporter construct
in which the transcription was driven by the RARE identiﬁed in the
promoter of the β2 subunit of retinoic acid receptor (β-RARE luc),
cloned upstream of SV40 promoter. Fig. S1C shows that the SK-N-
BE(2)C cells were fully responsive to ATRA treatment as the ex-
pression of the luciferase reporter gene increased 40-fold over that
of untreated cells (compare lanes 1 and 2). Treatment with vehicle
alone had no effect on the luciferase (Fig. S1C, lane 3). All of these
data further conﬁrm that the most relevant biological responses of
SK-N-BE(2)C cells to ATRA exposure were completely reproducible
under our experimental conditions.
Fig. 1A shows that the PHOX2A transcript [5] was considerably
induced after 24 h exposure to ATRA, and this level of expression
increased for up to 72 h (Fig. 1A, hatched vs grey bars), whereas
exposure to the vehicle alone did not affect PHOX2A expression at
any time (Fig. 1A, grey bars vs black bar). The induction of PHOX2A
mRNA by RA was reproducible and statistically signiﬁcant. On the
contrary, PHOX2B transcript expression decreased by 70% after 24 h
exposure, and by up to 90% after 72 h (Fig. 1B, white vs grey bars).
Western blot analysis was used to evaluate whether the in-
duction of PHOX2A mRNA and reduction in PHOX2B mRNA ex-
pression was paralleled by an adequate increase/decrease in the
corresponding protein. Fig. 1C shows that, after 24 h treatment
with ATRA, there was a substantial and statistically signiﬁcant
increase in PHOX2A protein levels (Fig. 1C, lanes 3 and 4 vs control
lanes 1 and 2); however, surprisingly, no trace of the protein was
found after 48 h and for up to 96 h (Fig. 1C, lanes 5–10). On the
contrary, PHOX2B protein was not detectable after no more than
24 h ATRA treatment (Fig. 1D, lanes 3, 5 and 7 vs lanes 2, 4 and 6).
3.2. ATRA acts at transcriptional level
We used nuclear run-on experiments to investigate whether
ATRA acts directly at transcriptional level. Fig. 2A and B (TOT RNA)
conﬁrmed that 24 h ATRA exposure induced a three-fold increase
in PHOX2A and three-fold decrease in PHOX2B mRNA expression,
and the quantitative run-on experiments showed that this changes
were due to the new induction or repression of transcription
caused by the drug (Fig. 2A and B, RUN-ON RNA). In brief, ATRA
increased PHOX2A and decreased PHOX2B mRNA levels by acting
on their transcription.
3.3. Mapping the retinoic acid responsive elements (RAREs)
The nuclear run-on analyses (Fig. 2) showed that the changes in
PHOX2A and PHOX2B relative expression was mainly due to a
Fig. 1. Effects of ATRA on PHOX2A and PHOX2B expression in SK-N-BE(2)C cells. (A and B) qPCR analyses of PHOX2A (panel A) and PHOX2B expression (panel B). SK-N-BE(2)C
cells were treated with ATRA for the indicated times, and gene expression was determined by means of real-time PCR using the GAPDH gene as an internal control. The bars
represent the mean values7SD of three independent experiments expressed as fold-induction in comparison with the untreated sample (black bars). Hatched (panel A) and
empty (panel B) bars¼treated cells; grey bars¼vehicle-treated samples. **po0.01; and ***po0.001 indicate statistically signiﬁcant differences in PHOX2A and PHOX2B
mRNA expression between the vehicle treated (grey bars) and the cells treated with ATRA for different periods of time (one-way ANOVA, post-Tukey's test). (C and D)
Western blots of total protein extracts obtained from SK-N-BE(2)C cells treated with ATRA 10 μM (lanes 3–10 in panel C, and lanes 3, 5 and 7 in panel D) or ethanol (lanes 11–
18 in panel C and 2, 4 and 6 in panel D) for different periods of time. The ﬁlter was probed with the anti-PHOX2A (panel C) or anti-PHOX2B antibody (panel D). The
membranes were probed with an antibody against β-tubulin for normalisation purposes. The negative and positive controls were protein extracts of HeLa (panel C, lane 19)
and IMR32 cells (panel C, lane 20, and panel D, lane 8). Lanes 1 and 2 (panel C), and lane 1 (panel D): untreated cells.
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transcriptional mechanism. A computer-assisted analysis of 10 Kb
of the PHOX2A promoter sequence using MatInspector software
(www.genomatix.de) revealed the presence of putative RAREs,
which may explain the increased PHOX2A expression induced in
the SK-N-BE(2)C cell line by ATRA treatment.
Ten putative RAREs were identiﬁed, two of which (#2 and #3)
partially overlapped. Most of the RAREs were directed repeats
separated by one nucleotide (DR1), two were DR2 (#6 and #8) and
only one was a DR5 (#7), although none of them perfectly mat-
ched the consensus (Fig. 3A). In order to test whether these sites
were functionally responsive to RA, we generated a series of
constructs spanning the PHOX2A promoter from position
10.53 Kb to position 0.35 Kb, and performed transient trans-
fections. The KpnI-NcoI fragment (Fig. 3B, 10.8/pGL4), which
contains all ten RAREs, and the SphI-NcoI fragment (Fig. 3B, 6.6/
pGL4), which contains RAREs 1–6, responded to ATRA treatment
with an almost ﬁve-fold induction of construct activity in com-
parison with the vehicle-treated cells. The SacI-NcoI fragment
(Fig. 3B, 4.5/pGL4), which spans 5.2 Kb of the promoter up-
stream of the transcriptional start site and contains RAREs 1–4,
was also responsive, although to a lesser extent (Fig. 3B). However,
further deletion of RARE 4 (construct 1.5/pGL4) did not affect the
activity of the PHOX2A promoter, which remained fully responsive
to ATRA. The 1.2/pGL4 construct containing only the RARE 1 se-
quence also remained responsive, and showed a statistically sig-
niﬁcant two-fold increase in promoter activity in comparison with
the vehicle-treated cells, whereas the deletion of RARE 1 (Fig. 3B,
0.35/pGL4) completely abolished the ability of ATRA to induce
PHOX2A promoter activity.
These data indicate that the responsiveness to ATRA is a result
of the contribution of the three RARE sequences located in the ﬁrst
1.5 Kb of the PHOX2A promoter.
On the other hand, in silico analysis of the PHOX2B promoter
did not reveal the presence of canonical RARE elements, thus
suggesting that the down-regulation of PHOX2B expression is not
mediated by the direct binding of RA receptors to the promoter,
and that other transcription factors mediate the effect of RA on
PHOX2B gene expression.
3.4. Down-regulation of PHOX2B expression is not due to a direct
effect of PHOX2A
Control of the temporal and spatial expression of PHOX2A and
PHOX2B is fundamental during the speciﬁcation of neuronal
identity, and many studies have tried to elucidate the exact mo-
lecular mechanisms involved in regulating their expression over
the last few years. We have previously demonstrated that PHOX2B
regulates the transcription of the PHOX2A gene by directly binding
and transactivating its promoter [5]. We have also characterised
the PHOX2B promoter, and demonstrated by means of biochemical
and functional assays that most of its transcriptional activity is
sustained by auto-regulatory mechanisms involving PHOX2B
binding and transactivation [4].
Chromatin immunoprecipitation (ChIP) assays show that
PHOX2A also participates in the transcriptional complex as-
sembled on the PHOX2B promoter [4] (Fig. 2S, panels A and B). The
PHOX2B promoter has ﬁve binding sites for homeodomain proteins
(Fig. S2D), and EMSA analysis (Fig. 2S, panel C) showed that
PHOX2A is also capable of binding the ATTA2 (Fig. 2S panel C, lanes
7–10) and ATTA3 (Fig. 2S panel C, lanes 12–15) sites in the PHOX2B
promoter; moreover, unlike PHOX2B, PHOX2A, binds also the
ATTA1 and ATTA5 sites (Fig. 2S, panel C, lanes 2–5 and 22–25),
although with lower afﬁnity.
We then asked whether the down-regulated expression of
PHOX2B was related to, and mediated by the increased expression
of PHOX2A induced by ATRA treatment. The over-expression of
PHOX2A in the SK(2)C NB cell lines showed a statistically sig-
niﬁcant 40% reduction in the expression of endogenous PHOX2B
(Fig. 4A, hatched vs black bar), thus suggesting that PHOX2A ne-
gatively modulates PHOX2B expression, although the reduction
was not as great as that observed after an ATRA challenge. These
data were conﬁrmed by silencing PHOX2A expression for 24 and
48 h (Fig. 4B, lanes 2 and 4 vs 1 and 3), and an approximately 50%
reduction in PHOX2A expression (Fig. 4C, black bars) corresponded
to a slight, but statistically signiﬁcant increase in PHOX2B ex-
pression (Fig. 4C, grey bars). In order to investigate whether the
down-regulation of PHOX2B induced by ATRA treatment was at
least partially due to an increase in PHOX2A expression, we
counteracted the ATRA-induced increase in PHOX2A expression in
SK(2)C cells transfected with PHOX2A shRNA, and measured the
corresponding level of PHOX2B mRNA. Fig. 4D (left panel) shows
that the presence of PHOX2A shRNA blocked the ATRA-induced
PHOX2A expression (grey vs hatched bars) for up to 72 h to an
extent that was not statistically different from that observed in the
samples transfected with a scrambled shRNA (shCTRL) and not
challenged to ATRA treatment (grey vs black bars). However, the
reduction in PHOX2B expression was not affected by the presence
of the PHOX2A shRNA (Fig. 4D, right panel; grey vs hatched bars) at
Fig. 2. Effects of ATRA on the transcription of PHOX2A and PHOX2B mRNA. (A and B) Run-on analysis. The SK-N-BE(2)C cells were treated with ATRA for 24 h, and PHOX2A
(panel A) and PHOX2B gene expression (panel B) was determined by means of real-time PCR using the GAPDH gene as an internal control. The bars represent the mean
values7SD of three independent experiments using total and nuclear run-on RNA in the treated cells (striped bars), expressed as fold-induction over the vehicle-treated
samples (black bars). **po0.01 and ***po0.001 (one-way ANOVA, post-Tukey's test).
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any time. These data suggest that PHOX2A and PHOX2B cross-
regulate their own expression, but this mechanism is not involved
in regulating ATRA-induced PHOX2B down-regulation.
3.5. ATRA reduces PHOX2A protein half-life by means of proteasomal
degradation
As shown in Fig. 1A, 24 h ATRA treatment led to a substantial
and statistically signiﬁcant increase in PHOX2A expression; how-
ever, surprisingly, no trace of the protein was found after 48 h
exposure and for up to 96 h (Fig. 1A). In order to investigate
whether the delayed effects of ATRA on PHOX2A protein expres-
sion correlated with decreased protein stability, we evaluated
PHOX2A protein half-life by treating SK-N-BE(2)C cells with ATRA
or ethanol for 24 h, followed by 10 μg/ml cycloheximide for dif-
ferent time periods (Fig. 5A). The half-life of the protein was sig-
niﬁcantly reduced (50%) in comparison with the levels observed in
the cells exposed to the vehicle alone (Fig. 5A, lanes 2–5 vs lanes
7–10) after no more than 90 min (Fig. 5B).
In order to conﬁrm that the effects of ATRA on protein stability
were PHOX2A speciﬁc, we studied the expression of the tran-
scription factor Sp1 after 300 min exposure to RA in the same
samples as those used in Fig. 5A: Fig. 5C shows that the presence
of RA had no effect on Sp1 expression.
In order to investigate whether the reduced stability of
PHOX2A protein was due to increased proteasome-mediated de-
gradation, SK-N-BE(2)C cells were treated with MG-132, an in-
hibitor of proteasomal activity. The cells were exposed to MG-132
for the last eight hours of a 32-h exposure period, and this in-
creased the amount of PHOX2A protein in comparison with the
amount induced by ATRA alone (Fig. 5D, lane 5 vs lane 4). The
simultaneous presence of the inhibitor for up to 24 h (a total of
48 h of ATRA treatment; Fig. 5D, lane 7), or for the last eight hours
of a 56 h exposure to ATRA (Fig. 5D, lane 9) rescued PHOX2A
protein expression from degradation (compare lanes 7 with 6 and
lanes 9 with 8). Furthermore, PHOX2A immunoprecipitation and
Fig. 3. Functional mapping of PHOX2A retinoic acid responsive elements. (A) Schematic illustration of the putative RAREs identiﬁed in the PHOX2A promoter region. Left: The
region spanning 5 Kb upstream of the PHOX2A transcriptional start site. Right: The region spanning nucleotides 10,530 to 5200 of the PHOX2A 5′-ﬂanking region. The
consensus RARE is also indicated. (B) Left: Schematic illustration of the constructs. The boxes represent the putative RARE sequences #1-#10, as assessed by means of
computer-assisted analysis (Genomatix, MatInspector), and the arrows the transcription start site. The ﬁgure shows the restriction sites used to clone the different parts of
the PHOX2A 5′-ﬂanking region; the grey oval represent the Fireﬂy luciferase reporter gene (luc). Right: Luciferase assays. SK-N-BE(2)C cells were transiently transfected with
the constructs shown on the left, and treated with ATRA for 24 h before luciferase assay. The bars show the transcriptional activity of the constructs expressed as fold-
inductions over vehicle-treated cells (mean values7SD of at least three independent experiments performed in triplicate). The asterisk indicates a statistically signiﬁcant
difference between the cells treated with ATRA or vehicle alone for the same period of time (Student's t test. *po0.05).
S. Di Lascio et al. / Experimental Cell Research 342 (2016) 62–71 67
Ubiquitin Western blotting revealed that PHOX2A-Ubiquitin con-
jugates are increased by treatment with ATRA combined with MG-
132 than treatment by ATRA alone (Fig. 5E, lane 8 vs lane 5), thus
conﬁrming that the disappearance of PHOX2A protein is due to
selective proteasomal degradation, whereas the mRNA remains
stably expressed.
4. Discussion
We investigated the effects of ATRA on the expression of
PHOX2A, a candidate tumour suppressor gene [14], using the un-
differentiated SK-N-BE(2)C human NB cell line as a model, and
found that they were apparently opposite: it initially acted as a
positive regulator of gene expression, but later triggered a process
that culminated in the complete disappearance of the transcrip-
tion factor. The positive effects of ATRA were mainly due to direct
stimulation of gene transcription by means of the contribution of
three RARE sequences located in the ﬁrst 1.5 Kb of the PHOX2A
promoter, but the identity of the RA nuclear receptor isoforms
involved in this regulation is still unknown.
The increase in PHOX2A protein product during the ﬁrst 24 h of
treatment, followed by its down-regulation after 48 h even though
the expression of PHOX2A mRNA remained constantly up-regu-
lated, led us to hypothesise that ATRA might promote the dis-
appearance of PHOX2A protein by means of two different mole-
cular mechanisms: translation inhibition and/or increased protein
degradation. Our data strongly suggest that the proteasome plays a
pivotal role, and raise the question as to which pathways link
ATRA exposure to PHOX2A degradation.
Fig. 4. PHOX2A induction does not mediate the ATRA-induced down-regulation of PHOX2B expression. (A) qPCR analysis of PHOX2B expression following PHOX2A over-
expression. SK-N-BE(2)C cells were transfected with PHOX2A cDNA expression vector (striped bar), and PHOX2B gene expression was determined by means of real-time PCR
using the GAPDH gene as an internal control. The bars represent the mean values7SD of three independent experiments expressed as fold-inductions in comparison with
the cells transfected with empty vector (black bar). ***po0.001 indicates statistically signiﬁcant differences in PHOX2B mRNA expression (Student's t test). (B) Western blots
of PHOX2A silencing. SK-N-BE(2)C cells were transfected with the shRNA construct targeting the 3′-UTR of PHOX2A (sh2a, lanes 2 and 4) or scrambled shRNA (shCTRL, lanes
1 and 3). PHOX2A protein levels were determined 24 (lanes 1 and 2) and 48 h after transfection (lanes 3 and 4), using an anti-PHOX2A antibody. The membrane was probed
with an antibody against β-tubulin for normalisation purposes. (C) qPCR analysis of PHOX2A (black bars) and PHOX2B expression (grey bars) upon PHOX2A silencing. SK-N-BE
(2)C cells were transfected with the shRNA construct targeting the 3′-UTR of PHOX2A (shPHOX2A) and gene expression was determined 24 and 48 h after transfection by
means of real-time PCR using the GAPDH gene as an internal control. The bars represent the mean values7SD of at least three independent experiments, expressed as fold
differences in comparison with the cells transfected with scrambled shRNA (shCTRL¼1). **po0.01 and ***po0.001 indicate statistically signiﬁcant differences in gene
expression relative to scramble transfected cells. (D) PHOX2A and PHOX2B mRNA expression upon ATRA treatment after PHOX2A silencing. SK-N-BE(2)C cells were trans-
fected with PHOX2A shRNA (shPHOX2A, grey bars) or scrambled shRNA constructs (shCTRL, striped and black bars), and treated with 10 mM ATRA (grey and striped bars) for
the indicated times. PHOX2A (left panel) and PHOX2B (right panel) gene expression was determined by means of real-time PCR using the GAPDH gene as an internal control.
The bars represent the mean values7SD of three independent experiments, expressed as relative mRNA levels calculated using the 2ΔCt method. Left panel: **po0.01 and
§§§po0.001 (one-way ANOVA, post-Tukey's test) indicate statistically signiﬁcant differences in PHOX2A mRNA expression between the cells transfected with scrambled
shRNA (striped bars) and the cells transfected with shPHOX2A (grey bars) treated with ATRA or between the cells transfected with scrambled shRNA treated with ATRA
(striped bars) or vehicle (black bars). There was no statistically signiﬁcant difference between the vehicle- and ATRA-treated cells respectively transfected with shCTRL (black
bars) and with shPHOX2A (grey bars). Right panel: ***po0.001 indicate statistically signiﬁcant differences in PHOX2B mRNA expression between the ATRA- and vehicle-
treated cells transfected with shCTRL (bars 2, 5, 8 and 11 vs 1, 4, 7 and 10) or shPHOX2A (bars 3, 6, 9 and 12 vs 1, 4, 7 and 10). There was no statistically signiﬁcant difference
between the ATRA-treated cells transfected with shPHOX2A (grey bars) and those transfected with shCTRL (striped bars).
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RA down-regulates cell proliferation and promotes neurogen-
esis by arresting cells in the G1 phase of the cell cycle [31]. Al-
though the underlying mechanism is still unclear, it is known that
RARβ is a necessary component of the inhibitory effects of ATRA
on the growth of NB cells [42]; furthermore, RA induces cell-cycle
arrest in G1 by decreasing the cyclin-dependent kinase (Cdk) ac-
tivity required for the G1/S transition and the accumulation of the
p27Kip1Cdk inhibitor (CKI) [43,44] that impair growth and activate
the differentiation programme. The stability of p27Kip1 is regulated
by the E3 ubiquitin ligase SKP2, and RA stabilises p27Kip1 by en-
hancing the proteasome-mediated degradation of SKP2 in a
number of cancer cell lines. Like PHOX2A, SKP2 protein disappears,
but its mRNA persists during the RA treatment of SH-SY5Y cells,
thus suggesting that RA post-transcriptionally regulates SKP2 [45].
Ballas et al. and Singh et al. [46,47] have shown that REST, a key
regulator of neuronal genes during neuronal differentiation, is
regulated by ATRA in a manner that is similar to the regulation of
PHOX2A, and suggested that the degradation of REST may facil-
itate a rapid transition to terminal differentiation; given that REST
is mainly a negative regulator, this permits the differential ex-
pression of a subset of genes with lower-afﬁnity REST binding
sites. These ﬁndings suggest that regulation of proteasome-medi-
ated degradation of the proteins involved in different aspects of
cell metabolism may be a common mechanism by means of which
RA controls the order of the signalling events necessary for a cell's
response to retinoid-induced differentiation.
Like PHOX2A, PHOX2B, is overexpressed in a number of tumours
and NB cell lines. However, there are conﬂicting hypotheses con-
cerning the signiﬁcance of this in the pathogenesis of NBs. Raabe
et al. [16] suggest that PHOX2B up-regulation is simply a marker of
tumour lineage and not a contributor to malignant phenotype,
given that neuroblastoma arise at a time when PHOX2B is normally
expressed during neurodevelopment, and its forced over-
expression decreases proliferation. Furthermore, they rule out
PHOX2A involvement in the pathogenesis of NBs because no
mutations have been found in the PHOX2A coding region [14,16].
As the expression of PHOX2B precedes that of PHOX2A during
development, and in vitro experiments have shown that the forced
over-expression of PHOX2B regulates PHOX2A [5,6], it is possible to
speculate that PHOX2A up-regulation may be due to a high level of
PHOX2B expression, because silencing PHOX2B in NB cell lines
leads to the down-regulation of PHOX2A [22].
However, in contrast to data described in Bachetti et al. [22],
our data suggest a new mechanism cross-regulating PHOX2A and
PHOX2B as they show that PHOX2A negatively modulates PHOX2B
expression. This discrepancy may be due to differences of cell
system (SK-N-BE(2)C cells as opposed to SH-SY5Y and IMR32 cell
lines), and so the up-regulated expression of PHOX2A and PHOX2B
in NBs might be the result of cross-regulation.
Conversely, the observation that the proliferation of un-
differentiated PHOX2Bþ neuronal progenitors promotes NB cell
proliferation and stemness indicates that PHOX2B is a critical
regulator in the pathogenesis of NBs [23]. It is not known what
decides whether PHOX2B is pro- or anti-proliferative, but it can be
hypothesised that the effects of PHOX2B over-expression depend
on cell context.
As we did not map any RARE in the PHOX2B promoter, we
wondered whether the PHOX2B down-regulation we observed
Fig. 5. ATRA induces the proteasome-mediated degradation of PHOX2A protein. (A) SK-N-BE(2)C cells exposed to ethanol (lanes 1–5) or 10 μM ATRA (lanes 6–10) for 24 h
were treated with cycloheximide at a ﬁnal concentration of 10 μg/ml. The total protein extracts were obtained after treatment with cycloheximide for the indicated periods
of time, and analysed by means of Western blotting. (B) Densitometric signal quantiﬁcation expressed as the percentage of PHOX2A expression after 24 h exposure to ethanol
(triangles) or ATRA (squares). The asterisk indicates a statistically signiﬁcant difference between the control and ATRA-treated cells after 300 min (Student's t test po0.05).
C) The same protein extracts as those used in the experiment shown in panel A (lanes 1, 5, 6 and 10) were analysed for the expression of the Sp1 transcription factor by
means of Western blotting. (D) Western blots of extracts from SK-N-BE(2)C cells treated with ATRA for 24 h (lane 3), 32 h (lane 4), 48 h (lanes 6), and 56 h (lane 8), alone or in
combination with the simultaneous treatment with the proteasome inhibitors MG-132 for eight (lanes 5 and 9) and 24 h (lane 7). The positive controls were untreated SK-N-
BE(2)C cells at time 0 (lane 2), and 10 μg of nuclear extract from IMR32 cells (lane 1) E) Total extracts from SK-N-BE(2)C cells treated with EtOH (vehicle, lanes 1–3) or 105
ATRA for 24 h (lanes 4–6), followed by simultaneous treatment with MG-132 for eight hours (lanes 7–9), were immunoprecipitated with anti-PHOX2A antibodies (IP2A,
lanes 2, 5, 8), and the level of ubiquitination was evaluated by means of Western blotting using an anti-ubiquitin (Ub) antibody (upper panel). Immunoprecipitation with
chicken pre-immune IgY was used as a control, (IgY, lanes 3, 6 and 9). Lanes 1, 4 and 7 show pre-immunoprecipitation total extract [10% input (In)]. The same membranes
were stripped and re-probed with anti-PHOX2A antibody (lower panel). The asterisk indicates an speciﬁc band due to IgY heavy chain. Ub-PHOX2A: Ubiquitin-PHOX2A
conjugates.
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during RA-driven differentiation was due to the up-regulation of
PHOX2A, which down-regulates the expression of PHOX2B. How-
ever, by silencing endogenous PHOX2A expression, we found that
PHOX2B regulation by PHOX2A is not the mechanism underlying
the effect of RA. The association between MYCN ampliﬁcation (an
important prognostic factor in NB) and PHOX2B expression in
human NB cell lines [23], the down-regulation of MYCN expression
after an RA challenge [48,49], the up-regulation of PHOX2B asso-
ciated with MYCN over-expression, and the down-regulation of
PHOX2B and Mash1 when siRNA is used to inhibit MYCN [23], all
support the hypothesis that a high PHOX2B expression level is due
to the direct regulation of PHOX2B by MYCN, and we are currently
investigating whether the down-regulation of PHOX2B is related to
a reduction in MYCN expression.
In any case, our ﬁndings highlight the importance of the reg-
ulation of gene dosage in the processes driving ﬁnal cells differ-
entiation. The action of ATRA on PHOX2A and PHOX2B expression
may not only determine a cell's fate, but also stabilise it by
maintaining lineage-speciﬁc expression patterns, as conﬁrmed by
the observation that PHOX2B is down-regulated during ﬁnal
neuronal differentiation [13]. The dysregulation of one of these
pathways (perhaps leading to the accumulation of PHOX2Bþ
progenitor cells) may be one of the major mechanisms involved in
the pathogenesis of NBs.
The down-regulation of PHOX2B expression induced by ATRA
supports the idea that PHOX2B up-regulation is due to a block in
the differentiation process, and so its down-regulation may force
the differentiation of NB cells. Experiments aimed at identifying
drugs capable of reducing PHOX2B expression in the IMR32 cell
line [50] have not found that ATRA has any effect, and this is in line
with our unpublished ﬁndings showing that PHOX2A and PHOX2B
are not regulated by ATRA in IMR32 cells, although the cells are
ATRA responsive as measured on the basis of RARE reporter vector
activation (data not shown). However, the SH-SY5Y NB cell line
responds to ATRA in a similar manner ([33] and data not shown),
albeit with different kinetics, thus conﬁrming that the effects of
ATRA on PHOX2A and PHOX2B expression are not peculiar to the
SK-N-BE(2)C cell line but may reﬂect a general mechanism that
could be important in retinoid-induced neuronal differentiation.
These observations reinforce the idea that PHOX2A and
PHOX2B may be useful biomarkers for NB staging, prognosis and
treatment decision making [13].
These ﬁndings and other published data [51,52] shed new light
on the pathways driving undifferentiated and proliferating cells to
activate a differentiation programme by regulating the activation/
deactivation of transcription factors such as PHOX2A and PHOX2B,
which control cell-speciﬁc genes such as the DβH and cell cycle
regulators such as p27kip1. In particular, the work of Andrisani's lab.
[52] has shown that PHOX2A is intrinsically programmed to be
active for a deﬁned period of time, although in our case it is not
the activity but the presence of PHOX2A that is temporally regu-
lated by ATRA. A better understanding of the molecular mechan-
isms underlying this control may provide new opportunities for
the development of new drugs that can be used in cancer therapy.
5. Conclusions
In conclusions, our ﬁndings demonstrate that PHOX2A ex-
pression is ﬁnely controlled during retinoic acid differentiation
and suggest that, together with PHOX2B down-regulation, they
may be useful biomarkers for NB staging, prognosis and treatment
decision making.
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